final program

Transcription

final program

FINAL
PROGRAM
www.eci-vienna2015.org
Coordination
ECI 2015
c/o WMA Ltd.
Alser Strasse 4 • 1090 Vienna • Austria
t: +43 1 405 13 83 16
f: +43 1 407 82 74
e: [email protected]
Layout:
Barbara Biegl, www.biegl-grafik.at
Photo Credits:
Unless otherwise indicated all pictures
© ECI – European Congress of Immunology
Copyright © 2015 ECI
All rights reserved. No part of this publication may be reproduced, distributed or transmitted without the prior written permission of ECI.
Some information may be subject to change.
CONGRESS INFORMATION
Registration Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Awards and Travel Grants . . . . . . . . . . . . . . . . . . . . . . . . . . .
Floor Plans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Opening Hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Congress Information A-Z. . . . . . . . . . . . . . . . . . . . . . . . . . . .
ECI Social Media Guide. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Information for Early Career Scientists . . . . . . . . . . . . . . . . .
Information for Speakers and Poster Presenters. . . . . . . . .
CME Accreditation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12
13
18
20
20
24
24
25
26
SCIENTIFIC PROGRAM
Program at a Glance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Session Type Description . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Related Pre-Congressional Events in Vienna
before the start of the 4th ECI Congress. . . . . . . . . . . . . . . . 40
SUNDAY
Schedule at a Glance Sunday. . . . . . . . . . . . . . . . . . . . . . .
Opening Ceremony. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Opening of Historic Exhibition
“Emerging Immunology – Vienna’s Contribution” . . . . . . .
Keynote Lecture of the Day . . . . . . . . . . . . . . . . . . . . . . . . .
Educational Courses & Scientific Satellite Symposia . . . . .
Business and Ancillary Meetings. . . . . . . . . . . . . . . . . . . . . .
42
43
43
44
44
44
MONDAY
Schedule at a Glance Monday . . . . . . . . . . . . . . . . . . . . . .
Overview per Track. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Joint-Symposia of the Day. . . . . . . . . . . . . . . . . . . . . . . . . . .
Other Sessions and Meetings. . . . . . . . . . . . . . . . . . . . . . . . .
Meet the Professor Breakfast. . . . . . . . . . . . . . . . . . . . . . . . .
Posters of the Day according to Tracks A, B, C, D, E . . . . .
46
48
48
49
51
53
56
58
58
59
59
60
62
64
64
65
67
69
71
72
73
73
73
74
74
WEDNESDAY
Schedule at a Glance Wednesday. . . . . . . . . . . . . . . . . . .
Track A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Educational Courses & Scientific Satellite Symposia . . . . .
Closing and Award Ceremony. . . . . . . . . . . . . . . . . . . . . . .
76
78
78
79
81
84
85
87
87
88
88
88
88
89
89
Related Post Congressional Events in Vienna after 4th ECI . . . 90
INDUSTRY SPONSORED SYMPOSIA,
SPONSORS AND EXHIBITORS
Acknowledgements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
Sponsors’ Company Descriptions. . . . . . . . . . . . . . . . . . . . . 95
Industry Sponsored Symposia . . . . . . . . . . . . . . . . . . . . . . . . 97
Exhibition Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Exhibition Floorplan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
EFIS
Info . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Appointments with EFIS during the ECI 2015. . . . . . . . . . . 109
Upcoming Meetings (Sponsored by EFIS) . . . . . . . . . . . . . 109
NETWORKING EVENTS
Networking Events. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
THE CITY OF VIENNA
The City of Vienna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Vienna City Map. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
Vienna Public Transport Map . . . . . . . . . . . . . . . . . . . . . . . 118
MONDAY
Addresses. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
About. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Committees. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Schedule at a Glance Tuesday. . . . . . . . . . . . . . . . . . . . . .
Track A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Track E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Final Program • 4th European Congress of Immunology • September 6–9, Vienna/AT • ECI 2015
1
TUESDAY
ORGANIZATION
TUESDAY
WEDNESDAY
2
4
5
6
INDUSTRY / EXHIBITION
Welcome by the ECI Organizers. . . . . . . . . . . . . . . . . . . . . . .
Welcome by the EFIS President. . . . . . . . . . . . . . . . . . . . . . . .
Welcome in Austria. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Welcome in Vienna . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SUNDAY
TABLE OF
CONTENTS
Welcomes
WELCOME BY THE ECI ORGANIZERS
Dear Colleagues and Friends,
with great pleasure we welcome you on behalf of the Austrian Society of Allergology and Immunology (ÖGAI) to the 4th European Congress of Immunology (ECI) in Vienna from September 6-9,
2015. After the scientifically and socially very successful congresses in Paris, Berlin and Glasgow,
we are honored to host the 4th ECI, which is organized under the auspices of the European Federation of Immunological Societies (EFIS), in the heart of Europe.
We have received more than 3.000 abstracts from Europe and Overseas and are especially proud
and very thankful for the large international recognition of the 4th ECI, which goes far beyond the
boundaries of Europe. In fact, more than 100 abstracts have been submitted by colleagues from
both USA and Brazil, more than 70 abstracts have been submitted by colleagues from Australia
and more than 60 abstracts have been submitted by colleagues from China. We take these
record-high numbers as clear indication for the international attractiveness of European immunology research and realize that ECI congresses are receiving worldwide attention.
The Scientific Program Committee has taken much effort to generate a timely and highly stimulating program consisting of four tracks covering the most recent developments in basic and
clinical immunology. Exciting latest results and novel developments will be presented in 46 keynote lectures and symposia. At this point, we cordially thank all the members of the Scientific
Program Committee, the Steering Committee and the Local Organizing Committee as well as the
93 reviewers for their invaluable contributions by critically evaluating all submitted abstracts. The
committee members have selected 432 abstracts to be orally presented and the most excellent
amongst them will be featured in specially dedicated ‘bright sparks’ workshops. In addition, more
than 2.500 abstracts will be presented and discussed in 126 guided poster sessions during the fourday congress.
We also express our deep gratitude to all related Societies dealing with immunology, clinical immunology, allergology and applied sciences, who have shown enormous enthusiasm in organizing
additional joint symposia with EFIS, amongst them the European Academy of Allergy and Clinical
Immunology (EAACI), the European Society for Immunodeficiencies (ESID), the European League
Against Rheumatism (EULAR), the American Association of Immunologists (AAI), the International
Union of Immunological Societies (IUIS), the World Allergy Organization (WAO), the International
Society for Advancement of Cytometry (ISAC) and the Society for Mucosal Immunology (SMI). In
addition to this fruitful cooperation the communication and collaboration with the related industry has been outstanding. As a result, more than 55 partners from industry will attend as exhibitors
and a considerable number of company sponsored symposia and ‘progress in technology’ sessions will introduce you to the latest developments in flow cytometry, immune-adsorbers, vaccination against infectious diseases and tumors and allergy diagnosis amongst other topics. Moreover,
the scientific program is framed by a considerable number of very interesting satellite symposia
and meetings taking place either shortly before or directly after the main congress. On top of that,
we invite you to the ‘EFIS Award Lectures’ on Monday 7th September presenting the recipients
of the prestigious Ita Askonas Prize and the ACTERIA Doctoral and Early Career Research Prizes.
The winners will give a short presentation about their awarded work. Finally, on Wednesday 9th
September, the ‘First EFIS President’s Symposium’, convened and chaired by outgoing EFIS President Lorenzo Moretta, will explore ‘NK Cells and NK Cell-based Therapies of Leukemias’.
2
ECI 2015 • September 6–9, Vienna/AT • 4th European Congress of Immunology • Final Program
Welcomes
WELCOME BY THE ECI ORGANIZERS
The support of the participation of early career scientists at events like the 4th ECI represents a
cornerstone of EFIS’ mission. Accordingly, EFIS has awarded more than 240 travel bursaries to European early career scientists. Similarly, the American Association of Immunologists (AAI), the International Union of Immunological Societies (IUIS) and ÖGAI provided grants of their own (40, 10
and 10, respectively) to applicants from developing countries. Moreover, many national societies
have allocated substantial support to stimulate and promote the participation of their younger
members at ECI 2015. To further promote early career scientists special lectures will be provided,
e.g. ‘How to publish in scientific journals’ and ‘Women in immunology’. In addition, early career
scientists will have the opportunity to meet keynote lecture and symposia speakers in an interactive discussion atmosphere during breakfasts. Furthermore, guided poster sessions chaired by
senior scientists and conducted at time-slots not interfering with workshops will encourage active
discussion of scientific results to acknowledge the large contribution of early career scientists to
this congress and to provide a stimulating feedback atmosphere for their scientific work. The best
poster presenters within each session will compete for 12 poster prizes to be awarded during the
closing ceremony.
Outstanding immunological research has a long and strong tradition in Vienna. In fact, More
than one hundred years ago, the Viennese Nobel laureate Karl Landsteiner discovered the blood
groups and Clemens von Pirquet coined the term ‘Allergy’ in Vienna. Vienna’s contributions to
the emerging field of immunology and allergology research at the turn of the last century will be
high-lighted by a special historic exhibition, kindly curated by Johann Eibl and Othmar Förster, in
the main lobby of the Austria Center Vienna. The exhibition will also be open to the lay public. We
are indebted to the curators as well as the institutional and corporate sponsors of this interesting
and eye-catching exhibition.
After the opening keynote lecture given by the doyen of B cell biology, Klaus Rajewsky, on ‘The
B cell receptor in B cell development, memory and malignancies’ we invite you to join us for the
networking mixer in the Austria Center Vienna, which will take place immediately after the opening ceremony. Moreover, please consider to exchange thoughts and scientific opinions with your
colleagues and friends on Tuesday, September 8, at the occasion of the Heurigen Networking
Evening in Gumpoldskirchen.
We express our deep gratitude to all those individuals and institutions, who made the 4th ECI possible. Many thanks to all committee members, who continuously contributed to the organization
of this congress during the last years. A big thank you also to the generous support from our corporate partners, without their contributions it would have been impossible to put such a fantastic
program together. Last but not least, we would like to thank the City of Vienna for kindly hosting us.
Finally, we hope you will feel very comfortable in Vienna and we wish you a most memorable
scientific, social and cultural stay!
Winfried F. Pickl, MD
President 4th ECI
Barbara Bohle, PhD
President Scientific Program
Committee 4th ECI
Rudolf Valenta, MD
President Local Organizing
Committee 4th ECI
3
Welcomes
WELCOME BY THE EFIS PRESIDENT
Dear Friends and Delegates,
As President of the European Federation of Immunological Societies (EFIS), it is a distinct pleasure
and honor for me to welcome you to the Fourth European Congress of Immunology – ECI 2015!
The ECI, the venue of which is selected every three years (six years in advance) through a bidding
process by the Federation’s 31 Member Societies, is the EFIS flagship event. At the 2nd ECI held in
Berlin in 2009, EFIS Members overwhelmingly chose the bid submitted by the Austrian Society of
Allergology and Immunology (ÖGAI) to host ECI 2015 in Vienna. And they did well to do so: I am
convinced – after having worked closely with our colleagues of the ÖGAI over the past three
years – that they are beyond worthy of the trust that EFIS Member Societies have placed in them!
Our Austrian hosts – so admirably coordinated by Winfried Pickl, Barbara Bohle and Rudolf Valenta,
respectively, Presidents of the ECI 2015 Steering Committee, Scientific Program Committee and
Local Organizing Committee – have put together what is poised to be a truly meaningful event.
A stellar lineup of speakers will explore over the next three days – in four Keynote addresses, more
than 40 symposia and 72 workshops – the most recent advances in the fields of innate immunity,
adaptive immunity, diseases of the immune system and immune interventions. And whether you
have a broad-ranging interest in the multiple facets of modern immunological research, or your
focus lies in a particular niche, you will surely come away from ECI 2015 satisfied by the fine balance between basic and applied/translational research contributions that the organizers have
assembled.
Also – in keeping with the mission of EFIS to foster young scientists – early career scientists will also
take center stage in a number of specially convened sessions: “poster walks” will be conducted
by leading scientists to encourage dynamic interaction with presenters, from among whom the 12
best will be selected; the “Bright Sparks Workshops” will feature the authors of the best submitted
abstracts scored and selected by European experts; and the ACTERIA Doctoral and Early Career
Research Prizes awarded by EFIS will be presented for the second time. In addition to these, EFIS
will acknowledge the work of the third EFIS-EJI Ita Askonas Prize, awarded to a prominent European female research group leader.
And beyond the wealth of science that will be explored in detail over the next three days in the
halls of the Austria Center, we cannot forget the cultural and social delights that Vienna – the
capital of Mitteleuropa, the City of Music, the Imperial City – has to offer.
Overall, as an ECI 2015 delegate, rest assured that a scientifically, socially and culturally rewarding
experience is waiting for you!
In closing, I cannot help but highlight that 2015 marks the 40th anniversary of the founding of EFIS,
which will be commemorated, among other occasions, with the inaugural “EFIS President’s Symposium”. On behalf of EFIS and the entirety of its membership, and together with our colleagues of the
ÖGAI, I am delighted that you have chosen to take part in what is arguably “the” showcase for the
European immunological community and that this year promises to be a truly memorable event.
Lorenzo Moretta
President, EFIS
4
Welcomes
WELCOME IN AUSTRIA
Ladies and Gentlemen,
Dear Participants,
I would like to welcome you to Austria and the beautiful city of Vienna. Medicine has a very long
tradition in Vienna. Today we have one of the world’s leading medical universities and many
research institutions of international acclaim.
It is a great honor that experts of immunology from all over the globe gather in Vienna for the
4th European Congress of Immunology to discuss the important issues of immunology. The huge
range of symposia, workshops and poster sessions will give the experts the opportunity to discuss
in-depth new forms of immune interventions, technological innovations and research results. I am
convinced that the scientific progress will be for the benefit of thousands of patients who suffer
from immune-mediated diseases and immunodeficiency.
I wish all participants a successful conference with many fruitful discussions!
Yours sincerely,
Dr.in Sabine Oberhauser, MAS
Minister of Health
Federal Ministry of Health Austria
5
Welcomes
WELCOME IN VIENNA
Dear participants of ECI 2015,
As host city of the 4th European Congress of Immunology, Vienna combines two key traditions:
its traditional role as an international meeting place for outstanding scientists, and the excellent
worldwide reputation of the Vienna School of Medicine. For our city, this reputation is both an
honour and a mission for the future. The important fact that this year’s ECI is hosted by the Austrian
Society of Allergology and Immunology serves as yet another proof of our traditionally close connection to science and research.
The network of medical services available to all population groups is a good indicator for assessing
a society. Vienna has an excellent international track record here, which is also due to research
in immunology and allergology - two medical fields of increasing importance. The ECI is bound
to provide new momentum in these fields as it provides for an exchange of experiences, expert
debates, and initiatives to promote education and training. This is what matters after all.
I would like to wish all participants an inspiring and interesting congress, and hope that you will
also keep good memories of your stay in Vienna.
Dr. Michael Häupl
Mayor and Governor of Vienna
6
ORGANIZATION
Addresses. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
About. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Committees. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
7
Organization
ADDRESSES
ECI 2015 Congress President
ao. Univ. Prof. Dr. Winfried F. Pickl
Institute of Immunology
Medical University of Vienna
Lazarettgasse 19, 1090 Vienna, Austria
[p]: 0043 1 40160 33245
[m]: 0043 664 80016 65017
[e]: [email protected]
EFIS Office
Thomas Wiley
EFIS Coordinator
Istituto Giannina Gaslini
Via Gerolamo Gaslini 5, 16147 Genova, Italy
[p]: 0039 010 563 6805 6554
[m]: 0039 347 197 7015
ECI 2015 Congress Organization and
Abstract Management
WMA Kongress GmbH
Alser Straße 4, 1090 Vienna, Austria
[p]: 0043 1 4051383 16
ÖGAI Office
Institut für Immunologie
Lazarettgasse 19, 1090 Vienna, Austria
[p]: 0043 660 4977161
ECI 2015 Exhibition and Sponsorship Management
MAW – Medizinische Ausstellungs- und Werbegesellschaft
Engerthstrasse 128, 1200 Vienna, Austria
City office: Freyung 6, 1010 Vienna, Austria
[p]: 0043 1 53663 71
[e] [email protected]
Congress Venue
Austria Center Vienna
Bruno-Kreisky-Platz 1, 1220 Vienna, Austria
[w]: www.acv.at
ABOUT
European Federation of Immunological Societies [EFIS]
The European Federation of Immunological Societies (EFIS) is a non-profit umbrella organization that represents 31 immunological societies from all across Europe, and even beyond the borders to Israel. Every active member of any of its member
societies is automatically considered an EFIS member and can as such benefit from EFIS programs. Thus EFIS represents more
than 14,000 individual immunologists.
The main goals of EFIS are the support of immunological research and education as well as strengthening scientific interaction
amongst its members. EFIS especially focuses on supporting early career scientists, e.g. through fellowships or travel grants.
European Congress of Immunology [ECI]
The European Congress of Immunology - ECI - is the triennial joint meeting of all EFIS member societies. It is one of the most
renowned international conferences in the field of basic and clinical immunology and attracts up to 5,000 delegates. The
ECI is "the“place to build your professional network as it offers the highest standards in terms of both scientific and social programs. Each EFIS member society can submit a bid to host an ECI. The 4th European Congress of Immunology is held under
the auspices of the Austrian Society for Allergology and Immunology (ÖGAI) and the European Federation of Immunological
Societies (EFIS).
Austrian Society for Allergology and Immunology [ÖGAI]
The ÖGAI was founded in 1971 and represents Austrian scientists and practitioners interested in the physiology and pathophysiology of the immune response as well as the phenotypic expression, diagnosis and therapy of all diseases involving the
immune system.
ÖGAI supports excellence in education and training in the fields of allergology and immunology and further provides and
also encourages the spread of specific information on the vital importance of the immune system and its disorders, such as
allergy, autoimmunity, immunodeficiencies, to the lay, legal and professional public.
Under the auspices of EFIS, European Federation of Immunological Societies
www.efis.org
and the Austrian Society for Allergology and Immunology, ÖGAI
www.oegai.org
8
Organization
COMMITTEES
STEERING COMMITTEE
FINANCE COMMITTEE
LOCAL ORGANIZING COMMITTEE
Winfried F. PICKL, President
Lorenzo MORETTA, EFIS President
Georg WICK, ÖGAI
Barbara BOHLE, ÖGAI
Fatima FERREIRA-BRIZA, ÖGAI
Rudolf VALENTA, ÖGAI
Peter OPENSHAW, BSI
Andreas RADBRUCH, DGfI
Reina MEBIUS, NVVI
Anna FOGDELL-HAHN, SSI
Luisa Maria VILLAR-GUMERANS, SEI
Vincenzo BARNABA, SIICA
Anne HOSMALIN, SFI
Günnur DENIZ, TSI
Hans ACHA-ORBEA, SGAI
Henrique VEIGA-FERNANDES, SPI
Hannes STOCKINGER, President
Carsten WATZL, DGfI
Lindsay NICHOLSON, BSI
René TOES, NVVI
Hanna JARVA, SSI
Clemens SCHEINECKER, ÖGAI
Eduard PALOU, SEI
Massimo LOCATI, SIICA
Paul GUGLIELMI, SFI
Rudolf VALENTA, President
Barbara BOHLE, ECI 2015 SPC President
Kaan BOZTUG
Meinrad BUSSLINGER
Thomas DECKER
Manfred DIERICH
Adelheid ELBE-BÜRGER
Martha EIBL
Wilfried ELLMEIER
Michelle EPSTEIN
Elisabeth FÖRSTER-WALDL
Alexander von GABAIN
Beatrix GRUBECK-LOEBENSTEIN
Franz-Xaver HEINZ
Wolfgang HOLTER
Sylvia KNAPP
Hans LASSMANN
Mathias MÜLLER
Josef PENNINGER
Alexander ROSENKRANZ
Armin SAALMÜLLER
Marcus SAEMANN
Clemens SCHEINECKER
Veronika SEXL
Maria SIBILIA
Josef SMOLEN
Georg STINGL
Hannes STOCKINGER
Giulio SUPERTI-FURGA
Peter VALENT
Arne VON BONIN
Thomas WECKERLE
Ursula WIEDERMANN
Christoph ZIELINSKI
Gerhard ZLABINGER
EFIS BOARD
Lorenzo MORETTA, President
René A.W. VAN LIER, President elect
Catherine SAUTÈS-FRIDMAN, Past President
Anna ERDEI, Secretary General
Hannes STOCKINGER, Treasurer
SCIENTIFIC PROGRAM COMMITTEE
Barbara BOHLE, ECI 2015 SPC President
Rudolf VALENTA, ECI 2015 LOC President
Winfried F. PICKL, ECI 2015 President
Leonie TAAMS, BSI
Hans Martin JÄCK, DGfI
Rene TOES, NVVI
Marie WAHREN-HERLENIUS, SSI
Ignacio MELERO, SEI
Massimo LOCATI, SIICA
Roland LIBLAU, SFI
Sabina RABATIC, CIS
Günnur DENIZ, TSI
Christian MUENZ, SGAI
Peter KOROSEC, ISS
9
2018
ECI
Istanbul, Turkey
5 European Congress of
th
Immunology
September 12 - 15, 2018
www.eci2018.org
Under the auspices of EFIS, European Federation of Immunological Societies
www.efis.org
and the Turkish Society of Immunology
www.turkimmunoloji.org.tr
EFIS
European Federation of
Immunological Societies
CONGRESS
INFORMATION
Registration Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Awards and Travel Grants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Floor Plans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Opening Hours. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Congress Information A-Z. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
ECI Social Media Guide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Information for Early Career Scientists . . . . . . . . . . . . . . . . . . . 24
Information for Speakers and Poster Presenters. . . . . . . . . . . 25
CME Accreditation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
11
Congress Information
REGISTRATION INFORMATION
before
June 30, 2015
(reduced rate)
from July 1
to August 23, 2015
(regular rate)
after
August 23, 2015
and on site
Day tickets
on site
EFIS Members1
EUR 420,-
EUR 480,-
EUR 540,-
EUR 270,-
Non-Members
EUR 570,-
EUR 630,-
EUR 690,-
EUR 360,-
Students2
EUR 210,-
EUR 240,-
EUR 270,-
EUR 150,-
Lunch bags standard3
(per day)
EUR 12,-
EUR 12,-
N/A
N/A
Lunch bags premium3
(per day)
EUR 19,50
EUR 19,50
N/A
N/A
Registration fees
Payment received:
Networking Event –
Heurigen Evening4
EUR 60,-
Abstract Book
(printed)
EUR 12,-
1
List of eligible national EFIS member societies can be found online at www.ecivienna2015.org/index.php/registration
2
Applies to under- and postgraduate students. Please provide a copy of a Student’s ID or a written confirmation
(in English) signed by the head of department during registration.
3
Lunch bags could only be ordered prior to the congress, no onsite orders for lunch bags are possible!
For those not ordering lunch bags a couple of onsite options are, however, available.
4
Entirely at participants’ expense
What is covered by the registration fee?
Cancellations and refunds
• Admission to all scientific sessions
• Admission to industry exhibition
• Admission to networking mixer
•Electronic abstract book on USB, printed final program
and printed poster listing
•Coffee/tea during breaks from Monday, September 7
to Wednesday, September 9
Notice of cancellation must be made in writing by email or
fax to the congress office. Registration fees may be refunded
as follows:
Payment of Registration fees may be made in cash (in Euro
only) or by credit/debit card (ECI accepts Mastercard, VISA
and Maestro).
The date of receipt of the email or fax ID will be the basis
for considering refunds. Refunds will be made after the congress. Cancelled lunch bags and Heurigen Tickets can not
be refunded.
Written cancellation received:
- before June 30, 2015: 75% refund
- between July 1 and August 23, 2015: 25% refund
- after August 23, 2015: no refund
Please note
The reduced registration fee is only applicable, if it has been
credited to the congress account before the deadline.
Registering before June 30 or respectively August 23, 2015
without performing the actual payment is not sufficient to
benefit from the reduction.
12
Abstract Book
A printed abstract book can be purchased at the onsite
registration desk for EUR 12,-.
AWARDS AND TRAVEL GRANTS
ACTERIA-PRIZES AWARDED BY EFIS
On the recommendations of the ACTERIA Prizes Selection Jury and
the Foundation ACTERIA, EFIS is delighted to announce the laureates
of the 2015 ACTERIA Prizes awarded by EFIS:
Doctoral Prize in Allergology:
Sandra Pahr
Nominated by the Austrian Society for Allergology and Immunology (ÖGAI)
Doctoral Prize in Immunology:
Chris Schiering
The Francis Crick Institute - Mill Hill Laboratory, London
Nominated by the British Society for Immunology (BSI)
Early Career Research Prize in Allergology:
Thomas Marichal
University of Liege
Nominated by the the Belgian Immunological Society (BIS)
Early Career Research Prize in Immunology:
Dietmar Zehn
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne
Nominated by the Swiss Society for Allergology and Immunology (SGAI)
The ACTERIA Prizes awarded by EFIS will be formally conferred at a specially organized Plenary Lecture Session of the
4th European Congress of Immunology on Monday, September 7 from 14:00 to 15:30 hrs, during which each of the four laureates will present her/his work.
The ACTERIA Doctoral Thesis Prizes carry a cash award of EUR 15,000, while the ACTERIA Early Career Research Prizes amount
to EUR 30,000 each. In addition, awardees automatically qualify for 3-year research grants of up to EUR 50,000 annually.
EFIS/EJI ITA ASKONAS AWARD
Dr. Karin Tarte, Director of the Microenvironement and Cancer Unit of the University of Rennes Faculty of Medicine (U 917
INSERM), has been chosen as the 2015 Laureate of the Ita Askonas Prize, awarded by EFIS together with its Official Journal,
European Journal of Immunology (EJI), in recognition of outstanding leadership by a female immunologist over the past
three years.
The prize was established by the European Federation of Immunological Societies (EFIS) and the European Journal of Immunology (EJI) in order to acknowledge female group leaders in immunology who have run an independent laboratory for a
minimum of four and no more than eight years. The board of EFIS had decided to establish this award also in consideration
of gender-specific differences of career opportunities, such as possible delays due to pregnancy and motherhood.
This prize consists of a EUR 20,000 cash award plus travel support to attend the European Congress of Immunology (ECI).
The laureate must be prepared to present her work at the ECI.
The EFIS-EJI Ita Askonas Prize, named after the renowned scientist who over a career spanning 60 years so heavily influenced
the field of immunology and who maintained that "good science gets recognition regardless of the sex of the scientist",
was awarded for the first time at the ECI 2009 in Berlin. The winner was Prof. Fiona Powrie from Oxford, UK. The second prize,
awarded during the ECI 2012 in Glasgow, went to Dr. Francesca Granucci of the University of Milano-Bicocca.
13
EFIS-IL MOST CITED PAPER AWARDS
EFIS/IL Most Cited Original Paper Award
Bermejo, P., Martín-Aragón, S., Benedí, J., Susín, C., Felici, E., Gil, P., Ribera, J.M., Villar, A.M.
Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease
Volume 117, Issue 2, 15 May 2008, Pages 198–202
Cited 72 times in its first 3 years after publication!
EFIS/IL Most Cited Review Award
K.S.Siveen, Girija Kuttan
Role of macrophages in tumour progression
Volume 123, Issue 2, 27 April 2009, Pages 97–102
Cited 131 times in its first 3 years after publication!
Description: The awards were established by the European Federation of Immunological Societies (EFIS) with general
support from Immunology Letters, in order to recognize the most often cited original paper and review, respectively, within
the first 3 years after publication, published in Immunology Letters. They are awarded triennially in combination with the
European Congress of Immunology (ECI), for the first time during ECI 2012 in Glasgow. This year we honor the Most Cited
Original Article and Review which appeared in IL from January 1, 2008 to March 15, 2015.
Each prize consists of a EUR 5,000 cash award plus invitation and support of the key author to attend the ECI.
TRAVEL GRANTS
ECI-EFIS 2015 Travel Grants for Early Career Scientists from EFIS Affiliated National Immunological Societies
The European Federation of Immunological Societies (EFIS), sponosred by the European Journal of Immunology and Immunology
Letters, is awarding 245 travel grants at the value of EUR 600.- each for young post-docs and PhD-students under 35 years of
age requesting financial support to attend the ECI 2015 and is pleased to announce the following EFIS travel grant awardees:
Austrian Society for Allergology and
Immunology (ÖGAI)
Karine De Amicis
Christoph Jandl
Sahar Kazemi*
Barbara Kronsteiner-Dobramysl
Xin Li
Shu-Hua Liu*
Simone Mader
Bharani Srinivasan*
Philipp Starkl
Marion Steger
Helen Strandt
* based in Vienna, Award value of EUR 200.-
Belgian Immunological Society (BIS)
Ellen Brisse
Pauline Lehebel
Arnaud Machelart
Valerie Martinet
Barbara Polese
Karen Put
Catherine Sabatel
British Society for Immunology (BSI)
Giuseppina Arbore
Dominic Boardman
Marianne Burbage
Joana Campos
Lewis Clarke
Ee Lyn Lim
Anna Malecka
Helen McGettrick
Paul Milne
Dhiren Patel
Ann-Kathrin Reuschl
14
Joanne Simpson
Nathalie Steinthal
David Tomaz
Bulgarian Society for Immunology (BuSI)
Marina Alexandrova
Ivaylo Balabanov
Tsvetelina Batsalova
Silviya Bradyanova
Maya Hadzhieva
Iva Ivanova
Maria Kazakova-Velinova
Iliyan Manoylov
Croatian Immunological Society (HID)
Marina Babic Cac
Vedrana Jelenčić
Tomislav Kelava
Lovro Lamot
Maja Lenartić
Marko Šestan
Czech Immunological Society (CIS)
Viktor Bugajev
Fabian Caja
Viktor Černý
Stepan Coufal
Adela Dusilova
Veronika Horková
Michaela Hornová
Jiri Hrdy
Klara Klimesova
Tomas Paulenda
Lucie Potůčková
Ladislav Sivak
Ivan Stepanek
Zuzana Zakostelska
Dutch Society for Immunology (NVVI)
Anne Marit de Groot
Ilse Dingjan
Jennifer Hope
Daniëlle Verboogen
Marjolein Wentink
French Society for Immunology (SFI)
Alexandra Audemard-Verger
Pascal Azar
Sara Basbous
Gaetan Blaize
Lloyd Bod
Laure Castan
Clotilde Guyon
Myriam Hayder
Mathieu Ing
Annaelle Jarossay
Régis Joulia
Clement Levin
Yuting Ma
Charlotte Pouchy
Emilie Ronin
Georgian Association of Allergology and
Clinical Immunology (GAACI)
Nino Nanava
Yan Sepiashvili
German Society for Immunology (DGfI)
Fatima Ahmetlic
Petra Bacher
Jonas Blume
Carola Bunse
Lucia Campos Carrascosa
Michael Delacher
Christiane Göpfert
Lukas Heger
Ann-Cathrin Hofer
Isabel John
Annett Kessler
Elisabeth Littwitz-Salomon
Anna Nowak
Lucas Otto
Friederike Raczkowski
Annika Reinhardt
Andreas Schlitzer
Franziska Schmidt
Kathrin Schulz
Ping Shen
Julia Spanier
Yilang Tang
Ulrike Träger
Alexander Ulges
Franziska Weber
Anne Willing
Kai Yu
Marija Stankovic
Milica Vujičić
Immunology Society of Slovenia (ISS)
Mark Kačar
Jelka Pohar
Irish Society for Immunology (ISI)
Laura Cahill
Jennifer Corbett
Maja Kristek
Paul Lohan
Kevin Lynch
Izabela Marszalowska
Ewa Oleszycka
Grace O'Malley
Mark Robinsdon
Ralitsa Vassileva
Mieszko Wilk
Hellenic Society of Immunology (HSI)
Maria Semitekolou
Panagiota Spantidea
Eleftheria Anastasopoulou
Antonios Gerofotis
Ioannis Panagoulias
Maria Rodi
Ioanna Zerva
Hungarian Society for Immunology (MIT)
Zsuzsanna Bankó
Beáta Szilvia Bolla
Marietta Budai
Judit Danis
Anikó Göblös
Adrienn Gyöngyösi
Zoltán Kohl
Mariann Kremlitzka
Réka Kugyelka
Adrienn Lajkó
Nikolett Lupsa
Anett Mázló
Barbara Molnár-Érsek
Kitti Linda Pázmándi
Judit Pozsgay
Lilla Prenek
Noémi Sándor
Florentina Sava
Eszter Szarka
Eszter Szlavicz
Márta Tóth
Dóra Vojkovics
Immunological Society of Serbia (ISoS)
Nemanja Jovicic
Ilija Jeftic
Jelena Demenesku
Tanja Dzopalic
Milan Marković
Emina Milosevic
Marina Ninkov
Verica Paunovic
Aleksandra Popov Aleksandrov
Suzana Stanisavljević
Italian Society for Immunology, Clinical
Immunology and Allergology (SIICA)
Paolo Ambrosini
Eduardo Bonavita
Francesco Borriello
Monica Castellucci
Valerio Chiurchiù
Sara Costa
Daniele Croxatto
Claudia De Pasquale
Cinzia Garofalo
Anna Kabanova
Monica Loi
Matteo Massara
Michela Mirenda
Martina Molgora
Eleonora Palella
Laura Pisapia
Nicla Porciello
Naths Grazia Sukubo
Rossana Tallerico
Eleonora Timperi
Latvian Association of Immunologists (LAI)
Aigars Dzalbs
Lithuanian Society for Immunology (LSI)
Dovile Dekaminaviciute
Polish Society for Fundamental and
Clinical Immunology (PTDiK)
Dorota Iwaszkiewicz-Grzes
Urszula Kozlowska
Natalia Marek-Trzonkowska
Katarzyna Nazimek
Justyna Roszkowiak
Urszula Skalska
Tomasz Wypych
Aneta Zegar
Agata Zerka
Portuguese Society for Immunology (SPI)
Ana Margarida Ferreira Teixeira
Liliana Oliveira
Sérgio Ribeiro
Ana Rita Santos
Russian Society for Immunology (RSI)
Alina Alshevskaya
Egor Batorov
Elena Blinova
Svetlana Falaleeva
Nikita Mitkin
Vadim Nazarov
Mikhail Pogorelyy
Lidia Putlyaeva
Baigalmaa Sangidorj
Ivan Zvyagin
Scandinavian Society for Immunology (SSI)
Magdalena Bosma
Madelene Dahlgren
Sophie Schussek
Kailash Singh
Slovak Immunological Society (SIS)
Lucia Paulovičová
Beata Gajdosechova
Spanish Society for Immunology (SEI)
Fernando Aranda
Selene Baos
Juan Antonio Calatayud Subias
Aranzazu Cruz Adalia
Marta Cuenca
Vanessa Daza Cajigal
Spanish Society for Immunology (SEI)
(cont’d)
Rebeca de Pablo
Carlos Del Fresno Sánchez
Sara Labiano
Maria Martinez López
Pascual Martínez-Peinado
Anna Mensa-Vilaró
Marta Mosquera Sáiz
Miguel Muñoz Ruiz
Carmen Picon
Dalia Raich-Regue
Swiss Society for Allergology and
Immunology (SSGAI)
Nicolo Brembilla
Marco Fischer
Samuel Philip Nobs
Carsten Riether
Turkish Society of Immunology (TSI)
Soner Yildiz
Lacin Cevhertas
Ersin Gül
Gurcan Gunaydin
Bilgi Güngör
Elif Senem Kayali
Ece Canan Sayitoglu
Burcu Sirin
Gurcan Tunali
Digdem Yoyen-Ermis
Ukrainian Society of Specialists in Clinical
Immunology and Allergy (UTIAI)
Dmytro Butov
Grants will be paid by bank transfer after ECI 2015 has taken place. In order to claim their award, grant holders will be
required to confirm their attendance during the congress to the EFIS booth in the ECI Immunology Village.
15
ECI-AAI Travel Grants for Trainees from Developing Countries
The European Congress of Immunology is pleased to announce the following travel grant awardees sponsored by
the American Association of Immunology (AAI) with EUR 600.- as a contribution towards travel expenses:
Lucas Arruda; Ribeirão Preto, Brazil
Tarcio Braga; Sao Paulo, Brazil
Abigael Buigut; Eldoret, Kenya
Saswati Das; New Delhi, India
Joao Paulo do Carmo; Porto Nacional,
Brazil
Yusuf Dolen; Ankara, Turkey
Syed Faisal; Aligarh, India
Wynand Goosen; Cape Town,
South Africa
Valeriia Guselnikova; St. Petersburg,
Russian Federation
Jaquelina Julia Guzmán Rodríguez;
Morelia, Mexico
Zeb Hussain; Karachi, Pakistan
Sevgi Irtegun; Diyarbakır, Turkey
Léanie Kleynhans; Cape Town,
South Africa
Manoj Kumar; New Delhi, India
Sushil Kumar; Bhopal, India
Neha Lohia; Patiala, Punjab, India
Andres Machicote; Buenos Aires, Argentina
José Maravillas-Montero; México, Mexico
Jelena Milovanovic; Kragujevac, Serbia
Ricardo Mora; San José, Costa Rica
Roman Moriev; Kyiv, Ukraine
Shibabrata Mukherjee; Kolkata, India
Anastasia Myrzakova; Moscow,
Russian Federation
Neema Negi; New Dlehi, India
Tetiana Nikolaienko; Kyiv, Ukraine
Viktoriia Nikulina; Kyiv, Ukraine
Tashnica Olivier; Cape Town, South Africa
Gustavo Olvera-García; Tlalpan, Mexico
Raphael Peres; Sao Paulo, Brazil
Ariel Podhorzer; Buenos Aires, Argentina
Susmita Roy; Kolkata, India
Iti Saraav; Delhi, India
Cristiane Secca da Silva; Rio de Janeiro,
Brazil
Ahmed Seida; Giza, Cairo, Egypt
Mahima Sharma; New Delhi, India
Om Singh; Varanasi, India
Sukrat Sinha; Allahabad, India
Shivendra Tenguria; Hyderabad, India
Vipin Tyagi; Delhi, India
Galyna Yeryomenko; Kharkov, Ukraine
Grants will be paid in cash onsite during registration.
IUIS Travel Grants for Early Career Scientists from IUIS Affiliated National Immunological Societies
the International Union of Immunological Societies (IUIS) with EUR 600.- as a contribution towards travel expenses:
Chidimma Atukpawu; Imo State, Nigeria
Donald Nyangahu; Cape Town, South Africa
Yung-Sen Chang; Taipei, Taiwan
Zahra Salahi; Tehran, Iran
Jeewon Lee; Daejeon, Korea, Republic of
Alberto Salazar; Mexico City , Mexico
Pu Li; Shanghai, China
Jimena Tosello-Boari; Córdoba, Egypt
Sakshi Malik; Faridabad, India
Nuria Zurro; São Paulo, Brazil
ÖGAI Travel Grants for Early Career Scientist from Developing Countries
the Austrian Society for Allergology and Immunology (ÖGAI) with EUR 600.- as a contribution towards travel expenses:
Olena Dzhus; Kyiv, Ukraine
Gaurab Sircar; Kolkata, India
Nevin Hammam; Assiut, Egypt
Roman Sydor; Kyiv, Ukraine
David Mzinza; Hannover, Germany
Maia Tsitsuashvili; Moscow, Russian Federation
Paul Ogongo; Nairobi, Kenya
Luan Vu; Sydney, Australia
Pramila Rijal; Oxford, United Kingdom
Michael Zulu ; Durban, South Africa
16
EFIS-BIOLEGEND BRIGHT SPARKS AWARDS
With the generous support of Biolegend, EFIS is able to sponsor 24 Bright Sparks Awards during the ECI 2015. The Scientific Committee selected the 24 best abstracts submitted by early career scientists. Those abstracts are presented in the
"Bright Sparks" Workshops, taking place throughout the day on Monday (Hall F1). In addition to recognition as an ECI 2015
"Bright Spark", all speakers will also receive a EUR 500,- cash prize.
Prizes will be awarded during the Closing and Award Ceremony on Wednesday, September 9, 17:45 – 18:45 hrs (Hall A).
EFIS POSTER PRESENTATION AWARDS
The EFIS proposes 12 Poster Presentation Awards for the best posters presented during the ECI 2015 in Vienna. The winners will
receive a EUR 300,- cash prize.
Poster Chairpersons will evaluate all posters presented during the guided poster sessions. Award Candidate Posters will be
moved to a designated area (on the left when entering the exhibition / poster area) by the congress staff and will be displayed during all congress days. Final decisions on winners will be made by an award jury on Wednesday.
Prizes will be awarded during the Closing and Award Ceremony on Wednesday, September 9, 17:45 – 18:45 hrs (Hall A).
17
Poster
Exhibition (X2)
FLOOR PLANS
€
LEVEL 0
Level
0
F1
E
Sp
Pre eaker
(0. view
93
)
F2
n
tio
tra
gis
Re
Business
Lounge
€
Re
gis
tra
tio
n
gs
Ba
€
Main entrance
LEVEL -2
Level
G
-2
K
Society Village
Society Village
Poster Award
Candidates
Poster
Poster
Exhibition (X2)
€
Level
18
FLOOR PLANS
LEVEL 2
Level
2
A
Me
(2. eting
12
Ro
)
o
m
7
m
oo 2)
g R (2.3
in
eet
M
ng
i
eet
Me
(2. eting
15
Ro
)
o
4
om
Ro .31)
(2
m
Me
(2. eting
17
Ro
)
o
M
m
Me
eti
LEVEL 1
Me
eti
ng
ng
Ro
om
(1. 8
62
)
6
3
5
om
Ro
ng )
eti .86
Me 85/1
(1.
Ro
om
(1. 2
61
)
M
1
Level
1
N
L8
L1
L7
L2
Level
2
19
OPENING HOURS
Opening
hours
Congress
Information
Desk
Registration
Desk
Speakers‘
Preview
Accommodation
&
City Desk
Poster Printing
Desk
Cloakroom
Sunday,
Sept 6
10:00 – 20:00 10:00 – 20:00 10:00 – 20:00
10:00 – 20:00
10:00 – 20:00 10:00 – 22:30
Monday,
Sept 7
07:30 – 19:30 07:00 – 19:30 07:30 – 19:30
07:30 – 19:30
07:30 – 18:00 07:30 – 21:00
Tuesday,
Sept 8
07:30 – 19:30 07:00 – 19:30 07:30 – 19:30
07:30 – 19:30
07:30 – 18:00 07:30 – 19:30
Wednesday,
Sept 9
07:30 – 16:30 07:00 – 16:30 07:30 – 16:30
closed
07:30 – 11:30 07:30 – 19:30
Opening
hours
Exhibition
Service Desk
Exhibition
poster
mounting
poster
removal
Saturday,
Sept 5
08:00 – 20:00
build up
no
no
Sunday,
Sept 6
08:00 – 20:00
build up
no
no
Monday,
Sept 7
08:00 – 18:30 09:00 – 18:00 07:30 – 08:30 18:00 – 19:30
Tuesday,
Sept 8
08:00 – 18:30 09:00 – 18:00 07:30 – 08:30 18:00 – 19:30
Wednesday,
Sept 9
08:00 – 22:00 09:00 – 16:30 07:30 – 08:30 16:00 – 17:45
CONGRESS INFORMATION A-Z
App information
Badges
The ECI smartphone app can help you to get the best out
of the ECI!
Each participant receives a name badge upon check-in
at Registration. As only registered participants will be permitted to attend the scientific sessions, the exhibition and
poster areas, you are required to wear your badge when
entering and while remaining in the congress venue. If you
have lost your badge, a new one can be purchased (with
proof of your original registration) at the Onsite Registration
Desk for EUR 60,-.
The app allows you to:
- browse, search and personalize the entire event
program
- access useful information about the congress
- access all abstracts
- create and synchronize events with your personal
calendar
The app allows users to access information offline to avoid
roaming costs. It can be downloaded from your app store
and works with iOS and Android. Search your app store for
ECI 2015.
ECI thanks Abbvie for their generous sponsorship of the
Congress App.
20
IMPORTANT: Please have your badge scanned daily at the
Congress Information Desk in order to claim the full amount
of CME credits.
Bank Services - Money Matters
Banks are generally open Monday to Friday from 09:00 –
15:00. Some banks are also open until 18:00 on weekdays.
Cash machines (ATMs), which accept all major international
bank cards, are available throughout the city. The currency
of Austria is the Euro (€). Major credit cards are widely accepted, but please always check beforehand.
The nearest bank is located on the way from the subway
station to the congress venue.
Business Centre
Drinking Water
The closest Business Centre is Repa Copy located on the way
from the subwaystation to the congress venue (Donaucitystraße 4). Opening hours : Monday to Friday – 08:00 – 20:00,
Saturday and Sunday - closed.
The tap water in Vienna is drinkable and is of very high quality
(mountain spring water).
Certificate of Attendance
ECI 2015 delegates are cordially invited to visit the EFIS Booth
c/o the Immunology Village for a coffee and to take part
in the traditional “EFIS Passport to Prizes” raffle for a chance
to win numerous prizes, including travel grants to future immunology events and subscriptions and textbooks from EFIS’
Official Journals.
Certificates of attendance will be issued at the registration
desk. CME accreditation certificates can be downloaded
from the congress website (www.eci-vienna2015.org) from
Friday, September 11, 2015. More details will be sent to you
via email after the congress. For more details, please ask at
the Congress Information Desk in the main Entrance Hall.
EFIS Booth
Emergencies
Climate
The average temperatures in September in Vienna are 20°C
(high) and 12°C (low). The average number of rainy days is
7 with an average rainfall of 45 mm.
Please contact a member of congress staff immediately
in the case of a real or suspected emergency situation.
The European emergency number applies in Austria, and
callers should dial: 112.
Coffee Breaks
During the session breaks, refreshments (coffee, tea and
water) will be served free of charge to participants wearing name badges. On Monday, Tuesday and Wednesday
coffee and lunch bags (pre-ordered ) will be served in the
exhibition area (Hall X1+X2).
Cloakroom
A cloakroom (with luggage storage) is located in the
entrance hall.
Charge: EUR 2.- per item
Free of charge on Wednesday, September 9
Opening Hours:
Sunday, September 6
Monday, September 7 Tuesday, September 8 Wednesday, September 9 10:00 – 22:30
07:30 – 21:00
07:30 – 19:30
07:30 – 19:30
Exhibition
The ECI 2015 industry exhibition will be open during the
following times:
09:00 – 18:00
09:00 – 16:30
The Publishers’ Corner and the Society Village are located
in the Exhibition Hall.
Flight Check-in
Flight check-in terminals will be available to delegates in the
registration area for online flight check-in. A printer will be
available to print boarding passes.
This service will be open from Tuesday, September 8 15:00
to Wednesday, September 9 16:30.
Continuing Medical Education (CME) Credits
ECI 2015 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME),
an institution of the European Union of Medical Specialists (UEMS) in cooperation with the European Board of Accreditation in Allergy and Clinical Immunology (EBAACI) to
provide the following CME activity for medical specialists.
The Congress is designated for up to 18 hours of European
external CME credits (ECMECs). Please see page 26 for more
information on how to claim your CME credits.
Currency
Austria is a member of the Economic and Currency Union
and the common currency is the Euro.
The official currency in the Austria is the EURO (EUR).
1 EUR = 1,10 USD = 0,70 GBP = 1,42 CAD = 136,20 JPY
= 1,06 CHF = 1,50 AUD as per August 1, 2015.
Food and Beverages
The main catering services (coffee and lunch bag stations)
as well as a snack bar and a smoothie bar are located in the
Exhibition Hall. In the entrance area you will find the Motto
Café offering cold and warm snacks as well as a curry bar
offering different curries each day. A traditional “Wiener
Würstelstand” offering different kinds of sausages is located
outside the main entrance.
Coffee and tea during official coffee breaks is included
in the registration fee. Lunch bags are not included in the
registration fee and had to be pre-ordered. For logistical
reasons lunch bags cannot be ordered onsite.
Lunch bags can be picked up from 12:15 – 14:15 on Monday,
Tuesday and Wednesday.
21
Opening Hours Food Outlets
Online Program Planner
Snack Bar and Smoothie Bar Exhibition Area
Monday, September 7 09:00 – 18:00
Tuesday, September 8 09:00 – 18:00
Wednesday, September 9 09:00 – 16:30
Motto Café Registration Area
Saturday, September 5
Sunday, September 6
08:00 – 17:00
08:00 – 19:00
08:00 – 19:00
08:00 – 17:00
Entrance Level Curry Bar
Sunday, September 6
Monday, September 7
Tuesday, September 8 Wednesday, September 9
11.30 – 15.00
11.30 – 15.00
11.30 – 15.00
11.30 – 15.00
Outside Coffee Bar / Würstelstand
Sunday, September 6
Monday, September 7
Tuesday, September 8
Wednesday, September 9
10.00 – 15.00
08.00 – 15.00
08.00 – 15.00
08.00 – 15.00
Internet Access
For WiFi access, choose the ECI 2015 network.
The password is eci2015.
Job Announcements
Job announcements can be displayed on a designated info
wall in the exhibition area.
Language
The official language of the congress is English.
No simultaneous translation is provided.
Lost and Found
Please contact the Congress Information Desk in the registration area for personal belongings that have been lost
or found.
Message Board
Message boards will be available in the exhibition area.
An online program planner to create your individual itinerary
including the full information on all sessions, speakers, chairs
and abstracts is available online on the Congress website:
www.eci-vienna2015.org. The online planner has a search
function with which you can find speakers, topics, session
types and much more. You can also build your personal
Congress itinerary by selecting presentations and sessions
from the program, using the search tool. The itinerary can be
printed, exported as csv/excel file. It can also be exported
to your calendar in various systems (such as MS Outlook and
Apple iCalendar). It is also possible to find single abstracts.
Alternatively, why not download the Congress app for full
information on the Scientific Program and more.
Parking
The Austria Center Vienna provides covered, secure parking
for delegates.
- Disabled parking spaces in the multi-storey garage
- Parking for about 40 coaches at main entrance level
- Ample HGV parking at „Ladehof West“
Parking fees
up to 30 minutes 1 hour: Each additional hour: Max. daily fee: free
EUR 3,EUR 1,EUR 10,-
Pharmacies
Most pharmacies are generally open weekdays from 8.0012.00 and 14:00 – 18:00 hrs, Saturdays from 8.00-12.00, some
until 18.00 hrs and closed on Sundays. After 18:00 you find a
list of “emergency” pharmacies (open during the night and
on weekends) in the surrounding.
Poster Exhibition
Scientific posters are displayed in the poster area in the
Exhibition Hall. Posters will be displayed for a full day either
on Monday, Tuesday or Wednesday. Each day, the posters
are organized in thematic groups of approx. 20 posters. During the poster sessions the presenters are required to stand
by their posters to deliver a concise poster presentation of
not more than 3 minutes and to answer questions from delegates. During this time, two chairpersons per group will also
visit each poster and ask the presenters to briefly present their
findings. Visit the Poster Information Desk for any questions
you might have regarding the poster presentations.
Mobile Phone Policy
Please respect the congress policy and keep mobile phones
on silent in all meeting rooms, the Exhibition Hall and Poster
Area.
22
Poster Removal
Insurance/Liabilities and Disclaimer
The organisers cannot assume any liability for loss or damage
of posters displayed in the poster area. Posters need to be
removed on the day of presentation between 18:00 – 19:30
hrs strict (16:00 – 17:45 hrs on Wednesday).
ECI will not be held liable for personal injuries or for loss of
or damage to property incurred by participants at the ECI
2015. Participants are encouraged to purchase insurance
to cover loss incurred in the event of cancellation, medical
expenses, or damage to or loss of personal effects when
travelling outside of their own countries. ECI cannot be held
liable for any hindrance or disruption of the ECI Congress
2015 proceedings arising from natural, political, social or
economic events or other unforeseen incidents beyond its
control. Registration of a participant implies acceptance
of this condition.
Access after 19:30 hrs (17:45 hrs on Wednesday) is not possible! Posters not removed until 19:30 hrs on the day of presentation (17:45 hrs on Wednesday), will be taken down by
the staff of the conference center and will not be stored or
sent to the authors after the meeting.
Photographing and Recording
Taking photographs or making any other form of electronic
recording (also with mobile phones) during the sessions in
the meeting rooms is forbidden.
Safety and Welfare
Vienna can be considered just as safe as other comparable
cities in Europe. Use of common sense is however (always)
required. Unfortunately, experience has shown that some
basic precautionary measures should always be kept in
mind in any city:
- Do not carry important items like flight tickets, passports
etc. with you when visiting the congress or strolling
through the city, leave them in the hotel safe during
your stay. Rather carry a Xerox copy of your passport
or an identity card with you.
- Try not to carry all documents, money, credit cards
and other essential items and valuables in one bag.
If it is lost or stolen, everything will be gone and might
be difficult to replace on short notice, especially
passports and visa to return to your country of
residence.
- Take off your name badge when leaving the congress
venue.
- In heavily frequented tourist zones, be aware of
attemps of scam and pickpocketing.
ECI / EFIS holds a very firm position against any form of discrimination or untoward behaviour by Congress participants.
If any participant feels that they have been subjected to any
inappropriate behaviour, please report it immediately to a
senior member of Congress staff at the General Information
Desk in the Registration Area and the matter will be referred
to the local authorities for further investigation.
Session Attendance
Sessions may fill up quickly. Please arrive in good time for the
start of the session. Due to security regulations, hosts and
hostesses are instructed to restrict access once the maximum
capacity of the room is reached.
Society Village
The society village is located in the exhibition hall. National
EFIS affiliated societies as well as international associations
will provide a platform for international exchange and inform
about the newest developments in their own countries.
Speaker Preview
The Speaker Preview is located on level 0 in room 0.93.
The opening hours are:
Sunday, Sept 6
Monday, Sept 7
Tuesday, Sept 8
Wednesday, Sept 9
10:00 – 20:00
07:30 – 19:30
07:30 – 19:30
07:30 – 16:30
Staff
If you should have any questions, the congress staff (recognizable by a badge and a blue t-shirt) will be pleased
to help you.
Telephone Calls
The country code of Austria is 43 and the area code for
Vienna is 1, followed by a 7 digit number. To call abroad,
dial 00 before the country code.
23
ECI SOCIAL MEDIA GUIDE
Get the latest news!
Follow us on twitter @2015ECI. For a live feed from the congress, follow @2015ECI on Twitter.
We will give you full congress coverage, daily photos, news and much more.
Share your thoughts – use the official hashtag
But that’s only the half of it. We want your comments, ideas, thoughts, and congress experiences.
Post them on your twitter, mention @2015ECI or use the official hashtag #ECI2015 in your tweets.
Spread the word!
Your friends back home can join us online.
Your colleagues can also join you at the ECI 2015, online and live via our twitter stream.
Just invite everyone to follow us @2015ECI
INFORMATION FOR EARLY CAREER SCIENTISTS
HOW TO GET THE MOST OUT OF YOUR FIRST ECI CONGRESS
1. Make a plan
5. Ask Questions
Spend some time thinking about the most important sessions
and talks that you would like to see. The meeting program
is also available online.
Don’t be shy about asking questions at the microphone!
Everyone in the audience is there to learn – and so if you
have a question, there’s every chance that others will have
the same question.
Familiarize yourself with the color coded session types: different types are designed for a different audience. Avoid
being disappointed by a session that will be too basic or
too specialized for your interests, despite an interesting title.
2. Pace Yourself
The meeting has a packed schedule. You will probably find
something interesting and useful from 8:30 until 19.30 hrs
each day – but we would not necessarily recommend to do
so! You will get saturated pretty quickly, and by Monday or
Tuesday your ability to absorb useful information will be severely diminished. Again, prioritize what is the most important.
6. Get There Early!
This is a principle that will serve you well on many fronts. We
have literally thousands of people attending the meeting,
and yet some people are surprised to find lines at the registration desk on Sunday afternoon. You will not want to miss the
opening ceremony – so get there early (registration opens
at 10:00 on Sunday morning) – and is open all day Sunday
to Wednesday.
It is similar for the queues for food at the Networking Mixer
reception (Monday evening). Just think, with 3000+ people,
it is IMPOSSIBLE for everyone to get served immediately.
3. Parallel Events
When you attend a session you might find that not all of the
session is relevant or interesting to you, or you might have
spotted a talk in another parallel session room that you’d like
to see. It is completely okay to leave one session and join
another (but etiquette dictates that you wait for the end of
a talk to leave / join the audience).
4. Interact
Make the most of the opportunity to network. Most people
(junior or senior) are delighted to meet new faces and to
chat about their work – so don’t be afraid to approach those
big names and introduce yourself, and just start chatting!
24
7. Stay cool and relax!
Sounds cheesy…. But the meeting is extremely busy, and you
could try and push yourself to run between every single talk
that you want to see, to try and see all 2500+ posters, to go
to every symposium, workshop and so on….. but you’ll be
exhausted! It is far better to have come away with some
new friends, have chatted with a ‘big name’ in your field,
and have two or three ‘nuggets’ of information that will
shape your research.
8. Business Cards
Although these are becoming a dying breed, we noted
that having business cards ready to exchange was helpful, especially when another meeting attendee passes you
theirs, but it is a matter of personal preference.
INFORMATION FOR SPEAKERS AND POSTER PRESENTERS
ORAL PRESENTATIONS
Speaking Time
The chairpersons of your session will be strict in allowing no more than the time allotted to present your work. Remember to allow
some time for chairperson's introduction, questions and discussion of your presentation as well as the changeover of speakers.
Commercial Disclosure information
Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest
is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may
include financial interests (eg. owning stocks of a related company, having received honoraria, consultancy fees), research
interests (research support by grants or otherwise), organizational interests and gifts. If you have nothing to disclose, please
state “I have no commercial disclosure”.
Projection and Technical Setting
PowerPoint is the only communication tool available in all session halls. Overhead projection, slide projection or flipcharts
are not available.
1.Speakers are kindly asked to observe that, in principle, only computers provided by the congress may be used for
showing presentations. All PowerPoint presentations must be handed in at the speaker preview.
Please contact the technicians in the speaker preview at least 2 hours prior to your session if you absolutely have to use
your own computer.
2.All presentations are loaded into a PowerPoint handling system that will store and distribute your presentation
to the session hall in time for your session.
3.All PowerPoint presentations should be handed in at least 2 hours before the session starts.
4.Please check your presentation carefully on the preview room computer assigned by the staff before the final sign off.
5.The professional staff of the speaker preview will load your presentation into the system so that it will be available on
the computer in your session hall when you come to speak.
6.If you are doing more than one speech during the congress, you may upload all your presentations at the same time
and they will be sent to their corresponding session halls at the time of your sessions.
7.The PowerPoint handling and distribution system is optimized for MS PowerPoint 2007 (Office 2007) and “*.pdf”
(Adobe Acrobat)-files. The uploading of “DVD-Movies” is not supported.
8.The supported data media are: CD, DVD (as Data-storage-medium) and USB-Memory Key. All needed files
(including the movie files!) - have to be saved on the data media. Presentations can also be taken off speakers
notebooks at the Preview centre.
9.The fonts that are used in the presentations should be “Latin-based fonts“. If the speaker needs special fonts, they
should be stored as “embedded fonts“ with the presentation (File -> save as “name of presentation“ and under “tools“
->save options mark the checkbox “embed True type fonts“ and select “embed all characters“).
10.When using mathematical symbols please use these which are available under Latin fonts
(unicode or DOS: Western Europe). These can be shown without any problems in Office 2007.
11.As format for embedded movies “MPEG2 - movies” are preferred (but can also be *.avi, *.wmv ).
If Codecs are used, the Code package DIVx in the current version should be chosen.
12.Presentations should be saved as “*.ppt“, “*.pptx” (= PowerPoint) or “*.pps“,*.ppsx“ (=PowerPoint Slideshow) file and movies as separate files on the data media.
13.The computers and projectors will be set up and optimised for 1024 x 768 resolution (ratio 4 : 3).
25
INFORMATION FOR SPEAKERS AND POSTER PRESENTERS
POSTER PRESENTATIONS
Schedule for display, mounting and removal
Posters will be changed every day. Your poster will be on display during one of the following days:
•Monday, September 7 (08:30 – 18:00 hrs)
•Tuesday, September 8 (08:30 – 18:00 hrs)
•Wednesday, September 9 (08:30 – 16:00 hrs)
Poster mounting on the respective days will be possible between 07:30 – 08:30 hrs strict.
Posters need to be removed on the day of presentation until 19:30 hrs strict (17:45 hrs on Wednesday).
Access after 19:30 hrs (17:45 hrs on Wednesday) is not possible! Posters not removed until 19:30 hrs on the day of
presentation (17:45 hrs on Wednesday), will be taken down by the staff of the congress venue and will not be stored or sent
to the authors after the meeting.
Contact the Poster Information Desk in the exhibition area if you need any assistance with your poster.
Important Guidelines
•Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the poster.
•When presenting data and health information (including photos) all presenters must have informed consent compliant
with human subjects and applicable regulations.
Poster Printing Service
The Poster Printing Service desk is located in the registration are. Onsite orders are possible.
All detailed information on the Poster Presentations can be found in the separate poster information booklet.
CME ACCREDITATION
The 4th European Congress of Immunology (ECI 2015) is accredited by the European Accreditation Council for Continuing
Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of
the European Union of Medical Specialists (UEMS).
The 4th European Congress of Immunology (ECI 2015) is designated for a maximum of 18 hours of European external CME credits.
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed
to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal
College of Physicians and Surgeons of Canada.
CME ACQUISITION PROCEDURE
The ECI 2015 is happy to introduce a digital CME acquisition system. Evaluation and CME acquisition will be possible online
after the congress. An according email will be sent to all participants. Each ECI delegate will be able to view and print a
confirmation stating the according number of CME credits. It is possible to claim a maximum of 18 CME points for attendance
of scientific sessions at the ECI 2015.
IMPORTANT: Please make sure to have your badge scanned daily at the Congress Information Desk in order to gain the
maximum amount of CME credits.
The printout of your record should be submitted to your national jurisdiction (usually responsible for accreditation) for approval
of your CME points. Please note that the record of attendance will be issued only to the participant. It will not be supplied to
any accreditation agency or other organisation.
Please note that the ECI 2015 does not provide printed CME certifications onsite.
26
SCIENTIFIC
PROGRAM
Program at a Glance. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
How to Read the Scientific Program . . . . . . . . . . . . . . . . . . . . 36
Related Pre-Congressional Events in Vienna
before the start of the 4th ECI Congress. . . . . . . . . . . . . . . . . . 40
Sunday. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Monday . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Tuesday . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Wednesday. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
27
Scientific Program
PROGRAM AT A GLANCE
Sunday, Sept. 6, 2015
Room
Hall A
L2
L1
L8
Meeting Room 1
(1.85-86)
Meeting Room 2
(1.61)
Level
2
1
1
1
1
1
07:30 – 07:45
07:45 – 08:00
08:00 – 08:15
08:15 – 08:30
08:30 – 08:45
08:45 – 09:00
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
BA.02
09:45 – 10:00
IUIS Executive
Committee Meeting
10:00 – 10:15
10:15 – 10:30
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
11:45 – 12:00
12:00 – 12:15
Scientific Satellite
Meeting
Educational Course
Immunosenescence:
Hot Topics and
Interventions - Day 2
Advanced
Cytometry Course
12:15 – 12:30
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
BA.04
ABIRISK Steering
Committee (SC)
Meeting
13:15 – 13:30
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
BA.05
14:15 – 14:30
German Society for
Immunology (DGfI)
Board Meeting
14:30 – 14:45
14:45 – 15:00
15:00 – 15:15
15:15 – 15:30
15:30 – 15:45
Meeting
ABIRISK - Immune
Reactions Against
Biopharmaceuticals
15:45 – 16:00
16:00 – 16:15
16:15 – 16:30
16:30 – 16:45
16:45 – 17:00
17:00 – 17:15
17:15 – 17:30
17:30 – 17:45
Opening Ceremony
17:45 – 18:00
18:00 – 18:15
KL.A.1
18:15 – 18:30 Adaptive Immunity
The B Cell Receptor in B
18:30 – 18:45 Cell Development, Memory
18:45 – 19:00 and Malignancies
19:00 – 19:15
Opening of Historic Exhibition “Emerging Immunology – Vienna’s Contribution”
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
20:00 – 20:15
20:15 – 20:30
Networking Mixer
20:30 – 20:45
20:45 – 21:00
21:00 – 22:00
28
Scientific Program
PROGRAM AT A GLANCE
Meeting Room 5
(2.17)
Meeting Room 8
(1.62)
2
1
Room
Level
07:30 – 07:45
07:45 – 08:00
08:00 – 08:15
08:15 – 08:30
08:30 – 08:45
08:45 – 09:00
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
09:45 – 10:00
10:00 – 10:15
10:15 – 10:30
BA.03
10:30 – 10:45
SysmedIBD
Consortium Meeting
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
11:45 – 12:00
12:00 – 12:15
12:15 – 12:30
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
13:15 – 13:30
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
Meeting
Get to know
SysmedIBD
(EU-FP7 Project Systems Medicine
of Chronic
Inflammatory Bowel
Disease)
BA.06
14:15 – 14:30
British Society for
Immunology (BSI)
Programme
Committee Meeting
14:30 – 14:45
14:45 – 15:00
15:00 – 15:15
15:15 – 15:30
15:30 – 15:45
15:45 – 16:00
16:00 – 16:15
16:15 – 16:30
16:30 – 16:45
16:45 – 17:00
17:00 – 17:15
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
18:15 – 18:30
18:30 – 18:45
18:45 – 19:00
19:00 – 19:15
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
Networking Mixer
20:00 – 20:15
20:15 – 20:30
20:30 – 20:45
20:45 – 21:00
21:00 – 22:00
29
Scientific Program
PROGRAM AT A GLANCE
Monday, Sept. 7, 2015
Room
Hall A
Hall E
Hall F1
Hall F2
Hall G
Hall K
Level
2
0
0
0
-2
-2
07:15 – 08:15
08:15 – 08:30
08:30 – 08:45
08:45 – 09:00
S.A.01
Adaptive Immunity
Protection by CD8
09:15 – 09:30 T Cells
09:00 – 09:15
S.B.01
Diseases
Chronic
Inflammation
BS.C.1
Bright Sparks
Breakthroughs in
Innate Immunity
WS.D.01
Immunosuppresive
Therapies and
Immunomodulation
WS.C.01
WS.C.02
Leukocyte Trafficking Innate Sensors
09:30 – 09:45
09:45 – 10:00
10:00 – 10:15
10:15 – 10:30
Poster Session and Guided Poster Walks / Coffee Break
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
S.C.01
11:45 – 12:00 Innate Immunity
12:00 – 12:15 Mucosal Immunity
S.D.01
Disease Intervention
Vaccines
12:15 – 12:30
BS.B.1
Bright Sparks
Insights in
Immunological
Disease Mechanisms
WS.A.01
Molecular & Cellular
Control of CD8+ T
Cells (part 1)
WS.B.02
WS.B.01
Generation of
Allergen Specific
Immune Responses
Control of
Inflammation
in Autoimmune
Diseases
12:30 – 12:45
12:45 – 13:00
KL.C.1
Intestinal
13:15 – 13:30 Homeostasis and its
13:30 – 13:45 Breakdown
13:45 – 14:00
14:00 – 14:15
JS.01
14:15 – 14:30 American
Association of
Immunologists (AAI)
14:45 – 15:00 Molecular
Mechanisms of the
15:00 – 15:15 Immune Response to
15:15 – 15:30 Infection
14:30 – 14:45
JS.02
European League
Against Rheumatism
(EULAR)
Resolution of
Inflammation
EF.01
EFIS Awards Lecture
Symposium
(Industry Sponsored)* ACTERIA Prizes and
EFIS-EJI Ita Askonas
Prize
IS.01
15:30 – 15:45
15:45 – 16:00
16:00 – 16:15
S.A.02
Th17 Cells in Human
16:30 – 16:45 Health and Disease
S.B.02
Diseases
Allergy and Asthma
WS.C.05
BS.D.1
Bright Sparks
Immunotherapy
NK and NKT Cell
Activation and
Mechanisms
16:45 – 17:00
WS.D.02
Drug
Immunogenicity
and Biomarkers of
Efficacy
WS.C.06
WS.A.03
WS.B.05
Innate Cell Signaling
17:00 – 17:15
Coffee Break
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
S.C.02
Mediators of
18:30 – 18:45 Inflammation
18:45 – 19:00
S.D.02
Immunological
Tolerance in Organ
Transplantation
BS.A.1
Bright Sparks
Adaptive Immunity
WS.B.04
Lymphocyte
Targeting Immune
Escape by Tumors
Molecular and
Cellular Control of
the Subsets
Local Tissue
Alteration in
Autoimmunity
19:00 – 19:15
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
20:00 – 20:15
SW.01
IS.04
(Industry Sponsored
Titles to Figure
(Industry Sponsored)*
Progress in
Legends: An Insider’s
Technology Session)*
Guide to Publishing
IS.03
Scientific Writing Session
20:15 – 20:30
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
* please see page 97 for details
30
Scientific Program
PROGRAM AT A GLANCE
Hall M
Hall N
1
1
Meeting Room Meeting Room Meeting Room Meeting Room Meeting Room
1
2
3
5
6
(1.85-86)
(1.61)
(2.15)
(2.17)
(2.12)
1
1
2
2
2
ME.01
Room
Level
07:15 – 08:15
Peter Openshaw
08:15 – 08:30
08:30 – 08:45
WS.C.03
Myeloid
Suppressor Cells
08:45 – 09:00
WS.C.04
Dendritic Cells &
Macrophages
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
09:45 – 10:00
Poster Session and
Guided Poster Walks /
Coffee Break
BA.10
BA.07
European Journal
DGfI Study
of Immunology
Groups
Editorial Board and
Board Meeting
Alumni Meeting
BA.08
BA.09
Dutch Society
for Immunology
(NVVI)
Board Meeting
Scandinavian
Society for
Immunology (SSI)
Council Meeting
10:00 – 10:15
10:15 – 10:30
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
WS.A.02
Germinal
Centers:
Genetic and
Transcriptional
Control
11:15 – 11:30
WS.B.03
11:30 – 11:45
Clinics, Pathophysiology and
Genetics of Primary Immunodeficiency Diseases
11:45 – 12:00
12:00 – 12:15
BA.10.1
IUIS-Frontiers
Partnership
Meeting
12:15 – 12:30
BA.11
Scandinavian
Society for
Immunology (SSI)
Retreat Follow-up
Meeting
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
13:15 – 13:30
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
JS.03
14:15 – 14:30
Russian-GeorgianIS.02
Austrian Sister
(Industry
Symposium
Sponsored)*
From Magic Bullets
14:30 – 14:45
14:45 – 15:00
to Targeted Therapy
Approaches
15:00 – 15:15
15:15 – 15:30
15:30 – 15:45
WS.D.03
15:45 – 16:00
BA.12
WS.D.04
16:00 – 16:15
IUIS-EFIS Annual
Collaboration
Review Meeting
Immune
Preventive &
Dissection of Anti- Therapeutic
Viral Vaccines
Approaches
16:15 – 16:30
16:30 – 16:45
16:45 – 17:00
17:00 – 17:15
Coffee Break
BA.12.1
Italian Society
of Immunology,
Clinical
Immunology
and Allergology
(SIICA)
Board Meeting
BA.13
WS.A.04
Lymphocyte
Subsets (part 1)
WS.A.05
Extrinsic Factors
in the Control of
B Cells
Scandinavian
Journal of
Immunology
Editorial Board
Meeting
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
18:15 – 18:30
18:30 – 18:45
18:45 – 19:00
19:00 – 19:15
IS.05
(Industry
Sponsored)*
BA.14
Italian Society
of Immunology,
Clinical
Immunology and
Allergology (SIICA)
General Assembly
19:15 – 19:30
BA.15
19:30 – 19:45
Hungarian
19:45 – 20:00
Society for
Immunology (MIT) 20:00 – 20:15
Board Meeting
20:15 – 20:30
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
31
Scientific Program
PROGRAM AT A GLANCE
Tuesday, Sept. 8, 2015
Room
Hall A
Hall E
Hall F1
Hall F2
Hall G
Hall K
Level
2
0
0
0
-2
-2
07:15 – 08:15
08:15 – 08:30
08:30 – 08:45
08:45 – 09:00
S.A.03
Adaptive Immunity
Immune Cell
09:15 – 09:30 Trafficking
09:00 – 09:15
S.B.03
Diseases
Immunity Against
Infections
WS.D.05
T Cell Based Cancer
Immunotherapy
WS.C.07
Macrophage
Signaling
WS.D.06
Stem Cells and CellBased Therapy
WS.C.08
Epigenetics in Innate
Immunity
09:30 – 09:45
09:45 – 10:00
10:00 – 10:15
10:15 – 10:30
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
S.C.03
Innate Effector
12:00 – 12:15 Functions
S.D.03
Antibody
Therapeutics
WS.A.06
Control of CD8+ T
Cells (part 2)
WS.B.06
Cytokines and
Chemokines in
Tumor Immunology
WS.A.07
WS.B.07
T Cell Signalling
Skin Diseases
12:15 – 12:30
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
KL.B.1
Diseases
13:15 – 13:30 Inflammasome
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
JS.04
14:15 – 14:30 International Union
14:30 – 14:45
14:45 – 15:00
15:00 – 15:15
15:15 – 15:30
of Immunological
Societies (IUIS)
Vaccine Development
Can Benefit from
Computational
Biology
JS.05
European Academy
of Allergy and
IS.07
Clinical Immunology
(EAACI)
T Helper Cell Subsets
in Health and Disease
JS.06
International
Society for the
Advancement of
Cytometry (ISAC)
Cytometry of the
21st Century
JS.07
Society for Mucosal
Immunity (SMI)
The Mucosal
Microbiome in Health
and Disease
15:30 – 15:45
15:45 – 16:00
16:00 – 16:15
S.A.04
Establishment of
16:30 – 16:45 B Cell Responses
S.B.04
Diseases
Primary
Immunodeficiencies
WS.D.07
Novel Approaches
for Vaccines
WS.C.10
Macrophages in
Diseases
WS.C.11
WS.B.09
WS.B.11
WS.A.11
Innate Lymphoid
Cells
Optimizing
Anti‑Tumor Immunity
16:45 – 17:00
17:00 – 17:15
Coffee Break
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
S.C.04
Antigen Uptake and
18:30 – 18:45 Presentation
S.D.04
Cancer
Immunotherapy
WS.A.10
WS.B.10
Treg Induction /
Subsets
Systemic
Autoimmune
Diseases
Allergens
B Cell Signaling
18:45 – 19:00
19:00 – 19:15
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
20:00 – 20:15
20:15 – 20:30
Heurigen Evening
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
32
Scientific Program
PROGRAM AT A GLANCE
Hall M
Hall N
1
1
Meeting Room Meeting Room Meeting Room Meeting Room
1
3
5
6
(1.85-86)
(2.15)
(2.17)
(2.12)
1
ME.02
Jürgen Wienands
2
ME.03
Ron Germain
2
ME.04
Nadine Cerf-Bensussan
2
L7
Room
1
Level
ME.05
07:15 – 08:15
Luke O’Neill
08:15 – 08:30
08:30 – 08:45
WS.C.09
WS.E.01
Structural Biology
and Imaging
08:45 – 09:00
Innate Cell
Signalling &
Function
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
09:45 – 10:00
Poster Session IS.06
BA.16
BA.17
BA.19
and
Scandinavian
German Society
Belgian
(Industry
BA.18
Guided
Sponsored Progress Society for
for Immunology
Immunological
French
Society
of
BA.19.1
Immunology (SSI) (DGfI)
Society (BIS)
Poster Walks / in Technology
Immunology
(SFI)
IUIS Quality
Session)*
General
Assembly
General
Assembly
General
Assembly
Coffee Break
Annual board
Assessment and
meeting
WS.A.08
B Cell
Development &
Homeostasis
WS.B.08
Standardization
Committee
Meeting
10:00 – 10:15
10:15 – 10:30
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
Innate Immune
Mechanisms in
Cancer
11:45 – 12:00
12:00 – 12:15
12:15 – 12:30
12:30 – 12:45
BA.20
12:45 – 13:00
EEIG ECI-EFIS
Meeting
13:00 – 13:15
13:15 – 13:30
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
WO.00
Women in
Immunology
Carreer Talks
BA.21
EFIS
General
Assembly
WS.A.09
Molecular
Control of T Cell
Development
WS.D.08
Solid Organ and
Bone Marrow
Transplantation
Coffee Break
14:30 – 14:45
14:45 – 15:00
15:00 – 15:15
15:15 – 15:30
15:30 – 15:45
15:45 – 16:00
16:00 – 16:15
16:15 – 16:30
BA.22
Inaugural
IUIS Vaccine
Committee
Meeting
16:30 – 16:45
16:45 – 17:00
17:00 – 17:15
BA.23
EFIS
Board Meeting
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
WS.B.12
Models and
Mechanisms of
Primary Immunodeficiency
booked out!
14:15 – 14:30
18:00 – 18:15
WS.B.13
18:15 – 18:30
Immune Disorders
18:30 – 18:45
18:45 – 19:00
19:00 – 19:15
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
Heurigen Evening
20:00 – 20:15
20:15 – 20:30
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
33
Scientific Program
PROGRAM AT A GLANCE
Wednesday, Sept. 9, 2015
Room
Hall A
Hall E
Hall F1
Hall F2
Hall G
Hall K
Level
2
0
0
0
-2
-2
07:15 – 08:15
08:15 – 08:30
08:30 – 08:45
08:45 – 09:00
S.A.05
Adaptive Immunity
09:00 – 09:15 Maintenance
09:15 – 09:30
09:30 – 09:45
of Lymphocyte
Memory
S.B.05
Diseases
Autoimmunity
WS.D.09
WS.C.12
Cancer
Dendritic Cell
Immunotherapy and Differentiation and
Anti-Tumor Vaccines Function
WS.D.10
WS.C.13
Intervention and
Therapy of Allergy
Mast Cells
09:45 – 10:00
10:00 – 10:15
EP.01
1st EFIS President's
Symposium
10:30 – 10:45 On NK Cells and NK
Cell-Based Therapy
10:45 – 11:00 of Leukemias
10:15 – 10:30
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
S.C.05
Innate Immunity
11:45 – 12:00 Innate Lymphocytes
12:00 – 12:15 - Backstage or
12:15 – 12:30
Centerstage
S.D.05
T Cell Mediated
Immunotherapy
WS.A.12
Control of CD8+ T
Cells (part 3)
WS.B.14
WS.B.15
Immune Recognition Immune Regulation
and Control of
at the Intestinal
Infections
Barrier
WS.B.16
Mediators of Airway
Inflammation
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
13:15 – 13:30
JS.08
KL.D.1
World Allergy
Association (WAO)
Mechanisms in
Allergy
13:30 – 13:45 Cancer Therapy
13:45 – 14:00
14:00 – 14:15
JS.09
European Society for
Immunodeficiencies
(ESID)
Newborn
Screening for
Immunodeficiency
14:15 – 14:30
14:30 – 14:45
14:45 – 15:00
15:00 – 15:15
S.A.06
Adaptive Immunity
15:15 – 15:30 Molecular Switches
15:30 – 15:45 in Adaptive
Immunity
15:45 – 16:00
S.B.06
Diseases
Stroma - Immune
Interactions in
Cancer and
Inflammation
WS.D.12
Immune Intervention
in Autoimmune
Diseases
WS.C.15
WS.A.15
WS.D.13
WS.A.16
WS.B.19
WS.B.20
Dendritic Cell
Subsets
Treg Function /
Biology
Immunotherapy of
Infectious Diseases
16:00 – 16:15
16:15 – 16:30
16:30 – 16:45
S.C.06
S.D.06
Inhibitory and
Aging and the
17:00 – 17:15 Activating Receptors Immune System
WS.B.18
Tumor Biology and
Immunosurveillance
Looking at the
"States and Fates of
T Cells"
Immune Modulation
by Infectious Agents
HIV Infection and
Immune Control
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
18:15 – 18:30
Closing and Award
Ceremony
18:30 – 18:45
18:45 – 19:00
19:00 – 19:15
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
20:00 – 20:15
20:15 – 20:30
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
34
Scientific Program
PROGRAM AT A GLANCE
Hall M
Hall N
Meeting Room 1
(1.85-86)
1
1
1
Meeting Room 2
(1.61)
Room
1
Level
ME.06
Mirjam Heemskerk
07:15 – 08:15
08:15 – 08:30
08:30 – 08:45
WS.C.14
NK and NKT Cell
Function
08:45 – 09:00
WS.D.11
Imaging & cancer
therapy
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
09:45 – 10:00
10:00 – 10:15
Poster Session and
Coffee Break
10:15 – 10:30
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
WS.A.13
Lymphocyte Subsets
(part 2)
WS.A.14
T Cell Mediated
Control of GC
Reactions
11:30 – 11:45
Meeting
IUIS The Importance of
Standardization for
Immunology
WO.01
11:45 – 12:00
12:00 – 12:15
12:15 – 12:30
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
13:15 – 13:30
Women in
Immunology
She is a genius
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
14:15 – 14:30
14:30 – 14:45
14:45 – 15:00
WS.E.02
Metabolism &
Immunity
15:00 – 15:15
WS.B.17
15:15 – 15:30
Immune
Dysregulation
15:30 – 15:45
15:45 – 16:00
16:00 – 16:15
WS.A.17
Extrinsic and Intrinsic
Control of Positive/
Negative T Cell
Selection
WS.A.18
Germinal
Centers: Survival
& Differentiation
Signals
BA.23.1
Österreichische
Gesellschaft für
Allergologie und
Immunologie (ÖGAI)
Board Meeting
(Vorstandssitzung)
16:15 – 16:30
16:30 – 16:45
16:45 – 17:00
17:00 – 17:15
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
18:15 – 18:30
18:30 – 18:45
18:45 – 19:00
19:00 – 19:15
BA.24
Österreichische
Gesellschaft für
Allergologie und
Immunologie (ÖGAI)
General Assembly
(Generalversammlung)
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
20:00 – 20:15
20:15 – 20:30
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
35
Scientific Program
HOW TO READ THE SCIENTIFIC PROGRAM
ECI 2015 CONTENT TRACKS
The scientific program of the ECI 2015 has been structured into four main tracks:
Track A – Adaptive Immunity
Track B – Diseases of the Immune System
Track C – Innate Immunity
Track D – Disease Intervention
Additionally a fifth track (Track E) combining topics which do not fit within the four main tracks was introduced. The 4-track
program will streamline keynote lectures, symposia, workshops as well as guided poster walks in a way that will promote easy
cross talk between the basic topics and types of sessions planned.
SESSION TYPE DESCRIPTION
Some sessions fill up quickly. Arrive early to guarantee your entry and avoid disappointment!
Invited Program
Keynote Lectures (KL.A.1 / KL.B.1 / KL.C.1 / KL.D.1)
The keynote lectures are the most prestigious sessions of the congress. These are exhaustive reviews of major subjects and
state of the art techniques within the field, addressed to all participants. Speakers in keynote lectures are invited and are
among the most renowned in their field of expertise.
Keynote lectures are scheduled at “prime time” in the program in order to achieve maximal attendance.
EFIS President`s Symposium (EP.01)
The EFIS President`s Symposium is a newly introduced format which will focus on the research area of the current EFIS president.
EFIS Awards Lectures (EF.01)
The work of the laureate of the EFIS/EJI Ita Askonas Award as well as the Acteria Prize winners (ACTERIA Doctoral Thesis Prizes
and ACTERIA Early Career Research Prizes) are presented within this session.
EFIS-IL Awards Poster Presentations (EFIS-IL.01-02)
The awards were established by the European Federation of Immunological Societies (EFIS) with general support from Immunology Letters, in order to recognize the most often cited original paper and review, respectively, within the first 3 years
after publication, published in Immunology Letters.
Symposia (S.A.01-06 / S.B.01-06 / S.C.01-06 / S.D.01-06)
The symposia are state-of the art educational sessions in which invited speakers share their newest results with other researchers on a given topic. The aim is to reflect and compare data with other perhaps contradictory results and to discuss new
hypotheses and concepts for further research with well-established colleagues.
In every concurrent symposium three 20+5-minute lectures will be presented that provide an update and understanding of
new developments and innovations in a certain research area.
Women in Immunology (WO.01)
Gender imbalance in science (and society) is a long-standing issue that has moved into the spotlight in the European Union
in recent years. This symposium highlights the historical perspective of exclusion of women in science and discusses the current situation of women in immunology. The symposium is supposed to increase visibility of women and their achievements
in science and especially within the field of immunology. A round table with all speakers and chairpersons will discuss the
most important points raised during the presentations, the most urgent goals and the most achievable goals as well as the
means to achieve these goals.
Scientific Writing Session (SW.01)
This session, which is dedicated primarily for PhD or MD students/early postdocs, will provide examples and tips of good
scientific writing.
36
Scientific Program
Joint Symposia (JS.01-09)
Joint symposia are sessions in which the ECI joins forces with important international scientific societies to facilitate knowledge
transfer and bring researchers from related disciplines and/or different continents together in order to foster exchange and
networking across all borders.
Joint society symposia consist of 3 speakers (30 minutes per talk) on a topic nominated by the partner society.
Meet the Professor Breakfasts (ME.01-06)
Informal breakfast event for early career scientists. The “Meet the Professor Breakfasts” will provide participants the opportunity
to meet the most renowned senior scientists in an interactive and casual manner.
Small breakfast will be provided. Registration is possible via email and onsite at a first-come-first-serve basis.
Maximum amount of participants per breakfast: 30
Submitted Program
Bright Sparks Workshops (BS.A.1 / BS.B.1 / BS.C.1 / BS.D.1)
The most notable and exciting work from abstracts submitted to the congress by early career scientists will be honored with
an oral presentation in one of the Bright Sparks Workshops. Presenters are expected to explain their work and answer questions from the audience.
Workshops (WS.A.01-18 / WS:B.01-20 / WS.C.01-15 / WS.D.01-13 / WS.E.01-02)
The most notable and exciting work from all abstracts submitted to the congress will be honored with an oral presentation in
these sessions. Presenters are expected to explain their work and answer questions from the audience.
Guided Poster Sessions (P.A.01-28 / P.B.01-42 / P.C.01-24 / P.D.01-27 / P.E.01-05)
Posters are numerically the major scientific presentations of the meeting. The majority of congress attendees present a poster
showing data and progress with their personal research. Posters offer an excellent opportunity for people interested in a
particular topic to meet and exchange ideas and network with other researchers. Posters should NOT be used to advertise
a product or service. Like a paper, a poster abstract should detail the focus of the presentation and the way(s) in which it
contributes to the body of knowledge in its field. Guided Poster Sessions (Monday, Tuesday and Wednesday from 09:45 to
11:15) will be chaired by ECI faculty members and senior researchers within the respective areas and should be used for
communication and interaction with the poster presenters, who are requested to be at their posters at these times.
Track A
Adaptive Immunity
Track B
Diseases
Track C
Innate Immunity
Track D
Track E
Other
Monday
P.A.01 - 10
P.B.01 - 14
P.C.01 - 08
P.D.01 - 10
P.E.01
Tuesday
P.A.11 - 19
P.B.15 - 28
P.C.09 - 16
P.D.11 - 18
P.E.02 - 03
Wednesday
P.A.20 - 28
P.B.29 - 42
P.C.17 - 24
P.D.19 - 27
P.E.04 - 05
The chairpersons of the guided poster sessions will also evaluate all posters and will select the candidates for the ECI 2015 Poster
Awards. Based on their evaluations a designated award jury will then select the awardees to receive the ECI 2015 Poster Awards.
Schedule for display, mounting and removal
Posters will be changed every day. Each poster will be on display during one of the following days:
Monday, September 7 08:30 – 18:00 hrs
Tuesday, September 8 08:30 – 18:00 hrs
Wednesday, September 9 08:30 – 16:00 hrs
Poster mounting on the respective days will be possible between 07:30 – 08:30 hrs strict.
Posters need to be removed on the day of presentation between 18:00 – 19:30 hrs strict (16:00 – 17:45 hrs on Wednesday).
Access after 19:30 hrs (17:45 hrs on Wednesday) is not possible! Posters not removed until 19:30 hrs on the day of presentation (17:45 hrs on Wednesday), will be taken down by the staff of the congress venue and will not be stored or sent to the
authors after the meeting.
All detailed information on the Guided Poster Sessions can be found in the separate poster information booklet.
37
Scientific Program
Sponsored Program
Industry Sponsored (Lunch) Symposia (IS.01-07)
Sponsors are approved as reputable and relevant by the Scientific Program Committee, but the detailed content of the presentations is proposed directly by the sponsors and under their responsibility. The organizers are not endorsing the content in any way.
Other Sessions and Meetings
Business and Ancillary Meetings (BA.01-24)
Business Meetings of scientific associations (e.g. general assemblies, board meetings) are generally meetings open to a designated group of individuals and are mostly on invitation only. Business meetings of scientific associations in conjunction with
the ECI 2015 can be held during the congress opening hours as preferred by the respective organizer(s).
Please note that all participants of business meetings must also be registered participants of the ECI 2015 as there will be a
centrally located access control.
Educational Courses / Scientific Satellite Meetings
The 4th European Congress of Immunology generally welcomes non-commercial educational courses and scientific satellites
around the ECI congress. Those are “open” meetings being of interest to the general ECI audience, going from a few hours
to 1-2 days, scheduled ahead or on and after the last day of the ECI congress.
Satellite meetings are organized by individuals and/or scientific associations and must conform to established criteria if they
are to be associated with the ECI 2015. Approval by the congress president and the president of the scientific program committee is required for a meeting to be granted satellite status.
HOW TO READ THE PRESENTATION NUMBERS
How to read the presentation numbers – for example: WS.B.02.5
WS.B.02.5: BS: EF: EP: IS: JS: KL: WS stands for one of the following session types (in alphabetical order):
Bright Sparks Workshop
EFIS Award Lecture
EFIS President’s Symposium
Industry Sponsored Symposium
Joint Symposium
Keynote Lecture
ME:
P: S: SW: WO: WS: Meet the Professor Breakfast
Guided Poster Walks
Symposia
Scientific Writing
Women in Immunology
Workshop
WS.B.02.5:B stands for one of the following tracks:
A:
B:
C:
D:
E: Adaptive Immunity
Diseases
Innate Immunity
Other Topics
WS.B.02.5:02 indicates the chronological order within the session type and track
WS.B.02.5: 5 indicates the chronological order of presentation within the respective session
OTHER MEETINGS:
BA: Business and Ancillary Meetings
ES: Educational Courses and Scientific Satellite Meetings
38
NEEDINFORMATIONONTHEECICONGRESS2015ATYOURFINGERTIPS?
THERE`SANAPPFORTHAT
Download the ECI 2015 app today and stay
up-to-date during the 2015 Congress
• Regularupdatestothescientificprogramme
• Practicalinformationaboutthevenue
• Findexhibitorseasily
• Download using the free WiFi in the Austria Center:
search your app store for “ECI 2015”
Scientific Program
RELATED PRE-CONGRESSIONAL EVENTS IN VIENNA
BEFORE THE START OF THE 4TH ECI CONGRESS
September 02 - 05, 2015
September 02, 2015
September 03, 2015
September 04, 2015
September 05, 2015
LUPUS 2015
September 02-06,2015
HOFBURG Vienna Congress Center
Heldenplatz, Vienna, Austria
European Veterinary Immunology Workshop
September 02-04, 2015
University of Veterinary Medicine (Vetmeduni Vienna),
Veterinaerplatz 1, 1210 Vienna
7. Wiener Komponentenschule
(Meeting Language = German)
Hotel Nestroy Wien, Rotensterngasse 10, 1020 Vienna
Scientific Satellite Meeting
Immunosenescence: Hot Topics
and Interventions
L2, Austria Center Vienna
BA.01
13:00 – 16:30
ABIRISK EPMT Meeting
Meeting Room 2 (1.61), ACV
CONGRESSES
September 02 - 06, 2015
LUPUS 2015
(Pre - Registration required)
HOFBURG Vienna Congress Center, Heldenplatz, Vienna
EDUCATIONAL COURSES &
SCIENTIFIC SATELLITE SYMPOSIA
September 02 - 04, 2015
European Veterinary Immunology Workshop
University of Veterinary Medicine (Vetmeduni Vienna),
Veterinaerplatz 1, 1210 Vienna
BUSINESS AND ANCILLARY MEETINGS
September 05, 2015
nnBA.01
ABIRISK EPMT Meeting
closed*
Meeting Room 2 (1.61)
13:00 – 16:30
* on invitation only
September 04 - 05, 2015
7. Wiener Komponentenschule /
7th Vienna School on Allgergy – Components
(Meeting Language = German)
Hotel Nestroy Wien, Rotensterngasse 10, 1020 Vienna
September 05 - 06, 2015
Immunosenescence: Hot Topics and Interventions
L2, Austria Center Vienna
40
SUNDAY
SUNDAY
Schedule at a Glance Sunday. . . . . . . . . . . . . . . . . . . . . . . . . 42
Opening Ceremony. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Keynote Lecture of the Day . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
“Emerging Immunology – Vienna’s Contribution” . . . . . . . . . 43
Educational Courses & Scientific Satellite Symposia . . . . . . . 44
Business and Ancillary Meetings. . . . . . . . . . . . . . . . . . . . . . . . 44
41
Program per Day
SUNDAY, SEPT. 6, 2015
SCHEDULE AT A GLANCE SUNDAY
SUNDAY
Room
Hall A
L2
L1
L8
Meeting Room 1
(1.85-86)
Meeting Room 2
(1.61)
Level
2
1
1
1
1
1
07:30 – 07:45
07:45 – 08:00
08:00 – 08:15
08:15 – 08:30
08:30 – 08:45
08:45 – 09:00
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
BA.02
09:45 – 10:00
IUIS Executive
Committee Meeting
10:00 – 10:15
10:15 – 10:30
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
11:45 – 12:00
12:00 – 12:15
Meeting
Educational Course
Immunosenescence:
Hot Topics and
Interventions - Day 2
Advanced
Cytometry Course
12:15 – 12:30
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
BA.04
ABIRISK Steering
Committee (SC)
Meeting
13:15 – 13:30
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
BA.05
14:15 – 14:30
German Society for
Immunology (DGfI)
Board Meeting
14:30 – 14:45
14:45 – 15:00
15:00 – 15:15
15:15 – 15:30
15:30 – 15:45
Meeting
ABIRISK - Immune
Reactions Against
Biopharmaceuticals
15:45 – 16:00
16:00 – 16:15
16:15 – 16:30
16:30 – 16:45
16:45 – 17:00
17:00 – 17:15
17:15 – 17:30
17:30 – 17:45
Opening Ceremony
17:45 – 18:00
18:00 – 18:15
KL.A.1
The B Cell Receptor in B
18:30 – 18:45 Cell Development, Memory
18:45 – 19:00 and Malignancies
19:00 – 19:15
Opening of Historic Exhibition “Emerging Immunology – Vienna’s Contribution”
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
20:00 – 20:15
20:15 – 20:30
Networking Mixer
20:30 – 20:45
20:45 – 21:00
21:00 – 22:00
42
Program per Day
SCHEDULE AT A GLANCE SUNDAY
OPENING CEREMONY
Meeting Room 5
(2.17)
Meeting Room 8
(1.62)
2
1
Room
Level
07:30 – 07:45
07:45 – 08:00
08:00 – 08:15
08:15 – 08:30
08:30 – 08:45
08:45 – 09:00
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
09:45 – 10:00
10:00 – 10:15
10:15 – 10:30
BA.03
10:30 – 10:45
SysmedIBD
Consortium Meeting
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
11:45 – 12:00
12:00 – 12:15
12:15 – 12:30
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
13:15 – 13:30
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
Meeting
Get to know
SysmedIBD
(EU-FP7 Project Systems Medicine
of Chronic
Inflammatory Bowel
Disease)
BA.06
14:15 – 14:30
British Society for
Immunology (BSI)
Programme
Committee Meeting
14:30 – 14:45
14:45 – 15:00
Ludwig van Beethoven (1770-1827)
Tempo di Menuetto quasi allegretto WoO 3
"Gratulations-Menuett"
Welcome message by the 4th ECI Congress President
Winfried F. Pickl
Franz Schubert (1797-1828)
Polonaise für Violine und Orchester D 580
Welcome message by the EFIS President
Lorenzo Moretta
Wolfgang Amadeus Mozart (1756-1791)
Sinfonie in D KV 385
"Haffner-Sinfonie"
I. Allegro con spirito
II. Andante
III. Menuetto
IV. Presto
Keynote Lecture
Klaus Rajewsky
The B cell receptor in B cell development,
memory and malignancies
Johann Strauß Vater (1804-1849)
Jubel-Quadrille op. 130
Music: Klangvereinigung Wien Orchestra
Conductor: Michael Zlabinger
After his studies in Vienna and Lucerne, the young Austrian
conductor Michael Zlabinger has been working at the
Salzburg Festival, Wiener Staatsoper, Opernhaus Zürich, Teatro
alla Scala di Milano and Grand Théatre de Genève.
He has conducted opera, ballet and symphonic repertoire
from baroque to the 21st century.
15:15 – 15:30
15:30 – 15:45
15:45 – 16:00
16:00 – 16:15
OPENING OF HISTORIC EXHIBITION
“EMERGING IMMUNOLOGY – VIENNA’S CONTRIBUTION”
16:30 – 16:45
19:00
16:45 – 17:00
Opening by: Lorenzo Moretta
17:00 – 17:15
In the presence of the curators: Johann Eibl, Othmar Förster
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
18:15 – 18:30
18:30 – 18:45
18:45 – 19:00
19:00 – 19:15
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
Networking Mixer
Hall A
15:00 – 15:15
16:15 – 16:30
17:00 – 18:00
SUNDAY
20:00 – 20:15
20:15 – 20:30
Level 0 / Main Foyer
Come and join us for the opening of the exhibition
“Emerging Immunology – Vienna’s Contribution”.
Vienna has been a cradle of immunology research at the end
of the 19th beginning of the 20th century.
Some of the outstanding Austrian immunologists - from Karl Landsteiner to Clemens von Pirquet including their colleagues and
contemporaries - will be commemorated in this exhibition, which
has been curated by Johann Eibl, Othmar Förster and Winfried
F. Pickl. Moreover, a short outlook describing major immunology
research centers in the Vienna area in the 21st century will be
provided.
20:30 – 20:45
20:45 – 21:00
21:00 – 22:00
43
Program per Day
Keynote Lecture of the Day - KL.A.1 – Innate Immunity
18:00 – 19:00
Chairperson:
Hall A
Winfried Pickl; Vienna, Austria
The B cell receptor in B cell development, memory and malignancies
SUNDAY
Klaus Rajewsky
Max-Delbrück-Center for Molecular Medicine Immune Regulation and Cancer; Berlin, Germany
Klaus Rajewsky and collaborators developed a general method of targeted mutagenesis in mouse embryonic
stem cells by introducing bacteriophage- and yeast-derived recombination systems, which opened the way
for conditional gene targeting. Using this and other methods in their immunological work, they developed,
together with N. A. Mitchison and N. K. Jerne, the antigen-bridge model of T-B cell cooperation, identified
germinal centers as the sites of antibody somatic hypermutation, the B cell antigen receptor as a survival
determinant of B cells, and the germinal center as a major site of human B cell lymphomagenesis, including Hodgkin lymphoma. Over the last years the work of his group has focused on mechanisms of microRNA
control and the development of mouse models of human B cell lymphomas.
Klaus Rajewsky obtained his degree in medicine (MD) at the University of Frankfurt in 1962. After postdoctoral
work at the Institut Pasteur in Paris he built an immunology department at the Institute for Genetics at the
University of Cologne where he stayed for 38 years, was the founding Program Coordinator of the EMBL
Mouse Biology Program at Monterotondo near Rome, worked for 10 years at Harvard Medical School in
Boston, and is since 2012 at the Max-Delbrück-Center for Molecular Medicine in Berlin.
Klaus Rajewsky won numerous scientific awards and is a member of several learned societies including the
National Academy of Sciences of the USA and the American Academy of Arts and Sciences.
nnBA.02
nnImmunosenescence: Hot Topics and Interventions
(Registration required)
L2
08:30 – 16:00 (Day 2)
nnABIRISK - Immune Reactions against
Biopharmaceuticals
L1
closed*
nnBA.03
Attendance is free of charge – no registration required!
15:30 – 16:30
closed*
nnAdvanced Cytometry Course
L8
nnBA.04
09.00 – 16.00
closed*
nnGet to know SysmedIBD
13:30 – 17:00
IUIS Executive Committee Meeting
nnBA.05
07:30 – 12:30
SysmedIBD Consortium Meeting
08:00 – 13:30
ABIRISK Steering Committee (SC) Meeting
Meeting Room 1 (1.85-86)
09:00 – 15:30
closed*
Board Meeting
nnBA.06
13:00 – 16:00
closed*
Programme Committee Meeting
13:00 – 16:30
44
MONDAY
MONDAY
Schedule at a Glance Monday . . . . . . . . . . . . . . . . . . . . . . . . 46
Overview per Track. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
Track A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
Track B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Track C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
Track D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
Joint-Symposia of the Day. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
Other Sessions and Meetings. . . . . . . . . . . . . . . . . . . . . . . . . . . 58
Meet the Professor Breakfast. . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Posters of the Day according to Tracks A, B, C, D, E . . . . . . . 60
45
Program per Day
MONDAY, SEPT. 7, 2015
SCHEDULE AT A GLANCE MONDAY
Room
Hall A
Hall E
Hall F1
Hall F2
Hall G
Hall K
Level
2
0
0
0
-2
-2
07:15 – 08:15
08:15 – 08:30
08:30 – 08:45
08:45 – 09:00
S.A.01
Adaptive Immunity
Protection by CD8
09:15 – 09:30 T Cells
09:00 – 09:15
S.B.01
Diseases
Chronic
Inflammation
BS.C.1
Bright Sparks
Breakthroughs in
Innate Immunity
WS.D.01
Immunosuppresive
Therapies and
Immunomodulation
WS.C.01
WS.C.02
Leukocyte Trafficking Innate Sensors
09:30 – 09:45
09:45 – 10:00
MONDAY
10:00 – 10:15
10:15 – 10:30
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
S.C.01
12:00 – 12:15 Mucosal Immunity
S.D.01
Vaccines
12:15 – 12:30
BS.B.1
Bright Sparks
Insights in
Immunological
Disease Mechanisms
WS.A.01
Control of CD8+ T
Cells (part 1)
WS.B.02
WS.B.01
Generation of
Allergen Specific
Immune Responses
Control of
Inflammation
in Autoimmune
Diseases
12:30 – 12:45
12:45 – 13:00
KL.C.1
Intestinal
13:15 – 13:30 Homeostasis and its
13:30 – 13:45 Breakdown
13:45 – 14:00
14:00 – 14:15
JS.01
14:15 – 14:30 American
Association of
Immunologists (AAI)
14:45 – 15:00 Molecular
Mechanisms of the
15:00 – 15:15 Immune Response to
15:15 – 15:30 Infection
14:30 – 14:45
JS.02
European League
Against Rheumatism
(EULAR)
Resolution of
Inflammation
EF.01
EFIS Awards Lecture
Symposium
(Industry Sponsored)* ACTERIA Prizes and
EFIS-EJI Ita Askonas
Prize
IS.01
15:30 – 15:45
15:45 – 16:00
16:00 – 16:15
S.A.02
Th17 Cells in Human
16:30 – 16:45 Health and Disease
S.B.02
Diseases
Allergy and Asthma
WS.C.05
BS.D.1
Bright Sparks
Immunotherapy
NK and NKT Cell
Activation and
Mechanisms
16:45 – 17:00
WS.D.02
Drug
Immunogenicity
and Biomarkers of
Efficacy
WS.C.06
WS.A.03
WS.B.05
17:00 – 17:15
Coffee Break
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
S.C.02
Mediators of
18:30 – 18:45 Inflammation
18:45 – 19:00
S.D.02
Immunological
Tolerance in Organ
Transplantation
BS.A.1
Bright Sparks
Adaptive Immunity
WS.B.04
Lymphocyte
Targeting Immune
Escape by Tumors
Molecular and
Cellular Control of
the Subsets
Local Tissue
Alteration in
Autoimmunity
19:00 – 19:15
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
20:00 – 20:15
SW.01
IS.04
(Industry Sponsored
Titles to Figure
Progress in
Legends: An Insider’s
Technology Session)*
Guide to Publishing
IS.03
20:15 – 20:30
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
46
Program per Day
SCHEDULE AT A GLANCE MONDAY
Hall M
Hall N
1
1
Meeting Room Meeting Room Meeting Room Meeting Room Meeting Room
1
2
3
5
6
(1.85-86)
(1.61)
(2.15)
(2.17)
(2.12)
1
1
2
2
2
ME.01
Room
Level
07:15 – 08:15
Peter Openshaw
08:15 – 08:30
08:30 – 08:45
WS.C.03
Myeloid
Suppressor Cells
08:45 – 09:00
WS.C.04
Dendritic Cells &
Macrophages
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
09:45 – 10:00
BA.07
European Journal
DGfI Study
of Immunology
Groups
Editorial Board and
Board Meeting
Alumni Meeting
BA.08
BA.09
Dutch Society
for Immunology
(NVVI)
Board Meeting
Scandinavian
Society for
Immunology (SSI)
Council Meeting
10:00 – 10:15
10:15 – 10:30
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
WS.A.02
Germinal
Centers:
Genetic and
Transcriptional
Control
11:15 – 11:30
WS.B.03
11:30 – 11:45
Clinics, Pathophysiology and
Genetics of Primary Immunodeficiency Diseases
11:45 – 12:00
12:00 – 12:15
BA.10.1
IUIS-Frontiers
Partnership
Meeting
12:15 – 12:30
BA.11
Scandinavian
Society for
Immunology (SSI)
Retreat Follow-up
Meeting
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
13:15 – 13:30
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
JS.03
14:15 – 14:30
Russian-GeorgianIS.02
Austrian Sister
(Industry
Symposium
Sponsored)*
From Magic Bullets
14:30 – 14:45
14:45 – 15:00
to Targeted Therapy
Approaches
15:00 – 15:15
15:15 – 15:30
15:30 – 15:45
WS.D.03
15:45 – 16:00
BA.12
WS.D.04
16:00 – 16:15
IUIS-EFIS Annual
Collaboration
Review Meeting
Immune
Preventive &
Dissection of Anti- Therapeutic
Viral Vaccines
Approaches
16:15 – 16:30
16:30 – 16:45
16:45 – 17:00
17:00 – 17:15
Coffee Break
BA.12.1
Italian Society
of Immunology,
Clinical
Immunology
and Allergology
(SIICA)
Board Meeting
BA.13
WS.A.04
Lymphocyte
Subsets (part 1)
WS.A.05
Extrinsic Factors
in the Control of
B Cells
Scandinavian
Journal of
Immunology
Editorial Board
Meeting
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
18:15 – 18:30
18:30 – 18:45
18:45 – 19:00
19:00 – 19:15
IS.05
(Industry
Sponsored)*
BA.14
Italian Society
of Immunology,
Clinical
Immunology and
Allergology (SIICA)
General Assembly
19:15 – 19:30
BA.15
19:30 – 19:45
Hungarian
19:45 – 20:00
Society for
Immunology (MIT) 20:00 – 20:15
Board Meeting
20:15 – 20:30
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
47
MONDAY
Poster Session and
Coffee Break
BA.10
Program per Day
OVERVIEW PER TRACK
Keynote Lecture of the Day - KL.C.1 – Innate Immunity
12:45 – 13:45
Chairperson:
Hall A
Lorenzo Moretta; Rome, Italy
Intestinal Homeostasis and its Breakdown
Fiona Powrie
Oxford, United Kingdom
MONDAY
Fiona Powrie is the Director of the Kennedy Institute of Rheumatology and Principal Investigator in the Translational Gastroenterology Unit, University of Oxford. Her research interests include characterisation of the
interaction between the intestinal microbiota and the host immune system and how this mutualistic relationship breaks down in inflammatory bowel disease. Her work has identified the functional role of regulatory T
cells in intestinal homeostasis and shed light on their development and mechanism of action. She has also
shown that both adaptive and innate immune mechanisms contribute to intestinal inflammation and identified the IL-23 pathway as a pivotal player in the pathogenesis of chronic intestinal inflammation. Her current
work seeks to translate findings from model systems into the clinic in inflammatory bowel disease patients.
Fiona Powrie received the Ita Askonas Award from the European Federation of Immunological Societies for
her contribution to immunology in Europe and the Louis Jeantet Prize for Medicine 2012. She was elected a
Fellow of the Royal Society in 2011, EMBO in 2013 and the Academy of Medical Sciences in 2014.
OVERVIEW PER TRACK
TRACK A – ADAPTIVE IMMUNITY
TRACK C – INNATE IMMUNITY
Symposia
S.A.01
Protection by CD8 T Cells
S.A.02
Th17 Cells in Human Health and Disease
Symposia
S.C.01
Mucosal Immunity
S.C.02
Mediators of Inflammation
BS.A.1
Bright Sparks Adaptive Immunity
BS.C.1
Bright Sparks - Breakthroughs in Innate Immunity
Workshops
WS.A.01
WS.A.02
WS.A.03
WS.A.04
WS.A.05
Workshops
WS.C.01
WS.C.02
WS.C.03
WS.C.04
WS.C.05
WS.C.06
Molecular & Cellular Control of CD8+ T Cells - Part 1
Germinal Centers: Genetic and Transcriptional Control
Molecular and Cellular Control of T Helper Cell Subsets
Lymphocyte subsets (part 1)
Extrinsic Factors in the Control of B Cells
TRACK B – DISEASES
Leukocyte Trafficking
Innate Sensors
Myeloid Suppressor Cells
Dendritic Cells & Macrophages
NK and NKT Cell Activation and Mechanisms
TRACK D – DISEASE INTERVENTION
Symposia
S.B.01
Chronic Inflammation
S.B.02
Allergy and Asthma
Symposia
S.D.01
Vaccines
S.D.02
Immunological Tolerance in Organ Transplantation
BS.B.1
Bright Sparks - Insights in Immunological Disease
Mechanisms
BS.D.1
Bright Sparks – Immunotherapy
Workshops
WS.B.01
Generation of Allergen Specific Immune Responses
WS.B.02
Control of Inflammation in Autoimmune Diseases
WS.B.03
Clinics, Pathophysiology and Genetics of Primary
Immunodeficiency Diseases
WS.B.04
Lymphocyte Targeting Immune Escape by Tumors
WS.B.05
Local Tissue Alteration in Autoimmunity
48
Workshops
WS.D.01
WS.D.02
WS.D.03
WS.D.04
Immunosuppresive Therapies and Immunomodulation
Drug Immunogenicity and Biomarkers of Efficacy
Immune Dissection of Anti-Viral Vaccines
Preventive & Therapeutic Approaches
Program per Day
Track A
TRACK A
BS.A.1.6 The discovery of intra‑sensory signalling in human
T lymphocytes
Alessio Lanna, A. Akbar; London, United Kingdom
Symposia
Workshops
Protection by CD8 T Cells
Hall A
08:30 -09:45
nnWS.A.01
Chairpersons: Vincenco Barnaba; Rome, Italy
Dietmar Zehn; Lausanne, Switzerland
Disparate individual CD8 T cell fates determine robust
immune protection
Dirk H. Busch; Munich, Germany
S.A.01.2 What T cells see on human cancer
Ton N. Schumacher; Amsterdam, Netherlands
S.A.01.3 The impact of macroautophagy on CD8
T cell‑mediated antiviral immunity
Matthew Albert; Paris, France
Th17 Cells in Human Health
and Disease
Hall A
15:45 – 17:00
Chairpersons: Michael Lohoff; Marburg, Germany
Maha Ayyoub; Villejuif, France
High‑salt diet and Th17 responses
David Hafler; New Haven, United States
S.A.02.2 Pathogen‑driven Th17 cells
Federica Sallusto; Bellinzona, Switzerland
S.A.02.3 Regulation of IL‑17 producing T cells in human
inflammatory disease
Leonie S. Taams; London, United Kingdom
Bright Sparks - Adaptive Immunity
Hall F1
17:45 – 19:00
Chairpersons: Rita Carsetti; Rome, Italy
Ari Waisman; Mainz, Germany
BS.A.1.2 BS.A.1.3
WS.A.01.1 A dominant role for Suv39h1 in heterochromatin
organization and gene expression programs
of short‑lived effector CD8+ T cells
Luigia Pace, J. Quivy, C. Goudot, E. Zueva, M. San
Roman, M. Maurin, G. Almouzni, S. Amigorena; Paris,
France
WS.A.01.2 CD8 T cell exhaustion is regulated by Dnmt3a
mediated de novo DNA methylation programming
Benjamin A. Youngblood, S. Hale, E. Ahn, H. Ghoniem,
H. Abdelsamed, S. Im, R. Ahmed; Memphis, United
States
WS.A.01.4 Tuning the functional avidity of virus‑specific CD8+
T cells
Jovana Cupovic, L. Staerck, V. Nindl, T. Luzyanina,
W. Uckert, G. Bocharov, B. Ludewig; St. Gallen,
Switzerland
BS.A.1.1 Chairpersons: Yvonne Samstag; Heidelberg, Germany
Matthew Albert; Paris, France
WS.A.01.3 T cell specific deletion of STAT1 mediates a protective
effect against Listeria monocytogenes infection
Roland Tschismarov, M. Aichinger, P. Shukla, C. Vogl,
M. Müller, T. Decker; Vienna, Austria
S.A.02.1 nnBS.A.1
Hall F2
11:15 – 12:30
S.A.01.1 nnS.A.02
Molecular & Cellular Control
of CD8+ T Cells - Part 1
T cell lipid peroxidation induces ferroptosis and
prevents immunity to infection
Mai Matsushita, S.B. Freigang, C. Schneider,
M. Conrad, G.W. Bornkamm, M. Kopf; Zurich,
Switzerland
Impact of a gain‑of‑function mutation of CXCR4 on
the germinal centre reaction and humoral immunity
V. Biajoux, J. Natt, C. Freitas, A. Sacquin, P. Hémon,
F. Gaudin, N. Fazilleau, Marion Espeli, K. Balabanian;
Clamart, France
Liver‑resident regulatory T cells
Ann‑Cathrin Hofer, A. Menevse, A. Schnell,
M. Delacher, D. Richards, A. Breiling, P. Angel, M. Essers,
U. Klingmüller, M. Feuerer; Heidelberg, Germany
WS.A.01.5 Human CD8+ lung resident memory T‑cells: different
populations with unique identities exhibit a controlled
state of alert
Pleun Hombrink, R.A. Backer, B. Piet, D. Amsen,
P.D. Moerland, R.A. van Lier; Amsterdam, Netherlands
WS.A.01.6 Novel targets of CTLA‑4‑mediated signaling in
differentiating CD8+ T lymphocytes
Holger Lingel, J. Wissing, A. Arra, F. Klawonn, M. Pierau,
L. Jänsch, M. Brunner‑Weinzierl; Magdeburg, Germany
nnWS.A.02
Germinal Centers:
Genetic and Transcriptional Control
Hall M
11:15 – 12:30
Chairpersons: Marta Rizzi; Freiburg, Germany
Thomas Grundström; Umea, Sweden
WS.A.02.1 Regulation of immunoglobulin diversification
by checkpoint signalling
S. Frankenberger, K. Davari, K. Braunschmidt,
K. Böttcher, Berit Jungnickel; Jena, Germany
BS.A.1.4 miR‑148a controls plasma cell differentiation and
survival
Katharina Pracht, J. Schmid, J. Côrte‑Real, P. Daum,
M. Porstner, J. Wittmann, H. Jäck; Erlangen, Germany
WS.A.02.2 Mediator facilitates transcriptional activation and
dynamic long‑range contacts at the IgH locus during
class switch recombination
Anne‑Sophie Thomas‑Claudepierre, E. Schiavo,
P.P. Rocha, R. Raviram, L. Gaudot, V. Heyer, J.K. Reddy,
T. Borggrefe, J.A. Skok, B. Reina‑San‑Martin; Illkirch,
France
BS.A.1.5 Role of the TCR in the development and function of
antigen‑specific Tregs
Ellen Hilgenberg, E. Kieback, U. Stervbo,
V. Lampropoulou, W. Uckert, S. Fillatreau; Berlin,
Germany
WS.A.02.3 Regulated localisation of a mutagenic protein
complex at the Igh locus during antibody
diversification
J. Hauser, C. Grundström, R. Kumar, A. Kumar,
T. Ahmed, Thomas Grundström; Umeå, Sweden
49
MONDAY
nnS.A.01
Program per Day
Track A
WS.A.02.4 Ig genes somatic mutation is spatially controlled
by IgH Eµ‑matrix attachment regions
Sandrine Le Noir, M. Marquet, A. Garot, S. Bender,
O. Martin, P. Rouaud, C. Carrion, J. Aldigier, Y. Denizot,
M. Cogné, C. Francastel, E. Pinaud; Limoges, France
WS.A.02.5 The role of KLF2 and KLF4 in generation, homing and
survival of plasma cells in vitro and in vivo
A. Wallrapp, R. Winkelmann, H. Jäck, Wolfgang Schuh;
Erlangen, Germany
WS.A.04.4 Myeloid derived suppressor cells inhibit cytotoxic
T cell immune responses during acute retroviral
infection.
Malgorzata Drabczyk, T. Werner, U. Dittmer,
G. Zelinskyy; Essen, Germany
WS.A.02.6 The ontogeny of human IgE‑expressing B cells and
plasma cells
Faruk Ramdani, H. Bowen, N. Upton, B. Sutton, D. Fear,
H. Gould; London, United Kingdom
WS.A.04.5 Thalidomide analogs implicate a novel pathway of
immune regulation
P.K. Epling‑Burnette, M.S. Beatty,
Rebecca L. Swearingen; Tampa, United States
nnWS.A.03
Molecular and Cellular Control
of T Helper Cell Subsets
Hall G
17:45 – 19:00
MONDAY
WS.A.04.3 Regulation of virus‑specific CD8 T cell responses by
galectin‑3
Sharvan Sehrawat, H. Ploegh, G. Fink; Mohali Punjab,
India
Chairpersons: Jochen Huehn; Braunschweig, Germany
Lucy S. Walker; London, United Kingdom
WS.A.03.1 Foxo1 is a T‑cell intrinsic inhibitor of the RORgt‑Th17
program
Alexandra Lainé, B. Martin, M. Luka, L. Mir, C. Auffray,
B. Lucas, G. Bismuth, C. Charvet; Paris, France
WS.A.03.2 Role of CD43 in mediating T helper type 17 cell
recruitment in inflammation and autoimmunity.
Francisco E. Velázquez, A. Grodecki, A. Salvador,
A. Knapp, T. Nevers, P. Alcaide; Boston, United States
WS.A.03.3 Klf4 expression in conventional dendritic cells is
required for T helper 2 cell responses
R. Tussiwand, Bart Everts, G.E. Grajales‑Reyes,
E.J. Pearce, K.M. Murphy; Basel, Switzerland
WS.A.03.4 RNA‑binding protein HuR regulates CD4+ Th2
differentiation and IL‑2 homeostasis and is required for
allergic airway inflammation
Ulus Atasoy, P. Techasintana, J. Magee, M. Gubin,
J. Glascock; Columbia, United States
WS.A.03.5 Liver sinusoidal endothelial cells induce
immunosuppressive IL‑10‑producing Th1 cells via the
Notch pathway
Katrin Neumann, C. Rudolph, C. Neumann, M. Janke,
D. Amsen, A. Scheffold; Hamburg, Germany
WS.A.03.6 The activating receptor NKG2D regulates IL‑10
expression in Th1 cells
Marina Babic Cac, Q. Hammer, B. Polic, A. Radbruch,
C. Romagnani; Berlin, Germany
nnWS.A.04
Lymphocyte Subsets - Part 1
Hall M
17:45 – 19:00
Chairpersons: Sylvain Cardinaud; Creteil, France
Guy Gorochov; Paris, France
WS.A.04.1 Functional characterization of different IgG
glycosylation variants
Daniela Kao, F. Nimmerjahn; Erlangen, Germany
WS.A.04.6 HIV‑1 antisense protein (ASP) is a novel CD8+ T cell
target
Anne Bet, E. Maze, A. Bansal, S. Graff‑Dubois,
I. Theodorou, J. Mesnard, A. Moris, P. Goepfert,
S. Cardinaud; Paris, France
nnWS.A.05
Extrinsic Factors in the Control
of B Cells
Hall N
17:45 – 19:00
Chairpersons: Marta E. Alarcon‑Riquelme; Granada, Spain
Lars Nitschke; Erlangen, Germany
WS.A.05.1 BANK1 controls TLR7 signaling in B cells
Y. Wu, R. Kumar, I. Georg, R. Iida, H. Bagavant,
M. Morell‑Hita, Marta E. Alarcon‑Riquelme; Granada,
Spain
WS.A.05.2 Bacterial suspension activates B cell differentiation
and IL‑10 production via Toll‑Like Receptor‑2
recognition
Alberto Salazar, A. Castillo‑Albarran, J. Nieto,
J. Galicia‑Carreon, M.C. Jimenez‑Martinez; Mexico
City, Mexico
WS.A.05.3 Regulation of B cell immunity by interferons
Barbara C. Mindt, C.U. Dürr, J.H. Fritz; Montreal,
Canada
WS.A.05.4 Optimal T cell activation and B cell antibody
responses in vivo require the interaction between
LFA‑1 and kindlin‑3
V.L. Morrison, Liisa M. Uotila, M. Llort Asens, T. Savinko,
S.C. Fagerholm; Helsinki, Finland
WS.A.05.5 TLR4‑ and IFNγR‑signaling drive hematopoietic stem
cell expansion and common lymphoid progenitor
depletion in a model of chronic endotoxemia
A. Liu, Y. Wang, N. Scharping, Y. Ding, I. Baez, K. Payne,
Lisa Borghesi; Pittsburgh, United States
WS.A.05.6 Impact of intestinal immune induction on
compartmentalized IgA production in submandibular/
sublingual salivary glands
Per Brandtzaeg, A. Aase, H. Sommerfelt, M. Bolstad,
R.J. Cox, N. Langeland, A.B. Guttormsen, H. Steinsland,
S. Skrede, L.B. Petersen; Oslo, Norway
WS.A.04.2 Cbl‑interacting protein of 85 kDa (CIN85) controls
B cell activation by multimerization of intracellular
signaling proteins
Julius Kühn, S. Pirkuliyeva, L. Wong, S. Becker,
C. Griesinger, J. Wienands; Göttingen, Germany
50
Program per Day
Track B
TRACK B
BS.B.1.5
Exostosin‑like glycosyl transferase 3 (EXTL3) gene
mutation causes a novel form of immuno‑osseous
dysplasia and unveils a critical role of heparan sulfate
in thymopoiesis
Stefano Volpi, D. Likun, E. Van Rooijen, A. Hayashaida,
k. Felgentreff, K. Capuder, A. Ohno, M. Di Rocco,
S. Giliani, E. Hagedorn, P. Poliani, L. Imberti,
K. Dobbs, F. Poulain, P. Park, L. Zon, A. Superti‑Furga,
L. Notarangelo; Boston, United States
BS.B.1.6
Neutrophils regulate Th2 inflammation by controlling
monocyte and dendritic cell development in a murine
model of allergic airway disease
Dhiren F. Patel, S. Akthar, T. Peiró, S.A. Walker,
L.G. Gregory, C.M. Lloyd, R.J. Snelgrove; London,
United Kingdom
Symposia
Chronic Inflammation
Hall E
08:30 – 09:45
Chairpersons: Anna Erdei; Budapest, Hungary
Hans Lassmann; Vienna, Austria
S.B.01.1 The many faces of multiple sclerosis
Hans Lassmann; Vienna, Austria
S.B.01.2
Chronic gut inflammation
Nadine Cerf‑Bensussan; Paris, France
S.B.01.3
Postranslational modifications of autoantigens
Lars Klareskog; Stockholm, Sweden
nnS.B.02
Allergy and Asthma
Workshops
Hall E
15:45 – 17:00
Chairpersons: Peter Korosec; Golnik, Slovenia
Revaz Sepiashvili; Moscow, Russian Federation
S.B.02.1
Environmental factors for the development of the
allergic immune response early in life
Erika von Mutius; Munich, Germany
S.B.02.2 How viruses trigger asthma
Peter Openshaw; London, United Kingdom
S.B.02.3
Novel allergy vaccines
Rudolf Valenta; Vienna, Austria
nnBS.B.1
Bright Sparks - Insights in Immunological
Disease Mechanisms
Hall F1
11:15 – 12:30
Chairpersons: Georges Coukos; Lausanne, Switzerland
Reinhold Schmidt; Hannover, Germany
BS.B.1.1 Apics deficiency reveals a role for lncRNA in dendritic
cell function and autoimmune disease
Edward P. Chu, M.P. Ashton, C.M. Elso, L. Mackin,
S.L. Ford, N.L. Payne, M.A. Alsayb, H.E. Thomas,
S.I. Mannering, T.W. Kay, A.T. Papenfuss, R.A. Kitching,
C.C. Bernard, G. Morahan, K. Shortman, M. O’Keeffe,
T.C. Brodnicki; Fitzroy, Victoria, Australia
BS.B.1.2
Accumulation of tolerogenic human 6‑sulfo LacNAc+
dendritic cells in renal cell carcinoma is associated
with poor prognosis
Rebekka Wehner, M. Toma, A. Kloß, S. Füssel, B. Seliger,
E. Noessner, K. Schäkel, M. Wirth, G. Baretton,
M. Schmitz; Dresden University of Technology, Dresden,
Germany
BS.B.1.3
The DH/PH domain of BCR‑ABL mediates iNKT cells
immunosubversion in chronic myeloid leukemia by
downregulating CD1d cell‑surface expression in
myeloid dendritic cells
Sara BASBOUS, A. Levescot, N. Piccirilli, C. Giraud,
L. Roy, F. Guilhot, N. Bourmeyster, A. Herbelin,
J. Gombert; Poitiers, France
BS.B.1.4
Concomitant Ezh1/2 inactivation, but not Ezh2 alone,
impairs growth of c‑MYC driven B‑cell lymphomas
Valentina Petrocelli, G. Varano, J. Jin, S. Casola; Milan,
Italy
nnWS.B.01
Generation of Allergen Specific
Immune Responses
Hall G
11:15 – 12:30
Chairpersons: Barbara Bohle; Vienna, Austria
Philippe Moingeon; Antony, France
WS.B.01.1 Massively expanded Foxp3+ regulatory T cells
directed against airborne antigens display
non‑overlapping target specificity with Th2 cells
Petra Bacher, O. Kniemeyer, A. Schönbrunn,
N. Koester‑Eiserfunke, B. Sawitzki, M. Assenmacher,
E. Rietschel, A. Steinbach, O. Cornely, C. Schwarz,
M. Worm, A. Brakhage, A. Thiel, A. Scheffold; Berlin,
Germany
WS.B.01.2 Tolerogenic dendritic cells generated by
activin‑A‑induced regulatory T cells protect against
allergic asthma through the instruction of Foxp3+
regulatory T cells
Maria Semitekolou, I. Morianos, T. Sparwasser,
G. Xanthou; Athens, Greece
WS.B.01.3 T cell‑derived exosomes suppress casein‑induced
delayed‑type hypersensitivity reaction in mice
Krzysztof Bryniarski, M. Santocki, K. Nazimek, M. Ptak,
W. Ptak; Krakow, Poland
WS.B.01.4 Perinatal exposure to galactooligosaccharides/inulin
prebiotics prevent food allergy by protecting intestine
and promoting tolerance.
Laure Castan, G. Bouchaud, J. Chabauty, P. Aubert,
M. Neunlist, A. Magnan, M. Bodinier; Nantes, France
WS.B.01.5 The effect of early postnatal colonisation of newborns
by probiotic vaccine Colinfant New Born on allergy
incidence and Tregs
Jiri Hrdy, O. Novotna, K. Vlachynska, L. Prokesova;
Prague, Czech Republic
WS.B.01.6 The environment alters allergenicity of ragweed pollen
Shu‑Hua Liu, M. Debiasi, C.B. Anea, G. Karrer,
A. Bellaire, P. Chaturvedi, W. Weckwerth, M.M. Epstein;
Vienna, Austria
51
MONDAY
nnS.B.01
Program per Day
Track B
nnWS.B.02
Control of Inflammation
in Autoimmune Diseases
Hall K
11:15 – 12:30
Chairpersons: Clemens Scheinecker; Vienna, Austria
Vivianne Malmström; Stockholm, Sweden
MONDAY
WS.B.02.1 Transient ablation of Foxp3+ regulatory T cells
unleashes overt diabetes in the NOD model of human
type 1 diabetes
Deepika Watts, M. Janßen, A. Hommel, T. Sparwasser,
S. Schallenberg, E. Bonifacio, K. Kretschmer; Dresden,
Germany
WS.B.02.2 Novel B cell‑derived peptide regulation of
homeostatic T‑cell trafficking is subverted in
rheumatoid arthritis.
Helen M. McGettrick, M. Chimen, A. Martin, F. Barone,
L. Walker, A. Filer, K. Raza, C.D. Buckley, P. Narendran,
G. Rainger; Birmingham, United Kingdom
WS.B.02.3 Cutaneous 4‑1BB/4‑1BBL signaling is crucially involved
in the induction of itch and inflammation
Kristian Holz, V. Kupas, C. Baumann, L. Klenner,
N. Sucker, M. Schneeweiß, M. Maurer, S. Beissert,
T. Luger, S. Ständer, K. Loser; Muenster, Germany
WS.B.02.4 Regulatory CD19+CD24hiCD38hi B cells are decreased
in patients with atherosclerosis and have impaired
interleukin‑10 production
Ingrid E. Dumitriu, P. Baruah, S. Dinkla, J.C. Kaski;
London, United Kingdom
WS.B.02.5 Relevance of the aryl hydrocarbon receptor in the
disease progression of murine and human systemic
lupus erythematosus
Christoph Baumann, E. Hesse, K. Holz, L. Klenner,
N. Sucker, M. Schneeweiß, A. Jacobi, C. Esser,
T.A. Luger, K. Loser; Münster, Germany
WS.B.02.6 Multiple sclerosis‑associated genetic variants of
CD226 impair regulatory T cell function
Anne Willing, M. Piédavent‑Salomon, J.B. Engler,
K. Steinbach, S. Bauer, B. Eggert, F. Ufer, N. Kursawe,
S. Wehrmann, J. Jäger, S. Reinhardt, M.A. Friese;
Hamburg, Germany
nnWS.B.03
Clinics, Pathophysiology and Genetics of
Primary Immunodeficiency Diseases Hall N
11:15 – 12:30
Chairpersons: Ellen Renner; Munich, Germany
Mirjam van der Burg; Rotterdam, Netherlands
WS.B.03.1 Cytidine triphosphate synthase 1 deficiency in humans
reveals its central role in lymphocyte proliferation
Emmanuel Martin, N. Palmic, S. Sanquer, C. Lenoir,
F. Hauck, C. Mongellaz, S. Fabrega, P. Nitschké,
C. Picard, A. Fischer, P. Arkwright, S. Latour; Paris,
France
WS.B.03.2 A novel primary immunodeficiency disorder with
multiple defects of the lymphoid system caused
by biallelic loss‑of‑function mutation in the NF‑κB
inducing kinase NIK
Katharina L. Willmann, S. Klaver, F. Doğu,
E. Santos‑Valente, W. Garncarz, I. Bilic, E. Mace,
E. Salzer, C. Domínguez Conde, H. Sic, P. Májek,
P.P. Banerjee, G.I. Vladimer, S. Haskoloğlu,
M.G. Bolkent, A. Küpesiz, A. Condino‑Neto, J. Colinge,
G. Superti‑Furga, W.F. Pickl, M.C. van Zelm, H. Eibel,
J.S. Orange, A. Ikincioğulları, K. Boztuğ; Vienna, Austria
52
WS.B.03.3 Human DOCK2 mutations underlie a novel, pleiotropic
immunodeficiency syndrome with early onset,
invasive infections
Cecilia Domínguez Conde*, K. Dobbs*, S. Zhang*,
S. Parolini*, M. Audry, J. Chou, E. Haapaniemi, S. Keles,
I. Bilic, M.J. Massaad, S. Rounioja, N.K. Serwas, C. Bock,
T. Chatila, A. Comeau, R.S. Geha, L. Abel, R.H. Buckley,
A. Ikincioğullari, W. Al‑Herz, M. Helminen, F. Doğu,
J. Casanova, L.D. Notarangelo, K. Boztug; Vienna,
Austria
WS.B.03.4 Different STAT1 gain‑of‑function mutations give rise to
different clinical presentations: from isolated chronic
mucocutaneos candidiasis to a complex combined
immunodeficiency
Laura Martinez‑Martinez, M. Lozano‑Rabella,
M. Rubiales, M. Barnadas, I. Badell,
C. Rodriguez‑Gallego, O. de la Calle‑Martin;
Barcelona, Spain
WS.B.03.5 Investigation of ASXL1 mutations in GATA2 deficient
individuals
Rachel E. Dickinson, Y. Li, S. Pagan, V. Bigley, M. Collin;
Newcastle upon Tyne, United Kingdom
WS.B.03.6 CD21 and CD19 deficiency: two defects in the same
complex leading to different disease modalities
Marjolein W. Wentink, L.J. Annechien, M.C. van Zelm,
E. Simons, J.J. van Dongen, H. IJspeert, E.H. Schölvinck,
M. van der Burg; Rotterdam, Netherlands
nnWS.B.04
Lymphocyte Targeting Immune
Escape by Tumors
Hall F2
17:45 – 19:00
Chairpersons: Ignacio J. Melero; Pamplona, Spain
Mirjam H.M. Heemskerk; Utrecht, Netherlands
WS.B.04.1 Tumor‑associated B cells induce therapy resistance of
melanoma
Stephan N. Wagner, R. Somasundaram, G. Zhang,
M. Perego, M. Fukunaga‑Kalabris, K. Garg, M. Maurer,
M. Herlyn; Vienna, Austria
WS.B.04.2 Intra‑tumor CD4+CD8+ double positive T cells:
a new target for IL‑9
Tiphaine Parrot, M. Allard, R. Oger, H. Benlalam,
D. Raingeard de la Blétière, L. Pressier, J. Desfrançois,
A. Khammari, B. Dréno, N. Labarrière, Y. Delneste,
P. Guardiola, N. Gervois; Nantes, France
WS.B.04.3 The impact of secondary iTreg clones in the TCR
repertoire of tumor patients.
Maria Xydia, E. Ruggiero, S. Mastitskaya, N. Halama,
M. Schmidt, C. von Kalle, P. Beckhove; Heidelberg,
Germany
WS.B.04.4 Multiple co‑inhibitory pathways contribute to
dysfunctionality of intra‑tumoral T cells in liver cancer
Guoying Zhou, D. Sprengers, P.P. Boor, W. Polak, J. de
Jonge, J.N. IJzermans, D. Grünhagen, C. Verhoef,
M. Doukas, M.J. Bruno, J. Kwekkeboom; Rotterdam,
Netherlands
WS.B.04.5 Dissecting early mechanisms of melanoma cell
resistance to cytotoxic T lymphocyte attack
Roxana Khazen, S. Muller, M. Puisségur, S. Valitutti;
Toulouse, France
Program per Day
Track C
nnWS.B.05
Local Tissue Alteration
in Autoimmunity
Hall K
TRACK C
Symposia
nnS.C.01
Mucosal Immunity
Hall A
11:15 – 12:30
Chairpersons: Andrea Cerutti; Barcelona, Spain
Per Brandtzaeg; Oslo, Norway
S.C.01.1
Microbiota and gut immunity
Andrew J. MacPherson; Bern, Switzerland
Chairpersons: Thomas Weichhart; Vienna, Austria
Albert Zlotnik; Irvine, United States
S.C.01.2
Adaptive humoral immunity repertoire
Oliver Pabst; Aachen, Germany
WS.B.05.1 Islet‑intrinsic susceptibility to apoptosis and
senescence in non‑obese diabetic mice
Susann Schonefeldt, L. Tian, J. Dooley, E.J. Carr,
J.E. Garcia‑Perez, J. Vandenbussche, J. Allemeersch,
D. Franckaert, V. Delghingaro‑Augusto, K. Gevaert,
P.A. Jeggo, C. Mathieu, A.M. Jetten, M.A. Linterman,
C.C. Goodnow, C.J. Nolan, S. Lesage, S.M. Schlenner,
A. Liston; Leuven, Belgium
S.C.01.3 Mucosal dendritic cells in immunity and inflammation
Maria Rescigno; Milan, Italy
WS.B.05.2 S100A8 and S100A9 proteins are expressed but
dispensable in the pathogenesis of experimental
epidermolysis bullosa acquisita and bullous
pemphigoid
Reza Akbarzadeh, X. Yu, T. Vogl, R.J. Ludwig,
D. Zillikens, F. Petersen; Borstel, Germany
S.C.02.1 Cytokine regulation of humoral innate immunity
Alberto Mantovani; Rozzano, Italy
S.C.02.2
TIR domains in mediation of MyD88‑dependent
signaling in innate immunity
Roman Jerala, M. Avbelj, M. Benčina, O. Fekonja,
G. Panter; Ljubljana, Slovenia
S.C.02.3
Complement
Claudia Kemper; London, United Kingdom
17:45 – 19:00
WS.B.05.3 Inflammasome activity is essential for one kidney/
deoxycorticosterone acetate/salt‑induced
hypertension in mice
Shalini M. Krishnan, J.K. Dowling, Y.H. Ling, H. Diep,
C.T. Chan, D. Ferens, M.K. Kett, A. Pinar, C.S. Samuel,
A. Vinh, T. Arumugam, T.D. Hewitson, B.K. Kemp‑Harper,
A.B. Robertson, M. Cooper, E. Latz, A. Mansell,
C.G. Sobey, G.R. Drummond; Clayton, Australia
WS.B.05.4 The chemokine platelet factor‑4 variant (PF‑4var)/
CXCL4L1 antagonizes vascular endothelial growth
factor functions and inhibits diabetes‑induced
blood‑retinal barrier breakdown
Sofie Struyf, G. Mohammad, M.I. Nawaz, K. Van
Raemdonck, G. De Hertogh, J. Van Damme,
A.M. El‑Asrar; Leuven, Belgium
WS.B.05.5 Identification of CXCR8, the new chemokine receptor
for the critical macrophage chemotactic factor
CXCL17
Amanda Burkhardt, J. Maravillas‑Montero, P. Hevezi,
C. Carnevale, M.J. Smit, A. Zlotnik; Irvine, United States
nnS.C.02
Hall A
17:45 – 19:00
Chairpersons: Thomas Decker; Vienna, Austria
Christian Bogdan; Erlangen, Germany
nnBS.C.1
Bright Sparks Breakthroughs in Innate Immunity
Hall F1
08:30 – 09:45
Chairpersons: Luke O’Neill; Dublin, Ireland
Angela Santoni; Rome, Italy
BS.C.1.1 Tick salivary Sialostatin L represses the initiation of
immune responses by targeting IRF4‑dependent
transcription in murine mast cells
Till‑Julius Brühl, M. Klein, S. Reuter, T. Bohn, N. Stergiou,
S. Dietzen, A. Ulges, M. Hoffmann, V. Staudt, T. Hain,
M. Kotsyfakis, E. Schmitt, T. Bopp; Mainz, Germany
BS.C.1.2
Identification of subset‑specific dendritic cell
progenitors reveals early lineage‑priming in the bone
marrow
Andreas Schlitzer, S. V, J. Chen, H. Rizal Bin Sumatoh,
J. Schreuder, J. Lum, B. Malleret, S. Zhang, A. Larbi,
F. Zolezzi, L. Renia, M. Poidinger, S. Naik, E. Newell,
P. Robson, F. Ginhoux; Bonn, Germany
BS.C.1.3
PTX3 is an extrinsic oncosuppressor regulating
complement‑dependent inflammation in cancer
Eduardo Bonavita, E. Magrini, S. Gentile, M. Rubino,
V. Maina, R. Papait, P. Kunderfranco, C. Greco,
F. Feruglio, M. Molgora, I. Laface, S. Tartari, A. Doni,
F. Pasqualini, E. Barbati, M.R. Galdiero, G. Basso,
M. Nebuloni, M. Roncalli, P. Colombo, L. Laghi,
J.D. Lambris, S. Jaillon, C. Garlanda, A. Mantovani;
Rozzano, Italy
WS.B.05.6 Effect of maternal AQP4‑IgG antibody transfer in
neuromyelitis optica pregnancies
Simone Mader, L. Brimberg, J.M. Crawford, A. Bonnin,
J.L. Bennett, P. Huerta, B.T. Volpe, B. Diamond;
Manhasset, United States
Mediators of Inflammation
53
MONDAY
WS.B.04.6 Hypoxia‑induced soluble CD137 in malignant cells
blocks CD137L‑costimulation as an immune escape
mechanism
Sara Labiano, A. Palazon, E. Bolaños, A. Azpilikueta,
A. Morales‑Kastresana, A.R. Sanchez‑Paulete,
J.I. Quetglas, J.L. Perez‑Gracia, A. Gurpide,
M. Rodriguez‑Ruiz, M.A. Aznar, M. Jure‑Kunkel,
P. Berraondo, I. Melero; Pamplona, Spain
Program per Day
Track C
BS.C.1.4
Humanized mouse model of mast cell‑mediated
passive cutaneous anaphylaxis and passive systemic
anaphylaxis
Laurie L. Kenney, P.J. Bryce, R. Falahati, C. Bebbington,
N. Tomasevic, L.D. Shultz, D.L. Greiner, M.A. Brehm;
Worcester, United States
BS.C.1.5
The role of Interleukin‑27 in regulation of type 2 innate
lymphoid cells
Tamar Mchedlidze, M. Kindermann, D. Voehringer,
M. Neurath, S. Wirtz; Erlangen, Germany
BS.C.1.6
Regulation of MHC class I endocytosis by the
macroautophagy machinery
Monica Loi, M. Gannagé, A. Lippmann, A. Becker,
J. Dengjel, C. Münz; Zurich, Switzerland
MONDAY
Workshops
nnWS.C.01
Leukocyte Trafficking
Hall G
08:30 – 09:45
Chairpersons: Ronen Alon; Rehovot, Israel
Johannes Huppa; Vienna, Austria
WS.C.01.1 Novel regulation of dendritic cell trafficking to lymph
nodes by the hyaluronan receptor LYVE‑1
Louise A. Johnson, W. Lawrance, Y. Roshorm, T. Hanke,
S. Banerji, D.G. Jackson; Oxford, United Kingdom
WS.C.01.2 CXCR8 is the receptor of the mucosal chemokine
CXCL17
José L. Maravillas‑Montero, A.M. Burkhardt, P.A. Hevezi,
C. Carnevale, M.J. Smit, A. Zlotnik; México DF, Mexico
WS.C.01.3 Platelets and neutrophils require different kindlin‑3
copy numbers to control integrin‑mediated functions
in vivo
Sarah Klapproth, F. Moretti, M. Zeiler, R. Ruppert,
U. Breithaupt, R. Haas, M. Mann, M. Sperandio,
R. Fässler, M. Moser; Martinsried, Germany
WS.C.01.4 The positively charged glycosaminoglycan‑binding
CXCL9‑derived peptide, CXCL9(74‑103), inhibits
CXCL8‑induced neutrophil extravasation and
monosodium urate crystal‑induced gout in mice.
Anneleen Mortier, V. Vanheule, R. Janssens, D. Boff,
N. Berghmans, I. Ronsse, F.A. Amaral, M.M. Teixeira,
J. Van Damme, P. Proost; Leuven, Belgium
WS.C.01.5 The endothelial protein PLVAP in lymphatics controls
the entry of leukocytes into lymph nodes
Pia Rantakari, N. Jäppinen, K. Auvinen, M. Kapraali,
M. Miyasaka, S. Jalkanen, M. Salmi; Turku, Finland
WS.C.01.6 Role of CD99 in leukocyte transendothelial migration
Debashree Goswami, D. Jing, S. Yan, K. Schaefer,
M. Araki, K. Araki, K. Yamamura, D. Vestweber;
Muenster, Germany
nnWS.C.02
Innate Sensors
Hall K
08:30 – 09:45
Chairpersons: Sergei A. Nedospasov; Moscow, Russian Federation
Ihsan Gursel; Ankara, Turkey
WS.C.02.1 AIM2 suppresses colon tumorigenesis by interfering
with DNA‑PK‑dependent Akt activation
Justin E. Wilson, A. Petrucelli, L. Chen, A. Koblanski,
A. Truax, Y. Wang, M. Muehlbauer, B. Davis, J.P. Ting;
Chapel Hill, United States
54
WS.C.02.2 Identification of the lipid‑modifying enzyme SMPDL3B
as novel regulator of innate immune responses
Leonhard X. Heinz, C.L. Baumann, M.S. Köberlin,
B. Snijder, M. Bruckner, R. Gawish, O. Sharif,
R.K. Kandasamy, J. Colinges, K.L. Bennett, A. Fauster,
G. Shui, M.R. Wenk, S. Knapp, G. Superti‑Furga; Vienna,
Austria
WS.C.02.3 Novel mouse models reveal in vivo functions of the
NAIP/NLRC4 inflammasomes in non‑hematopoietic
cells
Isabella Rauch, C. Kang, J. von Moltke, L.E. Sanman,
M. Bogyo; Berkeley, United States
WS.C.02.4 Fungal recognition mediated by C‑type lectin
receptors Dectin‑1 and Dectin‑2 is regulated
by E3 ubiquitin ligase Cbl‑b
Jian Zhang, Y. Xiao, H. Guo; Columbus, United States
WS.C.02.5 SHIP‑1 couples to activated Dectin‑1 selectively
adjusting ROS production in response to C. albicans in
dendritic cells
Carlos Del Fresno Sánchez, N. Blanco‑Menéndez,
S.R. Fernandes, E. Calvo, R. Conde‑Garrosa, W.G. Kerr,
D. Sancho; Madrid, Spain
WS.C.02.6 Complement‑regulated NLRP3 inflammasome
activation controls CD4+ Th1 responses
Giuseppina Arbore, E. West, A.A. Robertson, A. Klos,
T.M. Woodruff, R.C. Coll, L.A. O’Neill, W.J. Leonard,
P.N. Monk, M.A. Cooper, H.J. Lachmann, A. Cope,
K.D. Mayer‑Barber, C. Kemper; London, United
Kingdom
nnWS.C.03
Myeloid Suppressor Cells
Hall M
08:30 – 09:45
Chairpersons: Vincenzo Bronte; Verona, Italy
Reinhold Förster; Hannover, Germany
WS.C.03.1 Controversial effect of atRA in treatment of
Non‑Responders in therapeutic vaccination
Bastian Höchst; München, Germany
WS.C.03.2 Monocytes polarize in two steps into myeloid‑derived
suppressor cells requiring IRF‑1 and mTOR signals
E. Ribechini, J. Hutchinson, S. Walter, J. Lucas,
U. Schleicher, A. Jordán Garrote, S.J. Potter, N. Müller,
H. Raifer, I. Berberich, M. Huber, H. Hermanns,
A. Beilhack, M. Lohoff, C. Bogdan, E.K. Geissler,
Manfred B. Lutz; Würzburg, Germany
WS.C.03.3 Myeloid‑derived suppressor cells contribute to
lysosomal acid lipase deficiency‑induced endothelial
cell dysfunctions
Hong Du, T. Zhao, X. Ding, C. Yan; Indianapolis, United
States
WS.C.03.4 Generation and function of CCR7‑expressing
regulatory macrophages
Kai Yu, M. Galla, A. Janssen, R. Förster; Hannover,
Germany
WS.C.03.5 Establishment of lal‑/‑ myeloid lineage cell line that
resembles myeloid‑derived suppressive cells
Cong Yan, X. Ding, L. Wu, H. Du; Indianapolis, United
States
WS.C.03.6 Adipose‑derived mesenchymal stromal cells
modulate the lipid metabolism in regulatory
macrophage
Luciana Souza‑Moreira, V. Cardoso‑Soares,
E. Gonzalez‑rey, M. Delgado, P. Bozza; Rio de Janeiro,
Brazil
Program per Day
Track C
Dendritic Cells & Macrophages
Hall N
08:30 – 09:45
Chairpersons: Adelheid Elbe‑Bürger; Vienna, Austria
Greta Guarda; Lausanne, Switzerland
WS.C.04.1 Human BDCA2+CD123+CD56+ dendritic cells
(DCs) related to blastic plasmacytoid dendritic cell
neoplasm represent a unique myeloid DC subset
H. Yu, P. Zhang, X. Yin, Z. Yin, Q. Shi, Y. Cui, G. Liu,
S. Wang, P. Piccaluga, T. Jiang, Liguo Zhang; Beijing,
China
WS.C.04.2 Anti‑TNF promotes type I interferon‑driven
psoriasis‑like skin inflammation
C. Conrad, J. Di Domizio, Alessio Mylonas,
C. Belkhouja, O. Demaria, A. Lapointe, M. Vernez,
A. Navarini, L. French, M. Gilliet; Lausanne, Switzerland
WS.C.04.3 Endogenous glucocorticoids suppress dendritic
cell‑derived IL‑12 and prevent death in LPS‑induced
sepsis
Ivana Munitic, C.C. Li, P.R. Mittelstadt, E. Castro,
J.D. Ashwell; Rijeka, Croatia
WS.C.04.4 Polysialylation of CCR7 controls dendritic cell
trafficking by releasing CCL21 from an auto‑inhibited
state
Eva Kiermaier, C. Moussion, C. Veldkamp,
R. Gerardy‑Schahn, L. Williams, G. Chaffee, A. Phillips,
F. Freiberger, R. Imre, K. Mechtler, M. Mühlenhoff,
B. Volkman, M. Sixt; Klosterneuburg, Austria
WS.C.04.5 Kupffer cells regulate the onset of immune response
against Listeria monocytogenes infection
Chloé Abels, D. Torres, A. Kohler, M. Guilliams, P. De
Baetselier, V. Flamand, A. Beschin; Brussels, Belgium
nnWS.C.05
NK and NKT Cell Activation
and Mechanisms
Hall F2
15:45 – 17:00
Chairpersons: Rosa Molfetta; Rome, Italy
Carsten Watzl; Dortmund, Germany
WS.C.05.1 Identification of phenotypically and functionally
heterogeneous mouse Mucosal Associated Invariant
T cells using MR1 tetramers
Hui‑Fern F. Koay, A. Rahimpour, A. Enders, R. Clanchy,
S.B. Eckle, B. Meehan, Z. Chen, B. Whittle, L. Liu,
D.P. Fairlie, C.C. Goodnow, J. McCluskey, J. Rossjohn,
A.P. Uldrich, D.G. Pellicci, D.I. Godfrey; Parkville VIC,
Australia
WS.C.05.2 Ly49A and NKG2D co‑localise upon synapse
formation providing a molecular mechanism
for NK cell signal integration
David Tomaz, P. Pereira, R. Henriques, N. Guerra,
J. Dyson, K. Gould; London, United Kingdom
WS.C.05.5 CXCR6 marks a novel subset of human liver NK cells
with a T‑bet(lo)Eomes(hi) transcriptional profile
Kerstin A. Stegmann, F. Robertson, C. Pallant,
T. Christophides, G. Fusai, B.R. Davidson, L.J. Pallett,
D. Peppa, N. Hansi, P. Kennedy, V. Male, C. Dunn,
M.K. Maini; London, United Kingdom
WS.C.05.6 STAT5‑ the molecular switch from tumor surveillance to
tumor promotion
Dagmar Gotthardt, E.M. Putz, E. Grundschober, V. Sexl;
Vienna, Austria
nnWS.C.06
Hall K
15:45 – 17:00
Chairpersons: Birgit Strobl; Vienna, Austria
Toby Lawrence; Marseille, France
WS.C.06.1 STAT1 isoforms in transcriptional control ‑ distinct traits
Matthias Parrini, C. Semper, N. Leitner, C. Lassnig,
C. Vogl, S. Wienerroither, T. Decker, M. Müller, B. Strobl;
Vienna, Austria
WS.C.06.2 Protein tyrosine phosphatase receptor type γ is a JAK
phosphatase and negatively regulates leukocyte
integrin activation
Michela Mirenda, L. Toffali, A. Montresor, G. Scardoni,
C. Sorio, C. Laudanna; Verona, Italy
WS.C.06.3 The non‑canonical MAPK p38gamma controls
inflammatory response of airway epithelial cells and
promotes allergic airway inflammation
Michael Mihlan, A. Godel, F. Daubeuf, N. Frossard,
R. Ricci; Illkirch‑Grafenstaden, France
WS.C.06.4 p38‑MK2/3 is the key signaling module for
IL‑33‑induced effector functions in BMDCs
Christiane Göpfert, F. Weber, T. Kamradt, S. Drube;
Jena, Germany
WS.C.06.5 A novel Tsc2‑mTORC1‑CDK4 axis controls tissue
homeostasis by regulating polarization, proliferation,
and metabolism in macrophages
Monika Linke, H. Pham, T. Schnöller, A. Miller,
M. Schöller, K. Katholnig, M. Hirtl, F. Demel, S. Üstün,
A. Preitschopf, B. Niederreiter, S. Blüml, M. Mikula,
M. Müller, M. Hengstschläger, A. Haschemi, M. Susani,
W. Weckwerth, T. Weichhart; Vienna, Austria
WS.C.06.6 Myeloid dendritic cell‑specific mTORC2 deficiency
enhances Th1 and Th17 cell responses and inhibits B16
melanoma growth
Dalia Raich‑Regue, B.R. Rosborough, K.L. Fabian,
W.J. Storkus, A.W. Thomson; Pittsburgh, United States
WS.C.05.3 Modulation of NK cell function by interactions
between 2B4 and CD48 in cis and in trans
M. Claus, S. Wingert, Carsten Watzl; Dortmund,
Germany
WS.C.05.4 The TLR 2/6 agonist MALP‑2 mediates increased NK
cell cytotoxicity when PGE2 production by monocytes
is inhibited by COX‑2 blockade
D.M. Tufa, C. Müller, D. Chatterjee, P.F. Mühlradt,
R.E. Schmidt, Roland Jacobs; Hannover, Germany
55
MONDAY
nnWS.C.04
Program per Day
Track D
TRACK D
BS.D.1.5
Analysis of NK cells immune response in Ipilimumab
treated Melanoma patients
Rossana Tallerico, C.M. Cristiani, M. Capone,
G. Madonna, C. Garofalo, E. Staaf, E. Palella,
D. Mallardo, R. Sottile, E. Simeone, A.M. Grimaldi,
G. Ciliberto, E. Gulletta, F. Colucci, K. Kärre,
P.A. Ascierto, E. Carbone; Catanzaro, Italy
BS.D.1.6
PD‑L1 blockade impacts regulatory T‑cells in
HIV‑infection in a disease stage dependent manner
Cristina Peligero, J. Argilaguet, R. Güerri‑Fernandez,
B. Torres, C. Ligero, P. Colomer, M. Plana, H. Knobel,
F. García, A. Meyerhans; Barcelona, Spain
Symposia
nnS.D.01
Vaccines
Hall E
11:15 – 12:30
MONDAY
Chairpersons: Franz X. Heinz; Vienna, Austria
Riitta Lahesmaa; Turku, Finland
S.D.01.1
Influenza vaccines for the 21st century
Ethan Settembre; Cambridge, United States
S.D.01.2
Protective CD8 T cell immunity to malaria and Ebola
Adrian Hill; Oxford, United Kingdom
S.D.01.3
Current and future status of HIV vaccination
Brigitte Autran; Paris, France
nnS.D.02
Immunological Tolerance in Organ
Transplantation
nnWS.D.01
Hall E
Chairpersons: Thomas Wekerle; Vienna, Austria
Eva M Martínez‑Cáceres; Badalona, Spain
S.D.02.1
Deciphering the mechanism of operational tolerance
in transplantation
Sophie Brouard; Nantes, France
S.D.02.2
Regulatory cell therapy for tolerance in organ
transplantation
Kathryn Wood; Oxford, United Kingdom
S.D.02.3
Transplantation tolerance through mixed chimerism
Thomas Wekerle; Vienna, Austria
Bright Sparks – Immunotherapy
Hall F1
15:45 – 17:00
Chairpersons: Lucienne Chatenoud; Paris, France
Christina Mingari; Genoa, Italy
BS.D.1.1
BS.D.1.2
Interleukin‑2/anti‑interleukin‑2 antibody complexes
expand T regulatory cells which protect against
allergen‑induced airway hyperreactivity
Alina Neunkirchner, D. Wojta‑Stremayr,
K.G. Schmetterer, L. Mager, V. Reichl, E. Rosloniec,
R. Naumann, G. Dekan, B. Jahn‑Schmid,
B. Jahn‑Schmid, B. Bohle, W.F. Pickl; Vienna, Austria
CD8+CD45RClow T regulatory cells: a promising
cell‑based therapy to induce immune tolerance
Séverine Bézie, L. Boucault, V. Daguin, I. Anegon,
C. Guillonneau; Nantes, France
BS.D.1.3
Flexible antigen‑specific redirection of human
regulatory T cells via a novel universal chimeric
antigen receptor‑based system
Stefanie Koristka, M. Cartellieri, C. Arndt, A. Feldmann,
S. Loff, S. Albert, M. Bornhäuser, A. Ehninger,
G. Ehninger, M. Bachmann; Dresden, Germany
BS.D.1.4
A germinal center immunomodulator: The CTA1‑DD
adjuvant acts on follicular dendritic cells and
potentiates follicular T helper cell functions
Sophie Schussek, J. Mattsson, K. Schön, N. Lycke;
Göteborg, Sweden
56
Immunosuppresive Therapies and
Immunomodulation
Hall F2
08:30 – 09:45
17:45 – 19:00
nnBS.D.1
Workshops
Chairpersons: Thomas Kamradt; Jena, Germany
Güher Saruhan‑Direskeneli; Istanbul, Turkey
WS.D.01.1 Regulatory T cell identifies optimal responders to
fingolimod therapy in multiple sclerosis patients
Carmen Picon, S. Sainz de la Maza, E. Rodriguez,
M. Espiño, A. Bermejo, C. de Andrés, Y. Aladro,
J. Alvarez‑Cermeño, L. Villar; Madrid, Spain
WS.D.01.2 Generation of MHC class I allospecific regulatory
T cells using chimeric antigen receptors to elicit
targeted transplant tolerance
Dominic Boardman, M. Ibrahim, G. Fruhwirth,
R. Lechler, J. Maher, L. Smyth, G. Lombardi;
WS.D.01.3 Hepatic expression of an allogeneic MHC I molecule
induces specific regulatory CD8 T cells and prolongs
fully allogeneic graft survival in mice
Valentin Le Guen, J. Judor, F. Boeffard, V. Gauttier,
N. Ferry, S. Brouard, S. Conchon; Nantes, France
WS.D.01.4 The Jak1/3 inhibitor tofacitinib drives human
plasmacytoid dendritic cells into apoptosis and
inhibits IFN‑alpha production
Patrick P. Boor, P.E. de Ruiter, H.J. Metselaar, L.J. van
der Laan, J. Kwekkeboom, Gastroenterology and
Hepatology, Surgery; Rotterdam, Netherlands
WS.D.01.5 17‑phenyl trinor (pt)‑PGE2 counteracts LPS‑induced
acute pulmonary inflammation in mice and promotes
endothelial barrier function
Anna Theiler, V. Konya, I. Lanz, W. Platzer, R. Schuligoi,
A. Heinemann; Graz, Austria
WS.D.01.6 Selective blockade of the CD28/B7/CTLA4 pathway
with monovalent anti‑CD28 antibody versus targeting
of B7 with Belatacept, in non‑human primate kidney
allograft
Nicolas Poirier, S. Ville, J. Hervouet, D. Minault,
B. Vanhove, G. Blancho; Nantes, France
Program per Day
Track D
Drug Immunogenicity and
Biomarkers of Efficacy
Hall G
15:45 – 17:00
Chairpersons: Sylvie Bertholet-Girardin; Siena, Italy
Anna Fogdell‑Hahn; Stockholm, Sweden
WS.D.02.1 Detection of cell sensitization to infliximab in treated
patients without anti‑drug antibodies
Alessandra Vultaggio, F. Nencini, S. Pratesi, A. Matucci,
E. Maggi; Florence, Italy
WS.D.02.2 Identification of T cell response to inflliximab peptides
in treated patients.
Sara Pratesi, F. Nencini, E. Maggi, A. Matucci,
A. Vultaggio; Florence, Italy
WS.D.02.3 Complement C3 facilitates endocytosis of therapeutic
factor VIII by antigen‑presenting cells in hemophilia A
Mathieu Ing, J. Rayès, I. Peyron, S. Delignat,
C. Vogel, D. Fritzinger, V. Frémeaux‑Bacchi, S. Kaveri,
L. Roumenina, S. Lacroix‑Desmazes; Paris, France
WS.D.02.4 Why do some PEGylated biotherapeutics induce
antibodies against PEG?
Christian Lubich, M. Weiller, J. Siekmann, F.M. Horling,
M. de la Rosa, F. Scheiflinger, B.M. Reipert; Vienna,
Austria
WS.D.02.5 T‑cell subsets with T follicular helper features are
predictive of late antibody responses
F. Spensieri, E. Siena, E. Borgogni, L. Zedda,
R. Cantisani, N. Chiappini, D. Rosa, F. Schiavetti,
F. Castellino, E. Montomoli, D. Lewis, Sylvie Bertholet,
G. del Giudice; Siena, Italy
Immune Dissection
of Anti-Viral Vaccines
WS.D.03.6 A vaccine strategy that fully protects against
congenital CMV has to include the viral pentameric
glycoprotein complex in addition to other neutralizing
glycoprotein target antigens but does not require the
pp65 T cell target antigen
Alistair McGregor, D. Horvat, Y. Choi; College Station,
United States
nnWS.D.04
Preventive &
Therapeutic Approaches
Hall N
15:45 – 17:00
Chairpersons: Francesca Granucci; Milan, Italy
Beatrix Grubeck‑Loebenstein; Innsbruck, Austria
WS.D.04.1 Immunogenicity and efficacy of self‑amplifying RNA
vaccines expressing multiple conserved Influenza
antigens
Diletta Magini, S. Buccato, S. Mangiavacchi,
C. Giovani, E. Montomoli, D. Maione, L. Brito, A. Geall,
M. Brazzoli, S. Bertholet; Siena, Italy
WS.D.04.2 Single shot booster vaccinations against diphtheria do
not induce sufficient long‑term protection in a large
proportion of elderly people
Marco Grasse, B. Weinberger, A. Meryk,
B. Grubeck‑Loebenstein; Innsbruck, Austria
WS.D.04.3 Targeted therapeutic approached to rheumatoid
arthritis
Ahuva Nissim; London, United Kingdom
WS.D.02.6 Systems biology approach to dissecting
meningococcal vaccine responses
O’Connor Daniel, E.A. Clutterbuck, D.F. Kelly,
A.J. Pollard; Oxford, United Kingdom
nnWS.D.03
WS.D.03.5 RNA‑ and protein‑based vaccines induce CD8+ T cells
with different gene expression profiles
Trine Meldgaard, F. Blengio, C. Sammicheli, S. Tavarini,
F. Corrente, S. Mangiavacchi, M. Brazzoli, E. de
Gregorio, R. Rappuoli, A. Geall, E. Siena, S. Nuti,
R. Kratzer, S. Bertholet; Siena, Italy
Hall M
15:45 – 17:00
Chairpersons: Christian Muenz; Zurich, Switzerland
Ursula Wiedermann; Vienna, Austria
WS.D.03.1 Local skin reactions as potential indicators of
vaccine‑specific memory CD8+ T‑cell immune
responses to influenza vaccination
Helene Perrin, A. Soria, P. Loulergue, A. Rousseau,
O. Bonduelle, M. Cachanado, L. Ben Slama,
M. Dufossee, A. Vogt, S. Van Der Werf, S. Behillil,
T. Simon, O. Launay, B. Combadiere, B. Combadiere;
Paris, France
WS.D.04.4 IL‑37: therapeutic potential of a natural inhibitor
of innate immunity during acute and chronic joint
inflammation
Marije I. Koenders, G. Cavalli, P.M. van der Kraan,
W.B. van den Berg, L.A. Joosten, C.A. Dinarello;
Nijmegen, Netherlands
WS.D.04.5 NFATc1α is a key target to prevent acute rejection
after cardiac transplantation
J. Baur, U. Steger, T. Pusch, K. Murti, R. Busch,
C. Germer, E. Serfling, C. Otto, Andris Avots;
Wuerzburg, Germany
WS.D.04.6 Role of NFATc activation in innate immune cells in
acute transplant rejection
Clara Cigni, F. Mingozzi, R. Marzi, I. Zanoni, F. Granucci;
Milano, Italy
WS.D.03.2 Prime‑boost vaccination with viral vectors via
heterologous route maximizes both tissue‑resident and
circulating CD8+ T cell memory responses
Nicolas Çuburu; Bethesda, United States
WS.D.03.3 The kinetic of type I interferon responses regulates
induction of adaptive immunity and antiviral memory
Julia Spanier, P. Staeheli, U. Kalinke; Hannover,
Germany
WS.D.03.4 rVSV vaccine expressing Zaire ebola virus
glycoprotein: Data from the phase I trial in Germany
Christine Dahlke, M. Zinser, R. Kasonta, V. Krähling,
A. Nolting, H.C. Stubbe, N. Biedenkopf, M. Eickmann,
S.K. Fehling, T. Strecker, S. Borregard, A. Jambrecina,
F.R. Stahl, S. Becker, A.W. Lohse, S. Schmiedel,
M.M. Addo; Hamburg, Germany
57
MONDAY
nnWS.D.02
Program per Day
Joint-Symposia of the Day
JOINT-SYMPOSIA OF THE DAY
nnJS.01
OTHER SESSIONS AND MEETINGS
Molecular Mechanisms of the Immune
Response to Infection (jointly with AAI) Hall A
14:00 – 15:30
EFIS Awards Lecture Symposium
nnEF.01
MONDAY
Chairpersons: Jenny Ting; Chapel Hill, United States
Georg Stingl; Vienna, Austria
ACTERIA Prizes and
EFIS-EJI Ita Askonas Prize
Hall F2
14:00 – 15:30
JS.01.1 NLR family of innate immune sensors:
impact on immunity and beyond
Jenny Ting; Chapel Hill, United States
Chairpersons: Anne Hosmalin; Paris, France
Catherine Sautès‑Fridman; Paris, France
JS.01.2 TCR signal strength regulates antiviral T cell responses
via graded expression of IRF4
Leslie Berg; Worcester, United States
JS.01.3 Immunity to tuberculosis: a balancing act
Shabaana Khader; St.Louis, United States
The EFIS-IL Most Cited Article and Review Prizes
- Sagrario Martín-Aragón; Madrid, Spain /
EFIS-IL Most Cited original Article
- Girija Kuttan and K.S. Siveen; Kerala, India /
EFIS-IL Most Cited Review
nnJS.02
Resolution of Inflammation
(jointly with EULAR)
Hall E
14:00 – 15:30
Chairpersons: Christopher Buckley;
Birmingham, United Kingdom
Clemens Scheinecker; Vienna, Austria
JS.02.1
Lack of resolution of inflammation: Explaining
chronicity of human immune‑inflammatory diseases
Christopher Buckley; Birmingham, United Kingdom
The EFIS/EJI Ita Askonas Prize
EF.01.1
Follicular lymphoma cell niche: a criminal conspiracy
of T cells and stromal cells
Karin Tarte; Rennes, France
The ACTERIA Prizes Awarded by EFIS
EF.01.2
Characterization of allergens involved in IgE mediated
wheat allergy
Sandra Pahr; Vienna, Austria
ACTERIA Doctoral Prize in Allergology
EF.01.3
Too much, too little, or just enough: feedback control
of aryl hydrocarbon receptor signalling in intestinal
immunity
Chris Schiering; London, United Kingdom
ACTERIA Doctoral Prize in Immunology
JS.02.2
Resolution of inflammation by neutrophil NETosis ‑
a clue for understanding gout
Martin Herrmann; Erlangen, Germany
JS.02.3
Fosterin anti‑inflammatory mechanisms to stop arthritis
Fons van de Loo; Nijmegen, Netherlands
EF.01.4
From Magic Bullets to Targeted Therapy
Approaches (Russian-Georgian-Austrian
Sister Symposium)
Hall M
Immunoglobulin E enhances host resistance to venom
Thomas Marichal; Liege, Belgium
ACTERIA Early Career Research Prize in Allergology
EF.01.5
Enhanced understanding of CD8 T cell differentiation
and tolerance
Dietmar Zehn; Lausanne, Switzerland
ACTERIA Early Career Research Prize in Immunology
nnJS.03
14:00 – 15:30
Chairpersons: Revaz Sepiashvili;
Moscow, Russian Federation
Heimo Bereiteneder; Vienna, Austria
JS.03.1 Modern ImmunoPharmacology:
Magic bullets & combinatorial approaches
Alexander G. Gabibov; Moscow,
Russian Federation
JS.03.2
A new concept of tumor targeted delivery of
visualizing and cytotoxic agents
Deyev Sergey; Moscow, Russian Federation
JS.03.3
Camel single domain antibody‑based technological
innovations for research, diagnostics and therapy
Sergey Tillib; Moscow, Russian Federation
nnSW.01
Hall F2
19:15 – 20:15
A paper that is well-written and that presents and discusses the data
in a clear and structured manner makes the life of an editor (and
reviewers) much easier. Precise writing doesn’t guarantee that your
paper will be accepted – that depends on the significance and
validity of the results – but it does create a good first impression.
Importantly, clear writing prevents potential misunderstandings that
could, in the worst case scenario, result in your paper being rejected.
This session, which is aimed primarily at PhD students/early postdocs,
will provide examples and tips of good scientific writing.
Speaker: 58
Titles to Figure Legends:
An Insider's Guide to Publishing
Dr. Karen Chu,
Associate Editor, European Journal of Immunology
Program per Day
Business and Ancillary Meetings
nnBA.07
DGfI Study Groups Board Meeting
closed*
nnBA.08
09:45 – 11:15
Dutch Society for Immunology (NVVI)
closed*
Board Meeting
nnBA.09
09:45 – 11:15
closed*
nnBA.10
09:45 – 11:15
MEET THE PROFESSOR BREAKFAST
Informal breakfast event for early career scientists. The “Meet the Professor Sessions” will provide participants the opportunity to meet the
most renowned senior scientists in an interactive and casual manner.
Small breakfast will be provided. Registration is possible via email
and onsite at a first-come-first-serve basis.
Maximum amount of participants per breakfast: 30
nnME.01
Peter Openshaw
Meeting Room 1
(1.85-86)
07:15 – 08:15
European Journal of Immunology
nnBA.10.1
IUIS-Frontiers Partnership Meeting
closed*
nnBA.11
10:00 – 15:30
closed*
Retreat Follow-up Meeting
12:30 – 13:30
nnBA.12
IUIS-EFIS Annual Collaboration Review Meeting
closed*
15:30 – 17:00
nnBA.12.1
SIICA Board Meeting
closed*
nnBA.13
17:00 – 19:00
Scandinavian Journal of Immunology
Editorial Board Meeting
(open to members of the respective society only)
nnBA.14
17:30 – 18:45
Italian Society of Immunology,
Clinical Immunology and Allergology
(SIICA) General Assembly
(open to members of the
respective society only)
nnBA.15
MONDAY
closed*
Editorial Board and Alumni Meeting
10:00 – 11:00
19:15 – 20:45
Hungarian Society for Immunology (MIT)
Board Meeting
(open for all Hungarian participants)
19:15 – 20:45
59
Program per Day
Posters of the Day according to Tracks A, B, C, D, E
MONDAY
POSTERS OF THE DAY ACCORDING TO
TRACKS A, B, C, D, E
nnP.C.01
Granulocytes
nnP.C.02
NK and NKT Cells - Part 1
nnP.C.03
Innate Lymphocytes
nnP.A.01
Lineage Commitment
nnP.C.04
Immune Suppression
nnP.A.02
Lymphocyte Tolerance and Memory
nnP.C.05
Dendritic Cell Biology - Part 1
nnP.A.03
Antigen Processing and Presentation - Part 1
nnP.C.06
Pattern Recognition Receptors - Part 1
nnP.A.04
Th1 and Th2 Cells - Part 1
nnP.C.07
Cytosolic Sensing and Inflammasome
nnP.A.05
Th17 Cells - Part 1
nnP.C.08
Cell Signaling - Part 1
nnP.A.06
Regulatory T Cells - Part 1
nnP.A.07
CD8+ T Cells - Part 1
nnP.A.08
γδ T Cells
nnP.A.09
Germinal Centre Reaction - Part 1
nnP.A.10
B Cells in Autoimmunity and Tolerance
Track B – Diseases
nnP.B.01
Immunity to Bacterial Infection - Part 1
nnP.B.02
Immunity to Bacterial Infection - Part 2
nnP.B.03
Immunity to Fungi, Helminths and Malaria
nnP.B.04
Primary Immunodeficiencies - Part 1
nnP.B.05
Autoinflammatory Diseases
nnP.B.06
Diseases - Inflammation - Part 1
nnP.B.07
Neuroimmunology
nnP.B.08
Diabetes and (chronic) Inflammatory Joint
Diseases
nnP.B.09
(Chronic) Inflammatory Joint Diseases - Part 1
nnP.B.10
Inflammatory Skin and Joint Diseases
nnP.B.11
Allergen Specific Immune Responses - Part 1
nnP.B.12
Allergic Disorders - Part 1
nnP.B.13
Tumor Immunity - Part 1
nnP.B.14
Tumorantigens and Tumorstroma
60
nnP.D.01
Bone Marrow Transplantation and GVHD Part 1
nnP.D.02
Vaccines - Part 1
nnP.D.03
Vaccines & Veterinary Immunology - Part 1
nnP.D.04
Immune Interventions in Autoimmunity - Part 1
nnP.D.05
Intervention & Therapy of Allergy - Part 1
nnP.D.06
Cancer Immunotherapy - Part 1
nnP.D.07
Stem Cells & Cell Based Therapies - Part 1
nnP.D.08
Biomarkers of Human Immune Responses &
Immunogenicity against Biopharmaceuticals Part 1
nnP.D.09
Bone Marrow Transplantation and GVHD Part 2
nnP.D.10
Immunomodulation by Nutrients & Vitamines
Track E – Other
nnP.E.01
Structural Biology & Imaging
of the Immune System
TUESDAY
Schedule at a Glance Tuesday. . . . . . . . . . . . . . . . . . . . . . . . . 62
TUESDAY
Track A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Track B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
Track C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Track D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
Track E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
Meet the Professor Breakfasts. . . . . . . . . . . . . . . . . . . . . . . . . . 74
61
Program per Day
TUESDAY, SEPT. 8, 2015
SCHEDULE AT A GLANCE TUESDAY
Room
Hall A
Hall E
Hall F1
Hall F2
Hall G
Hall K
Level
2
0
0
0
-2
-2
07:15 – 08:15
08:15 – 08:30
08:30 – 08:45
08:45 – 09:00
S.A.03
Adaptive Immunity
Immune Cell
09:15 – 09:30 Trafficking
09:00 – 09:15
S.B.03
Diseases
Immunity Against
Infections
WS.D.05
T Cell Based Cancer
Immunotherapy
WS.C.07
Macrophage
Signaling
WS.D.06
Stem Cells and CellBased Therapy
WS.C.08
Epigenetics in Innate
Immunity
09:30 – 09:45
09:45 – 10:00
10:00 – 10:15
10:15 – 10:30
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
S.C.03
Innate Effector
12:00 – 12:15 Functions
S.D.03
Antibody
Therapeutics
WS.A.06
Control of CD8+ T
Cells (part 2)
WS.B.06
Cytokines and
Chemokines in
Tumor Immunology
WS.A.07
WS.B.07
T Cell Signalling
Skin Diseases
12:15 – 12:30
TUESDAY
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
KL.B.1
Diseases
13:15 – 13:30 Inflammasome
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
JS.04
14:15 – 14:30 International Union
14:30 – 14:45
14:45 – 15:00
15:00 – 15:15
15:15 – 15:30
of Immunological
Societies (IUIS)
Vaccine Development
Can Benefit from
Computational
Biology
JS.05
European Academy
of Allergy and
IS.07
Clinical Immunology
(EAACI)
T Helper Cell Subsets
in Health and Disease
JS.06
International
Society for the
Advancement of
Cytometry (ISAC)
Cytometry of the
21st Century
JS.07
Society for Mucosal
Immunity (SMI)
The Mucosal
Microbiome in Health
and Disease
15:30 – 15:45
15:45 – 16:00
16:00 – 16:15
S.A.04
Establishment of
16:30 – 16:45 B Cell Responses
S.B.04
Diseases
Primary
Immunodeficiencies
WS.D.07
Novel Approaches
for Vaccines
WS.C.10
Macrophages in
Diseases
WS.C.11
WS.B.09
WS.B.11
WS.A.11
Innate Lymphoid
Cells
Optimizing
Anti‑Tumor Immunity
16:45 – 17:00
17:00 – 17:15
Coffee Break
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
S.C.04
Antigen Uptake and
18:30 – 18:45 Presentation
S.D.04
Cancer
Immunotherapy
WS.A.10
WS.B.10
Treg Induction /
Subsets
Systemic
Autoimmune
Diseases
Allergens
B Cell Signaling
18:45 – 19:00
19:00 – 19:15
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
20:00 – 20:15
20:15 – 20:30
Heurigen Evening
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
62
Program per Day
SCHEDULE AT A GLANCE TUESDAY
Hall M
Hall N
1
1
Meeting Room Meeting Room Meeting Room Meeting Room
1
3
5
6
(1.85-86)
(2.15)
(2.17)
(2.12)
1
ME.02
Jürgen Wienands
2
ME.03
Ron Germain
2
ME.04
2
L7
Room
1
Level
ME.05
07:15 – 08:15
Luke O’Neill
08:15 – 08:30
08:30 – 08:45
WS.C.09
WS.E.01
Structural Biology
and Imaging
08:45 – 09:00
Innate Cell
Signalling &
Function
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
09:45 – 10:00
Poster Session IS.06
BA.16
BA.17
BA.19
and
Scandinavian
German Society
Belgian
(Industry
BA.18
Guided
Sponsored Progress Society for
for Immunology
Immunological
French
Society
of
BA.19.1
Immunology (SSI) (DGfI)
Society (BIS)
Poster Walks / in Technology
Immunology
(SFI)
IUIS Quality
Session)*
General
Assembly
General
Assembly
General
Assembly
Coffee Break
Annual board
Assessment and
meeting
WS.A.08
B Cell
Development &
Homeostasis
WS.B.08
Standardization
Committee
Meeting
10:00 – 10:15
10:15 – 10:30
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
Innate Immune
Mechanisms in
Cancer
11:45 – 12:00
12:00 – 12:15
12:15 – 12:30
12:45 – 13:00
EEIG ECI-EFIS
Meeting
13:00 – 13:15
13:15 – 13:30
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
WO.00
Women in
Immunology
Carreer Talks
BA.21
EFIS
General
Assembly
WS.A.09
Molecular
Control of T Cell
Development
WS.D.08
Solid Organ and
Bone Marrow
Transplantation
Coffee Break
14:30 – 14:45
14:45 – 15:00
15:00 – 15:15
15:15 – 15:30
15:30 – 15:45
15:45 – 16:00
16:00 – 16:15
16:15 – 16:30
BA.22
Inaugural
IUIS Vaccine
Committee
Meeting
16:30 – 16:45
16:45 – 17:00
17:00 – 17:15
BA.23
EFIS
Board Meeting
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
WS.B.12
Models and
Mechanisms of
Primary Immunodeficiency
booked out!
14:15 – 14:30
18:00 – 18:15
WS.B.13
18:15 – 18:30
Immune Disorders
18:30 – 18:45
18:45 – 19:00
19:00 – 19:15
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
Heurigen Evening
20:00 – 20:15
20:15 – 20:30
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
63
TUESDAY
12:30 – 12:45
BA.20
Program per Day
OVERVIEW PER TRACK
Keynote Lecture of the Day - KL.B.1 – Diseases
12:45 – 13:45
Chairperson:
Hall A
Fiona Powrie; Oxford, United Kingdom
Inflammasome
Luke O’Neill
Trinity College Dublin, Department of Biochemistry and Immunology; Dublin, Ireland
Professor Luke O’Neill was appointed to the Chair of Biochemistry at Trinity College Dublin in 2008, where he
leads the Inflammation Research Group. He has a PhD in Pharmacology from the University of London and
carried out Post-Doctoral research at Cambridge, U.K., on the pro-inflammatory cytokine IL-1 and innate
immune signaling. His research is in the area of the molecular basis to inflammatory diseases. He has won
numerous awards for his research, notably the Royal Irish Academy Medal for Biochemistry, The Irish Society
for Immunology medal, the Royal Dublin Society/ Irish Times Boyle medal for Scientific Excellence, the Science Foundation Ireland Researcher of the Year Award and in 2014 the European Federation of Immunology
Societies Medal. He was elected a member of EMBO in 2005. In 2014 he was named by Thompson Reuters
as one of the world’s most influential scientists, being in the top 1% in both Immunology and Pharmacology/Toxicology. He is a co-founder and director of Opsona Therapeutics, a drug development company
working in the area of Toll-like receptors.
TUESDAY
OVERVIEW PER TRACK
Symposia
S.A.03
Immune Cell Trafficking
S.A.04
Establishment of B Cell Responses
Symposia
S.C.03
Innate Effector Functions
S.C.04
Antigen Uptake and Presentation
Workshops
WS.A.06
WS.A.07
WS.A.08
WS.A.09
WS.A.10
WS.A.11
Workshops
WS.C.07
WS.C.08
WS.C.09
WS.C.10
WS.C.11
T Cell Signalling
B Cell Development & Homeostasis
Molecular Control of T Cell Development
Treg Induction / Subsets
B Cell Signaling
Symposia
S.B.03
Immunity Against Infections
S.B.04
Primary Immunodeficiencies
Workshops
WS.B.06
Cytokines and Chemokines in Tumor Immunology
WS.B.07
Skin Diseases
WS.B.08
Innate Immune Mechanisms in Cancer
WS.B.09
Optimizing Anti-Tumor Immunity
WS.B.10
Systemic Autoimmune Diseases
WS.B.11Allergens
WS.B.12
Models and Mechanisms of Primary Immunodeficiency
WS.B.13
Immune Disorders
64
Macrophage Signaling
Epigenetics in Innate Immunity
Innate Cell Signalling & Function
Macrophages in Diseases
Innate Lymphoid Cells
Symposia
S.D.03
Antibody Therapeutics
S.D.04
Cancer Immunotherapy
Workshops
WS.D.05
WS.D.06
WS.D.07
WS.D.08
T Cell Based Cancer Immunotherapy
Stem Cells and Cell-based Therapy
Novel Approaches for Vaccines
Solid Organ and Bone Marrow Transplantation
TRACK E – OTHER
Workshop
WS.E.01
Structural Biology and Imaging
Program per Day
Track A
Symposia
nnS.A.03
Immune Cell Trafficking
Hall A
08:30 – 09:45
Chairpersons: Ronen Alon; Rehovot, Israel
Britta Engelhardt; Bern, Switzerland
S.A.03.1 DC and B cell trafficking
Reinhold Förster; Hannover, Germany
S.A.03.2 T cell trafficking
Ronald N. Germain, T. Laemmermann, P. Torabi‑Parizi,
T. Honda, J. Egen, Z. Liu, A.Y. Rudensky, A. Levine, W. Li,
M.Y. Gerner; Bethesda, United States
S.A.03.3
Immune cell‑to‑cell communication: Mechanisms of
microRNA and proteins sorting into exosomes
Francisco Sánchez‑Madrid; Madrid, Spain
nnS.A.04
Establishment of B Cell Responses
Hall A
15:45 – 17:00
Chairpersons: Rita Carsetti; Rome, Italy
Simon Fillatreau; Berlin, Germany
S.A.04.1
Control of plasma cell differentiation by the
transcription factor Blimp1
M. Minnich, H. Tagoh, P. Bönelt, E. Axelsson, M. Fischer,
M. Jaritz, Meinrad Busslinger; Vienna, Austria
S.A.04.2
Human Marginal Zone B Cells
Jean C. Weill; Paris, France
S.A.04.3
Germinal center formation
Balbino Alarcon; Madrid, Spain
Hall F1
11:15 – 12:30
Chairpersons: Axel Kallies; Parkville, Australia
Thomas Schüler; Magdeburg, Germany
WS.A.06.1 Mitochondrial biogenesis in naive CD8+ T cells occurs
early after activation and before the first division
Marco Fischer, G.R. Bantug, L. Razik, R. Belle,
S. Dimeloe, J. Graehlert, U. Sauders, C. Hess; Basel,
Switzerland
WS.A.06.2 T cell cross‑reactivity between a highly immunogenic
Epstein‑Barr virus epitope and a self‑peptide naturally
presented by HLA‑B*18:01+ cells
Scott R. Burrows, M.J. Rist, K.M. Hibbert, N.P. Croft,
A.W. Purcell, J. Rossjohn; Brisbane, Australia
WS.A.06.3 The MAZR/Runx3 complex is integrated into the
transcriptional network controlling effector CD8+ T cell
differentiation
Shinya Sakaguchi, C. Tizian, D. Hainberger, K. Khamina,
T. Penz, C. Bock, I. Taniuchi, A. Bergthaler, W. Ellmeier;
Vienna, Austria
WS.A.06.4 Immunosurveillance of the liver by intravascular
effector CD8+ T cells
Matteo Iannacone; Milan, Italy
WS.A.06.6 CD11b+ dermal dendritic cells are competent to
induce protective skin homing CD8+ T Cells
Tobias Hain, S. Muth, F. Melchior, H. Schild, H. Probst;
Mainz, Germany
nnWS.A.07
T Cell Signalling
Hall G
11:15 – 12:30
Chairpersons: Burkhart Schraven; Magdeburg, Germany
Nicole Boucheron; Vienna, Austria
WS.A.07.1 Lipid in T‑cell receptor transmembrane signaling
H. Li, X. Guo, C. Yan, X. Shi, C. Wong, J. Chou, Y. Cao,
Chenqi Xu; Shanghai, China
WS.A.07.2 PTPN22: a sticking point during integrin signalling in
T lymphocytes
Garth L. Burn, G. Cornish, L. Svensson, D. Owen,
A.P. Cope; London, United Kingdom
WS.A.07.3 Phosphatidylinositol 4‑phosphate 5‑kinase (PIP5Kα)
and Vav1: critical regulators of CD28‑mediated
signaling functions
Nicla Porciello, M. Muscolini, C. Camperio, S. Caristi,
C. Capuano, A. Viola, R. Galandrini, L. Tuosto; Rome,
Italy
WS.A.07.4 Proteomic analysis revealed Vav1 as a key effector of
CD226 signaling in CD4 T cells
Guillaume Gaud, R. Roncagalli, J. Familiades,
A. Gonzalez de Peredo, K. Chaoui, C. Colacios,
B. Malissen, A. Saoudi; Toulouse, France
Workshops
nnWS.A.06
WS.A.06.5 Hobit and Blimp‑1 mediate a unified transcriptional
program of tissue‑residency in lymphocytes
L. Mackay, M. Minnich, C. Seillet, B. Nota, W. Shi,
J. Liao, A. Braun, T. Gebhardt, S. Preston, M. Pellegrini,
D. Pellicci, D. Godfrey, G. Belz, M. Busslinger,
F. Carbone, R. van Lier, N. Kragten, A. Kallies,
Klaas van Gisbergen; Amsterdam, Netherlands
WS.A.07.5 The deubiquination of SMAD7 by CYLD is required for
T cell homeostasis and canonical TGF‑β signaling
Yilang Tang, S. Reißig, A. Waisman; Mainz, Germany
WS.A.07.6 Neuroserpin expressed by human T cells regulates
the proteolytic balance controlling homotypic T cell
interactions.
Evert J. Loef, N. Lorenz, A.E. Brooks, R. Dunbar,
N.P. Birch; Auckland, New Zealand
nnWS.A.08
B Cell Development & Homeostasis
Hall M
11:15 – 12:30
Chairpersons: Andreas Radbruch; Berlin, Germany
Klaus Rajewsky; Berlin, Germany
WS.A.08.1 Mapping the human liver B cell compartment in health
and disease
Sudha Purswani, G. Reynolds, J. Harris, R. Smith,
S. Davies, E. Triantafyllou, K. Petrovic, B. Wiggins,
G. Webb, E. Liaskou, D. Adams, Z. Stamataki;
WS.A.08.2 IL4I1 slows‑down BCR crosslinking and regulates B cell
homeostasis
Lloyd Bod, R. Lengagne, L. Douguet,
V. Molinier‑Frenkel, F. Castellano, Y. Richard,
A. Prévost‑Blondel; Paris, France
65
TUESDAY
TRACK A
Program per Day
Track A
WS.A.08.3 B‑cell survival is controlled by tetraspanin CD37;
implications for lymphomagenesis
C. de Winde, S. Veenbergen, K. Young, M. van
den Brand, A. van der Schaaf, N. Muthusamy,
D. Tarlinton, H. van Krieken, M. Wright, C. Figdor,
Annemiek van Spriel; Nijmegen, Netherlands
WS.A.08.4 Testing Bim as a functional target of miR‑17‑92 in
B cells
Verena Labi, F. Klironomos, S. Peng, T. Chakraborty,
M. Munschauer, A. Villunger, M. Landthaler,
N. Rajewsky, K. Rajewsky; Innsbruck, Austria
WS.A.08.5 Microprocessor component DGCR8 is essential
for early B cell development
W. Schuh, A. Brandl, S. Brenner, Patrick Daum, M. Bösl,
J. Wittmann, H. Jäck; Erlangen, Germany
WS.A.08.6 Early B cell development requires balanced
expression of miR‑191
Jonas Blume, M. Lyszkiewicz, K. Witzlau, A. Krueger;
Hannover, Germany
nnWS.A.09
Molecular Control
of T Cell Development
Hall M
15:45 – 17:00
TUESDAY
Chairpersons: Thorsten Buch; Zurich, Switzerland
Adrian Hayday; London, United Kingdom
WS.A.09.1 The actin remodeling protein cofilin is crucial for early
T‑cell development
Isabel John, D. Deibel, S. Prokosch, G. Küblbeck,
B. Arnold, Y. Samstag; Heidelberg, Germany
WS.A.10.2 IL‑1R1 is expressed on both Helios+ and Helios‑
FOXP3+ CD4+ T cells in the rheumatic joint
M. Müller, J. Herrath, Vivianne Malmström; Stockholm,
Sweden
WS.A.10.3 Ex‑Th17 Foxp3+ T cells ‑ a novel subset of Foxp3+
T cells in sterile inflammation
Natasa Obermajer, S. Downs‑Canner,
R. Ravindranathan, F.C. Popp, Y. Soeder, J. Haarer,
E.K. Geissler, H.J. Schlitt, R.P. Edwards, K. Odunsi,
P. Kalinski, M.H. Dahlke, D.L. Bartlett; Pittsburgh, United
States
WS.A.10.4 Generation and maintenance of tissue regulatory
T cells
D.F. Pinheiro, S.K. Kitzmueller, M.M. Maurano,
M.M. Klicznik, R. Holly, G. Achatz‑Straussberger,
A.K. Abbas, Iris K. Gratz; Salzburg, Austria
WS.A.10.5 IL‑2/Blimp‑1/mir9 axis regulates IL‑10 expression in
CD39+ Tregs
Chansavath Phetsouphanh, D.D. Murray, D.C. Hsu,
Y. Xu, L. Cook, J. Zaunders, A. Kelleher, N. Seddiki;
Kensington, Australia
WS.A.10.6 Cholera toxin mediates cAMP‑dependent CTLA‑2
secretion by dendritic cells to enhance regulatory
T cell conversion
C. Silva Vilches, T. Müller, J. Bodem, Manfred B. Lutz;
Würzburg, Germany
nnWS.A.11
B Cell Signaling
Hall K
17:45 – 19:00
Chairpersons: Lars Nitschke; Erlangen, Germany
Gertrude Achatz‑Straussberger; Salzburg, Austria
WS.A.09.2 Characterizing the functional role of WWOX in
thymocyte development
Tsung Hao Chang, L. Hsu; Tainan, Taiwan
WS.A.09.3 MAZR and Runx factors synergistically repress ThPOK
during CD8+ T cell lineage development
S. Sakaguchi, Daniela Hainberger, C. Tizian, H. Tanaka,
T. Okuda, I. Taniuchi, W. Ellmeier; Vienna, Austria
WS.A.11.1 New roles of MALT1 proteolysis in B cell function
deciphered using multiplexed N‑terminal proteomics
using TAILS
Theo Klein, S.Y. Fung, F. Renner, M.A. Blank, R.I. Viner,
C.H. Regnier, S.E. Turvey, C.M. Overall; Vancouver,
Canada
WS.A.09.4 TCR/CD3 signaling requirements for thymic γδ T cell
effector differentiation
Miguel Muñoz‑Ruiz, J. Ribot, D.J. Pennington,
J.R. Regueiro, E. Fernández Malavé, B. Silva Santos;
Madrid, Spain
WS.A.11.2 Ly9 (CD229) functions as a regulator controlling innate
B cell homeostasis and antibody responses
Marta Cuenca, X. Romero, J. Sintes, P. Engel;
Barcelona, Spain
WS.A.09.5 Does CXCL8 production define a stage in human T cell
development?
A. Das, G. Lavender, C. Furness, T. Hayday,
M. Greaves, A.C. Hayday, Deena L. Gibbons; London,
United Kingdom
WS.A.11.3 Cdc42 is an essential regulator of antiviral humoral
immunity.
Marianne Burbage, S.J. Keppler, F. Gasparrini,
N. Martínez‑Martín, M. Gaya, C. Feest, M. Domart,
L. Collinson, A. Bruckbauer, F.D. Batista; London, United
Kingdom
WS.A.09.6 TECs are a non‑redundant source of Wnt ligands
in the thymus
Fabian Brunk, I. Augustin, M. Meister, M. Boutros,
B. Kyewski; Heidelberg, Germany
nnWS.A.10
Treg Induction / Subsets
Hall F1
17:45 – 19:00
Chairpersons: Petra Hoffmann; Regensburg, Germany
Pascale Plence; Montpellier, France
WS.A.10.1 ILT‑3 expressing regulatory T cells, steered by Protein
Kinase CK2, fail to control vigorous Th2 responses
in vivo
Alexander Ulges, T. Bopp; Mainz, Germany
66
WS.A.11.4 DEC1 as a master regulator of B lymphocyte activation
and apoptosis
Laura Todi, C. Lazzeri, C. Cristofoletti, A. Camponeschi,
R. Marrapodi, M. Del Padre, M. Mitrevski, M. Fiorilli,
M. Visentini; Rome, Italy
WS.A.11.5 HAX1 deletion affects BCR‑internalization by leading
to delayed BCR‑mediated apoptosis
Gertrude Achatz‑Straussberger, I.K. Gratz; Salzburg,
Austria
WS.A.11.6 Enhanced Bruton’s tyrosine kinase expression in B cells
drives autoimmunity by disrupting T cell homeostasis
O. Corneth, M.J. De Bruijn, M. Lukkes, J. Rip,
P. Asmawidjaja, E. Lubberts, G.M. Verstappen,
H. Bootsma, F.G. Kroese, L.P. Kil, Rudi W. Hendriks;
Rotterdam, Netherlands
Program per Day
Track B
TRACK B
WS.B.06.6 TH9 cells drive IL‑9 mediated colitis‑associated
colorectal cancer (CAC)
Katharina Gerlach, S. Wirtz, A. McKenzie, M.F. Neurath,
B. Weigmann; Erlangen, Germany
Symposia
nnS.B.03
Immunity Against Infections
Hall E
nnWS.B.07
Skin Diseases
Hall K
11:15 – 12:30
08:30 – 09:45
Chairpersons: Brigitte Autran; Paris, France
George Kassiotis; London, United Kingdom
Chairpersons: Karin Loser; Münster, Germany
Georg Stary; Vienna, Austria
S.B.03.1
HCMV‑specific immunity
Rene van Lier; Amsterdam, Netherlands
S.B.03.2
HIV‑specific immunity
Philip Goulder; Oxford, United Kingdom
WS.B.07.1 Hair follicle epithelial cells are responsible for chronic
inflammation in acne inversa
Michele Boniotto, C. Hotz, A. Guguin, M. Surenaud,
F. Jean‑Louis, P. Tisserand, P. Wolkenstein, H. Hocini,
Y. Lévy, S. Hüe; Créteil, France
S.B.03.3
Inflammation in tuberculosis
Stefan H.E. Kaufmann; Berlin, Germany
Primary Immunodeficiencies
Hall E
15:45 – 17:00
Chairpersons: Genevieve de Saint Basile; Paris, France
Martha Eibl; Vienna, Austria
S.B.04.1
Antibody deficiencies in man
Bodo Grimbacher; Freiburg, Germany
S.B.04.2
Immune disorder and enteropathy resulting from
TTC7A‑deficiency
R. Lemoine, A.E. Bigorgne, M. El‑Daher,
C. Leveau, H.F. Farin, F.E. Sepulveda, A. Fischer,
Genevieve de Saint‑Basile; Paris, France
S.B.04.3
Neutrophil defects in man
Kaan Boztug; Vienna, Austria
Cytokines and Chemokines
in Tumor Immunology
WS.B.07.4 The role of basophils and dendritic cells in atopic
dermatitis
C. Schwartz, Jörg U. Eberle, T. Hoyler, A. Diefenbach,
M. Lechmann, D. Voehringer; Erlangen, Germany
WS.B.07.5 Functional beta2‑integrins restrict skin inflammation
in vivo
Terhi S. Savinko, V.L. Morrison, L.M. Uotila, C.J. Wolff,
H.T. Alenius, S.C. Fagerholm; Helsinki, Finland
Workshops
nnWS.B.06
WS.B.07.3 Tight interplay of actin cytoskeleton and filaggrin
control epidermal differentiation and cornification as
revealed by quantitative nanoscopy
Danuta Gutowska‑Owsiak, J.B. de la Serna,
M. Fritzsche, C. Eggeling, G.S. Ogg; Oxford, United
Kingdom
Hall F2
11:15 – 12:30
WS.B.07.6 IgE autoreactivity in bullous pemphigoid
Patricia C. Freire, P. Heil, G. Stingl; Vienna, Austria
Chairpersons: Vito Pistoia; Genoa, Italy
Maria Sibilia; Vienna, Austria
nnWS.B.08
WS.B.06.1 The atypical chemokine receptor 2 promotes breast
cancer lung metastatization through modulation of the
metastatic niche
Matteo Massara, B. Savino, N. Caronni, O. Bonavita,
C. Recordati, A. Mantovani, M. Locati, R. Bonecchi;
Rozzano, Italy
Chairpersons: Sophie Ugolini; Marseille, France
Mathias Müller; Vienna, Austria
WS.B.06.2 TNF and IFN‑γ‑dependent signaling pathways in
cytokine‑induced cancer cell senescence
Heidi Braumueller, N. Simon, M. Rentschler, T. Wieder,
E. Brenner, M. Röcken; Tuebingen, Germany
WS.B.06.3 Notch1 and IL‑7R interplay in the pathogenesis of
T‑cell acute lymphoblastic leukemia
Marta Mosquera‑Sáiz, S. González‑García, J. Alcain,
P. Fuentes, M. García‑Peydró, B. De Andrés,
M.L. Gaspar, A. Corcoran, M.L. Toribio; Madrid, Spain
WS.B.06.4 The IL‑25/IL‑25R axis in B cell lymphomas of germinal
centre origin
E. Ferretti, E. Di Carlo, C. Tripodo, M. Ponzoni,
Vito Pistoia; Genova, Italy
WS.B.06.5 Extracellular HSP110 from colorectal cancer cells skew
macrophages polarization
Kevin Berthenet, C. Garrido, G. Jego; Dijon, France
TUESDAY
nnS.B.04
WS.B.07.2 Lesional skin of psoriatic patients is characterized by
an overexpression of IL‑17E producing keratinocytes
and IL‑17E positive dermal macrophages
Nicolo C. Brembilla, R. Stalder, M. Fernandez,
B. Shafaeddin Schreve, D. Alvarez Martinez, L. Fontao,
G. Kaya, C. Chizzolini, W. Boehncke; Geneva,
Switzerland
Innate Immune Mechanisms
in Cancer
Hall N
11:15 – 12:30
WS.B.08.1 Treatment with BRAF inhibitor impacts on melanoma
cell immunogenicity to NK cells
Marina Colombo, E. Neves, A. Frazao,
M. Messaoudene, F. Bouquet, A. Savina, M. Avril,
A. Caignard; Paris, France
WS.B.08.2 In vivo tumour surveillance by NK cells requires Tyk2
but not its kinase activity
Agnieszka Witalisz‑Siepracka, M. Prchal‑Murphy,
K.T. Bednarik, E.M. Putz, D. Gotthardt, K. Meissl, V. Sexl,
M. Müller, B. Strobl; Vienna, Austria
WS.B.08.3 A genome‑wide shRNA screening identifies novel
potential ligands for activating NK cell receptors
Paolo Romania, L. Cifaldi, E. Giorda, D. Fruci,
F. Locatelli; Rome, Italy
WS.B.08.4 TLR7 promotes tumor progression, chemotherapy
resistance, and poor clinical outcomes in non‑small
cell lung cancer
M. Dajon, K. Iribarren, D. Damotte, C. Sautès‑Fridman,
H. Fridman, Isabelle Cremer; Paris, France
67
Program per Day
Track B
WS.B.08.6 IL‑27 induces the expression of immune‑regulatory
molecules in ovarian cancer
Silvano Ferrini, G. Carbotti, D. Mezzanzanica, I. Airoldi,
M. Fabbi; Genova, Italy
nnWS.B.09
Optimizing Anti-Tumor Immunity
Hall K
15:45 – 17:00
Chairpersons: Christine S. Falk; Hannover, Germany
Annemiek von Spriel; Nijmegen, Netherlands
WS.B.09.1 Cytotoxic T‑cell transfer in combination with
programd cell death 1 blockade eradicates chronic
myelogenous leukemia stem cells
Carsten Riether, T. Gschwend, A. Huguenin,
C.M. Schuerch, A.F. Ochsenbein; Bern, Switzerland
WS.B.09.2 The cold shock protein YB‑1 (Y‑box binding protein 1)
regulates resistance against apoptosis
in T‑lymphocytes
Stefan Meltendorf, S. Gieseler, J. Handschuh,
M. Pierau, P.R. Mertens, U. Thomas,
M.C. Brunner‑Weinzierl; Magdeburg, Germany
TUESDAY
WS.B.09.3 CXCR4 inhibition in tumor microenvironment facilitates
anti‑PD‑1 immunotherapy in sorafenib‑treated
hepatocellular carcinoma in mice
Rakesh R. Ramjiawan, T. Reiberger, Y. Chen, M.R. Ng,
T. Hato, H. Ochiai, S. Kitahara, E.C. Unan, T.P. Reddy,
C. Fan, P. Huang, N. Bardeesy, A.X. Zhu, R.K. Jain,
D.G. Duda; Amsterdam, Netherlands
WS.B.09.4 Exchange of cytosolic content between T cells and
tumor cells activates CD4 T cells and impedes cancer
growth
Thorsten Lieke, M. Hardtke‑Wolenski, L. Kraus,
C. Schmetz, B. Trautewig, F. Noyan, H. Bektas,
F. Vondran, E. Jäckel; Hannover, Germany
WS.B.09.5 Breadth of melanoma antigen expression determines
clinical outcome following immunotherapy
Antonia L. Pritchard, J. Burel, M. Neller, N. Hayward,
M. Fatho, V. Lennerz, T. Wolfel, C. Schmidt;
Brisbane, Australia
nnWS.B.10
Systemic Autoimmune Disease
Hall F2
17:45 – 19:00
Chairpersons: Wlodzimierz Maslinski; Warsaw, Poland
Andrey I. Tchorbanov; Sofia, Bulgaria
WS.B.10.1 Crosstalk between isoaspartyl modification and
phosphorylation in ZAP70‑mediated lupus T cell
autoimmunity
Mei‑Ling Yang, M.J. Mamula; New Haven, United
States
WS.B.10.2 Defective autophagy in lymphocytes from patients
with SLE causes accelerated apoptosis, impaired
efferocytosis, and reduced induction of an
anti‑inflammatory immune response.
Joanne E. Simpson, K. Phadwal, M. Gray; Edinburgh,
United Kingdom
WS.B.10.3 Suppression of autoreactive cells by antibody
therapy in MRL/lpr murine model of systemic lupus
erythematosus
N. Mihaylova, S. Bradyanova, P. Chipinski,
S. Chausheva, M. Herbáth, F. D’Acquisto, J. Prechl,
Andrey I. Tchorbanov; Sofia, Bulgaria
68
WS.B.10.4 IL‑3 contributes to development of lupus nephritis in
MRL/lpr mice
Kerstin Renner, F. Hermann, K. Schmidbauer, Y. Talke,
M. Rodriguez Gomez, G. Schiechl, J. Schlossmann,
H. Brühl, H. Anders, M. Mack; Regensburg, Germany
WS.B.10.5 Altered micro‑RNA‑21 expression contributes to the
inflammatory environment observed in patients with
primary Sjögren‘s syndrome
Joan N. Gabhann, Q. Pilson, C.C. Murphy,
C.A. Jefferies; Dublin, Ireland
WS.B.10.6 A critical involvement of regulatory B cells in the
pathogenesis of experimental Sjogren’s syndrome
Liwei Lu; Hong Kong, Hong Kong
nnWS.B.11
Allergens
Hall G
17:45 – 19:00
Chairpersons: Heimo Breiteneder; Vienna, Austria
Hans Grönlund; Stockholm, Sweden
WS.B.11.1 A new fungal aspartic protease allergen Rhi o 1 and
its IgE epitopes: the first major allergen from Rhizopus
oryzae
Gaurab Sircar, S. Gupta Bhattacharya; Kolkata, India
WS.B.11.2 Heme‑induced polyreactivity of IgE antibodies
Maya Hadzhieva, T. Vassilev, L. Roumenina,
S. Lacroix‑Desmazes, J. Dimitrov; Sofia, Bulgaria
WS.B.11.3 Characterization of the allergic T cell response to
Dau c 1, the Bet v 1 homolog in carrot
Nora Zulehner, B. Nagl, G. Zlabinger, B. Bohle; Vienna,
Austria
WS.B.11.4 Biochemical and biophysical characterization of
recombinant CD23 in the trimeric complex with IgE
and allergen
Regina Selb, T. Twaroch, A. Teufelberger, C. Lupinek,
B. Linhart, J. Eckl‑Dorna, W. Keller, A. Ellinger, K.H. Roux,
V. Niederberger, R. Valenta; Vienna, Austria
WS.B.11.5 The sensitization pattern and cross‑reactivity profiles of
allergenic pectate lyases
U. Pichler, M. Hauser, M. Wolf, M. Bernardi,
G. Gadermaier, R. Weiss, C. Ebner, H. Yokoi, T. Takai,
A. Didierlaurent, C. Rafaiani, P. Briza, A. Mari,
H. Behrendt, F. Ferreira, Michael Wallner; Salzburg,
Austria
WS.B.11.6 Towards the characterization of the allergenic activity
of carbohydrate‑reactive IgE
Pia Gattinger, I. Mittermann, S. Pahr, W. Keller,
B. Linhart, R. Valenta; Vienna, Austria
nnWS.B.12
Models and Mechanisms
of Primary Immunodeficiency
Hall M
17:45 – 19:00
Chairpersons: Kaan Boztug; Vienna, Austria
Géraldine Schlecht‑Louf; Clamart, France
WS.B.12.1 EVER2 deficiency leads to altered T cell differentiation
Myriam Hayder, B. Pignolet, A. Barbaria, E. Mauré,
M. Vocanson, J. Nicolas, R.S. Liblau; Toulouse, France
WS.B.12.2 Selective deficiency of WASP in Treg cells is sufficient
to cause autoimmunity in mice
Stefano Volpi, F. Beca, M. Mizui, K. Capuder, E. Santori,
E. Csizmadia, A. Thrasher, F. Candotti, L. Notarangelo;
Epalinges, Switzerland
Program per Day
Track C
WS.B.12.4IFNγ drives disease in TLR9‑mediated secondary
hemophagocytic lymphohistiocytosis (sHLH) in mice
Vanessa Buatois, L. Chatel, L. Cons, F. Richard,
C. Bracaglia, F. De Benedetti, C. de Min,
M. Kosco‑Vilbois, W. Ferlin; Geneva, Switzerland
WS.B.12.5 Mouse cytomegalovirus infection in BALB/c
mice resembles virus‑associated secondary
hemophagocytic lymphohistiocytosis (HLH) and shows
a pathogenesis distinct from primary HLH
Ellen Brisse, M. Imbrechts, K. Put, A. Avau, T. Mitera,
C.H. Wouters, G. Andrei, P. Matthys; Leuven, Belgium
WS.B.12.6 STIM1 controls T cell‑mediated immune regulation and
inflammation in chronic infection
Carl Weidinger, L. Desvignes, P. Shaw, M. Vaeth,
T. Ribierre, M. Lui, T. Ferrgus, L. Kozhaya, L. McVoy,
D. Unutmaz, J. Ernst, S. Feske; Berlin, Germany
nnWS.B.13
Immune Disorders
Hall N
17:45 – 19:00
Chairpersons: Josef Penninger; Vienna, Austria
Gerhard Zlabinger; Vienna, Austria
WS.B.13.1 Characterization of novel PI3Kd inhibitors as potential
therapeutics for SLE and lupus nephritis
Philipp Haselmayer, M. Camps, M. Muzerelle,
R. Grenningloh, H. Ji; Darmstadt, Germany
WS.B.13.2 Persistent expression and function of P‑glycoprotein on
peripheral blood lymphocytes identifies corticosteroid
resistance in corticosteroid naïve patients with
systemic lupus erythematosus
Mohit K. Rai; Lucknow, India
WS.B.13.3 A pore ring mutation in the protein‑conducting Sec61
channel is causing plasma cell deficiency in humans.
Desirée Schubert, J. Kemming, S. Hassdenteufel,
M. Klein, J. Kühn, M. Fliegauf, S. Winzer, A. Schäffer,
J. Puck, R. Hostoffer, A. Köttgen, M. Rizzi, H. Eibel,
R. Zimmermann, B. Grimbacher; Freiburg, Germany
WS.B.13.4 Dual functionality of Mer in experimental arthritis:
anti‑inflammatory signaling and efferocytosis
Claire E.J. Waterborg, S. Beermann, M.B. Bennink,
G. Lemke, F.A. van de Loo; Nijmegen, Netherlands
WS.B.13.5 The tumor suppressor Hace1 controls intestinal
homeostasis by mediating TNF‑driven cell fate
Luigi Tortola, R. Nitsch, I. Kozieradzki, I. Uribesalgo,
M. Floderer, M.J. Bertrand, M. Daugaard, H. Klug,
Y. Redouane, G. Wirnsberger, N. Takahashi,
G. Superti‑Furga, A. Pichler, G. Kroemer,
P. Vandenabeele, P.H. Sorensen, J.M. Penninger;
Vienna, Austria
WS.B.13.6 Angiotensin II promotes regulatory B cells in the
presence of BAFF and reduces experimental
atherosclerosis
Padmapriya Ponnuswamy, J. Joffre, Y. Quang,
B. Esposito, M. Dalloz, T. Tedder, A. Tedgui, C. Binder,
Z. Mallat, H. Ait‑Oufella; Paris, France
TRACK C
Symposia
nnS.C.03
Innate Effector Functions
Hall A
11:15 – 12:30
Chairpersons: Francesca Granucci; Milan, Italy
James Philip Di Santo; Paris, France
S.C.03.1
Macrophage function in parasitic infection
Judith Allen; Edinburgh, United Kingdom
S.C.03.2
Mast cells and basophils
Massimo Triggiani; Salerno, Italy
S.C.03.3
Effector functions of neutrophils
Arturo Zychlinsky; Berlin, Germany
nnS.C.04
Antigen Uptake and Presentation
Hall A
17:45 – 19:00
Chairpersons: Thomas Brocker; Munich, Germany
Sebastian Amigorena; Paris, France
S.C.04.1Cross‑presentation
Christian Kurts; Bonn, Germany
S.C.04.2
Antigen presentation via C-type lectins to design
DC targeting vaccines
Yvette van Kooyk; Amsterdam, Netherlands
S.C.04.3
How B cells capture, process and present antigens:
a crucial role for cell polarity
Anna Maria Lennon Dumenil; Paris, France
TUESDAY
WS.B.12.3 CXCR4 desensitization exerts subset‑specific control of
dendritic cell homeostasis and function in vivo
M. Roriz, J. Calmette, N. Pionnier, M. Aknin,
M. Evrard, P. Hémon, F. Gaudin, K. Balabanian, L. Ng,
F. Bachelerie, Géraldine Schlecht‑Louf; Clamart,
France
Workshops
nnWS.C.07
Macrophage Signaling
Hall F2
08:30 – 09:45
Chairpersons: Thomas Decker; Vienna, Austria
Holger Heine; Borstel, Germany
WS.C.07.1 Lysophosphatidylcholine acyltransferase (LPCAT) 2
regulates macrophage inflammatory gene expression
in response to Toll‑like receptor stimulation
Wondwossen Abate, M. Thanabalasingam, S. Jackson;
Plymouth, United Kingdom
WS.C.07.2 The embryonic journey toward tissue‑resident
macrophage development
Guillaume Hoeffel, J. Chen, Y. Lavin, D. Low,
F.F. Almeida, P. See, A.E. Beaudin, E.C. Forsberg,
M. Poidinger, F. Zolezzi, A. Larbi, L.G. Ng, J.K. Chan,
M. Greter, B. Becher, I.M. Samokhvalov, M. Merad,
F. Ginhoux; Singapore, Singapore
WS.C.07.3 FLT1 signaling in metastasis‑associated macrophages
activates an inflammatory signature that promotes
breast cancer distal metastasis
Bin‑Zhi Z. Qian, H. Zhang, J. Li, T. He, E. Yeo, R.A. Lang,
J.W. Pollard; Edinburgh, United Kingdom
WS.C.07.4 Early life antigen and adjuvant trafficking
Floriane Auderset, B. Mastelic Gavillet, P. Lambert,
C. Siegrist; Geneva, Switzerland
69
Program per Day
Track C
WS.C.07.5 DNA polymerase µ protects macrophages from
double‑strand DNA breaks produced during
pro‑inflammatory activation
Juan A. Calatayud‑Subias, C. Sebastian,
S. Pereira‑Lopes, M. Serra, L. Valverde‑Estrella,
A. Bernad, J. Lloberas, A. Celada; Barcelona, Spain
WS.C.07.6 mTORC2 regulates macrophage polarization and the
cellular energy metabolism
Karl Katholnig, M. Hirtl, M. Hengstschläger, T. Weichhart;
Vienna, Austria
nnWS.C.08
Epigenetics in Innate Immunity
Hall K
08:30 – 09:45
WS.C.08.1 Roquin regulates microRNA homeostasis
in T lymphocytes
Monika Srivastava; Canberra, Australia
WS.C.08.2 MicroRNA‑146a controls the functional plasticity of
gamma‑delta T cells
N. Schmolka, T. Amado, B. Silva‑Santos, Anita Gomes;
Lisbon, Portugal
WS.C.08.3 microRNA‑135b: the pivot of macrophage polarization
balance
Naths Grazia Sukubo, M. Pesant, M. Locati; Rozzano
(MI), Italy
TUESDAY
WS.C.09.5 Lamellipodia and filopodia promote environmental
exploration but are dispensable for locomotion of
leukocytes
A. Eichner, Alexander Leithner, J. Mueller, A. Reversat,
M. Brown, J. Schwarz, J. Merrin, D.J. de Gorter,
F. Schur, J. Bayerl, I. de Vries, S. Wieser, R. Hauschild,
F.P. Lai, M. Moser, D. Kerjaschki, K. Rottner, J.V. Small,
T.E. Stradal, M. Sixt; Klosterneuburg, Austria
WS.C.09.6 Histone methyltransferase Ezh2 controls cell adhesion
and migration through direct methylation of the
extra‑nuclear protein, talin
L. Jia Tong, M. Gunawan, N. Venkatesan, J. Wong,
H. Berger, S. Yamazak, A. Gingras, F. Ginhoux, I‑hsin Su;
Singapore, Singapore
Chairpersons: Anita Gomes; Lisboa, Portugal
Herbert Strobl; Graz, Austria
WS.C.08.4 Altered miR‑125a expression in monocytes contributes
to dysregulated IL‑16 levels in SLE.
Siobhan Smith, J. Ní Gabhann, E. McCarthy, G. Kearns,
C. Jefferies; Dublin, Ireland
WS.C.08.5 Tracking myeloid cell development using methylation
patterns
Ulrike Träger, G. Raddatz, R. Schulz, A. Breiling,
M. Feuerer; Heidelberg, Germany
WS.C.08.6 Histone deacetylase 2 couples Interleukin‑10
anti‑inflammatory activity with Interleukin‑8
transcriptional repression: implication for Chronic
obstructive pulmonary disease patients
Monica Castellucci, M. Rossato, N. Tamassia,
S. Gasperini, B. Mariotti, M.A. Cassatella, F. Bazzoni;
Verona, Italy
nnWS.C.09
WS.C.09.4 Calcineurin‑NFAT signaling control of the innate
response
Jan Fric, T. Zelante, A. Wong, A. Mencarelli, B. Lee,
M. Poindinger, P. Ricciardi‑Castagnoli; Brno, Czech
Republic
Innate Cell Signalling & Function
Hall N
08:30 – 09:45
Chairpersons: Pavel Kovarik; Vienna, Austria
Elke Scandella; St. Gallen, Switzerland
WS.C.09.1 DNAM‑1 expression marks an alternative program of
NK cell maturation
Ludovic Martinet, L. Ferrari De Andrade, C. Guillerey,
J. Lee, N. Huntington, M.J. Smyth; Toulouse, France
WS.C.09.2 NK cells in human glioma tumor control: evidence of
a distinct immune microenvironment in tumor vs non
tumor infiltrated brain
Elena Ciaglia, M. Abate, F. Montella, V. Seneca, G. Di
Nuzzo, S. Pisanti, C. Laezza, G. Torelli, G. Catapano,
M. Bifulco; Fisciano, Italy
nnWS.C.10
Macrophages in Diseases
Hall F2
15:45 – 17:00
Chairpersons: Judith Allen; Edinburgh, United Kingdom
Chiara Porta; Rozzano, Italy
WS.C.10.1 Alveolar macrophages modulate innate immune
responses to respiratory syncytial virus (RSV) infection
through MAVS signalling and type I interferons
M. Goritzka, S. Makris, F. Kausar, S. Akira,
Cecilia Johansson; London, United Kingdom
WS.C.10.2 Autophagy as a key regulator of parasite survival in
macrophages and dendritic cells
P. Crauwels, L. Roßmann, R. Bohn, L. Miller, Z. Waibler,
C. van Kooten, Ger van Zandbergen; Langen,
Germany
WS.C.10.3 Modulation of monocytes by bioactive lipid
anandamide in multiple sclerosis involve distinct
Toll‑like receptors
Valerio Chiurchiu, M. Cencioni, M. De Bardi, A. Leuti,
D. Centonze, L. Battistini, M. Maccarrone; Rome, Italy
WS.C.10.4 Modulation of influenza virus‑induced macrophage
activation by decoy receptor 3 (DcR3)
M. Huang, S. Chen, H. Wu, Y. Chen, T. Chou,
Shie‑Liang Hsieh; Taipei, Taiwan
WS.C.10.5 Efferocytosis of CD8 T cells induces parasite‑permissive
M2 macrophages in mice infected with Trypanosoma
cruzi
M.C. Piccin, L.C. Guillermo, N.S. Vellozo, S.P. Marques,
T.S. Rigoni, G.A. DosReis, Marcela F. Lopes; Rio de
Janeiro, Brazil
WS.C.10.6 Ly6C+ monocytes and neutrophils promote renal
kidney injury in a mouse model of shiga toxin‑induced
hemolytic uremic syndrome
Judith M. Pohl, J. Volke, S. Thiebes, F. Kerstin,
B.J. Pichler, D.R. Engel; Essen, Germany
WS.C.09.3 The innate immune sensor IFI16 moves along dsDNA to
distinguish self from nonself.
Sarah A. Stratmann, S. Morrone, J. Sohn, A.M. van
Oijen; Groningen, Netherlands
70
Program per Day
Track D
Innate Lymphoid Cells
Hall G
15:45 – 17:00
Chairpersons: Chiara Romagnani; Berlin, Germany
Marcel B. Teunissen; Amsterdam, Netherlands
WS.C.11.1 Human RORgt+ CD34+ cells are lineage‑specified
progenitors of group 3 RORgt+ innate lymphoid cells
Elisa Montaldo, K. Juelke, C. Romagnani; Genova,
Italy
WS.C.11.2 Regulation of group 2 innate lymphoid cells in the lung
Claudia U. Duerr, C.D. McCarthy, B.C. Mindt, J.H. Fritz;
Montreal, Canada
WS.C.11.3 Notch signaling controls innate lymphoid cells
balance
S. Chea, N. Serafini, S. Schmutz, O. Burlen‑defranoux,
D. Guy‑Grand, A. Cumano, J. Di Santo, Rachel Golub;
Paris, France
WS.C.11.4TGF‑β is required for the development of intestinal
CD103+CD11b+ dendritic cells which control group 3
innate lymphoid cell homeostasis
Yasmina Laouar; Ann Arbor, United States
WS.C.11.5 Id2 expression in human thymic progenitor cells drives
commitment of innate lymphoid cell development
Maho Nagasawa, B. Blom, H. Spits; Amsterdam,
Netherlands
WS.C.11.6 PLZF expression maps the early stages of ILC1 lineage
development
Michael G. Constantinides, H. Gudjonson,
B.D. McDonald, I.E. Ishizuka, P.A. Verhoef, A.R. Dinner,
A. Bendelac; Bethesda, United States
TRACK D
Symposia
nnS.D.03
Antibody Therapeutics
Hall E
11:15 – 12:30
Chairpersons: Lucienne Chatenoud; Paris, France
John McCafferty; Cambridge, United Kingdom
S.D.03.1
From broadly neutralizing antibodies to a new
mechanism of diversification
Antonio Lanzavecchia; Bellinzona, Switzerland
Treatment of Autoimmune disease with antibodies
Falk Nimmerjahn; Erlangen, Germany
S.D.03.3
Antibody effector function‑modulation through
glycosylation
Roy Jefferis; Birmingham, United Kingdom
Hall E
17:45 -19:00
Chairpersons: Christoph Zielinski; Vienna, Austria
Paul Parren; Utrecht, Netherlands
S.D.04.1
Making the most of CD137 (4‑1BB) in cancer
immunotherapy
Ignacio Melero; Pamplona, Spain
S.D.04.2
Cancer immunotherapy by PD‑1 blockade
Tasuku Honjo; Kyoto, Japan
S.D.04.3
New concepts on cancer immunotherapy
Laurence Zitvogel; Villejuif, France
nnWS.D.05
T Cell Based Cancer Immunotherapy Hall F1
08:30 – 09:45
Chairpersons: Mirjam H.M. Heemskerk; Leiden, Netherlands
Tim D. Sparwasser; Munich, Germany
WS.D.05.1 PD‑1 expression conditions T‑cell avidity within an
antigen‑specific repertoire
Sylvain Simon, V. Vignard, L. Florenceau, B. Dréno,
A. Khammari, F. Lang, N. Labarriere; Nantes, France
WS.D.05.2 The microenvironment at the invasive margin between
metastatic colorectal cancer tissue and adjacent liver
represents a T cell trap and supports tumor survival ‑
an option for therapeutic intervention for metastatic
colorectal cancer patients
Christine S. Falk, N. Halama, I. Zörnig, A. Spille,
C. Kahlert, C. Brandt, J. Krauss, T. Lerchl, M. Koch,
N. Grabe, D. Jäger; Hannover, Germany
WS.D.05.3 Adenosine receptor 2A blockade increases the
efficacy of anti‑PD‑1 through enhanced anti‑tumor
T cell responses
Paul A. Beavis; Melbourne, Australia
WS.D.05.4 T cell receptor sequencing indicates its potential
use as predictive biomarker for dendritic cell‑based
cancer immunotherapy in glioblastoma patients
I. Sloma, S. Klingenbrunner, K. Fischhuber,
R. Reitermaier, S. Efroni, T. Felzmann, Carmen Visus;
Vienna, Austria
WS.D.05.5 CAR T cells inflict sequential killing of multiple tumour
target cells
Alexander J. Davenport, M.R. Jenkins, R.S. Cross,
C.S. Yong, D.S. Ritchie, J.A. Trapani, M.H. Kershaw,
P.K. Darcy, P.J. Neeson; Melbourne, Australia
WS.D.05.6 How do PI3K inhibitors affect the CD8 cytotoxic
immune response?
Ee Lyn Lim, D.R. Soond, K. Okkenhaug; Cambridge,
United Kingdom
nnWS.D.06
Stem Cells and Cell-Based Therapy
Hall G
08:30 – 09:45
Chairpersons: Silke Appel; Bergen, Norway
Idit Shachar; Rehovot, Israel
S.D.03.2
nnS.D.04
Workshops
WS.D.06.1 Pluripotent stem cells varying in a single antigen from
recipients elicit upon transplantation cellular and
humoral immune responses that can mediate graft
rejection
Sebastian Monecke, C. Hamann, L. Elsner, J. Nolte,
W. Engel, G. Hasenfuß, A. Mansouri, K. Guan,
R. Dressel; Göttingen, Germany
WS.D.06.2 Human induced pluripotent stem cells are targets for
allogeneic and autologous natural killer (NK) cells and
killing is partly mediated by the activating NK receptor
DNAM‑1
Carina Hamann, V. Kruse, S. Monecke, L. Cyganek,
L. Elsner, D. Hübscher, L. Walter, K. Streckfuss‑Bömeke,
K. Guan, R. Dressel; Göttingen, Germany
WS.D.06.3 Modulation of microglia responses via mesenchymal
stromal cells derived‑ microvesicles
Yarúa Jaimes, Y. Naaldijk, K. Wenk, F. Emmrich; Leipzig,
Germany
71
TUESDAY
nnWS.C.11
Program per Day
Track E
WS.D.06.4 Mesenchymal stem cells modulate experimental arthritis
by inducing an early regulatory adaptive T response
M. Lopez‑Santalla, P. Mancheño‑Corvo, R. Menta,
J. Lopez‑Belmonte, O. DelaRosa, W. Dalemans,
E. Lombardo, J.A. Bueren, Marina Garin; Madrid, Spain
WS.D.08.3 The involvement of the homing receptors CCR7 and
CD62L in the pathogenesis of graft‑versus‑host disease
Federico Herrera, V. Gomez Garcia De Soria, I. Portero
Sainz, C. Fernandez Arandojo, A. Marcos Jimenez,
A. Kreutzman, C. Muñoz Calleja; Madrid, Spain
WS.D.06.5 alloCELL: established procedure for donor selection
and GMP‑compliant manufacturing of cellular
products for therapeutic purpose
S. Tischer, C. Priesner, L. Arseniev, J. Martens,
L. Goudeva, H. Heuft, M. Hallersleben, C. Figueiredo,
S. Immenschuh, U. Köhl, R. Blasczyk, B. Maecker‑Kolhoff,
Bitta Eiz‑Vesper; Hannover, Germany
WS.D.08.4 In vitro‑generated myeloid‑derived suppressor cells
(MDSCs) prevent murine graft‑versus‑host disease
(GVHD) by inducing type 2 T cells without disabling
anti‑tumor cytotoxicity
J.J. Messmann, T. Reisser, F. Leithäuser, S. Muche,
M. Lutz, K. Debatin, Gudrun Strauss; Ulm, Germany
WS.D.06.6 Isolation of antigen‑specific TCRs for immunotherapy
using an MHC cell library and next generation
sequencing
Felix K. Lorenz, C. Ellinger, E. Kieback, S. Wilde,
D.J. Schendel, W. Uckert; Berlin, Germany
nnWS.D.07
Novel Approaches for Vaccines
Hall F1
15:45 – 17:00
Chairpersons: África González‑Fernández; Vigo, Spain
Richard Lo‑Man; Paris, France
TUESDAY
WS.D.07.1 Polyethylenimine‑based polyplex delivery of
self‑replicating RNA vaccines
Thomas Démoulins, P. Milona, P. Englezou, R. Suter,
C. Pichon, N. Ruggli, K.C. McCullough; Mittelhäusern,
Switzerland
WS.D.07.2 Novel combined antigen M2e‑NP‑HAs is a potential
candidate for research and development of universal
influenza vaccines
Wenling Wang, B. Huang, X. Wang, Y. Deng, W. Tan,
L. Ruan; Beijing, China
WS.D.07.3 Selected TLR agonists improve vaccination outcome in
nicotine exposed mice
Mahyar Nouri‑Shirazi, M. Zeng, B. Bible, S. Tamjidi; Boca
Raton, United States
WS.D.07.4 Nanoparticulation of a STING pathway ligand, cyclic
di‑GMP, enhances cancer immunotherapy against
metastatic melanoma
Takashi Nakamura, H. Miyabe, M. Hyodo, Y. Sato,
Y. Hayakawa, H. Harashima; Sapporo, Japan
WS.D.08.5 IL‑6 dysregulation and graft‑versus‑host disease:
A new therapeutic target
Antiopi Varelias, G.A. Kennedy, S. Vuckovic, L. Le
Texier, P. Zhang, K.H. Gartlan, G. Thomas, G. Boyle,
N. Cloonan, S.D. Olver, R.D. Kuns, M. Koyama,
J. Leach, E. Sturgeon, J. Avery, P. Reddy, G.A. Yanik,
A.D. Clouston, K.P. MacDonald, B.R. Blazar, K.R. Cooke,
S. Tey, G.R. Hill; Brisbane, Australia
WS.D.08.6 Interplay between donor PD‑L1 and recipient
PD‑1 regulates acute graft rejection after liver
transplantation
X. Shi, S. Mancham, B. Hansen, J. de Jonge,
L.J. van der Laan, F. Rivadeneira, H.J. Metselaar,
Jaap Kwekkeboom; Rotterdam, Netherlands
TRACK E
Workshop
nnWS.E.01
Structural Biology and Imaging
Hall M
08:30 – 09:45
Chairpersons: Walter Keller; Graz, Austria
Hans Brandstetter; Salzburg, Austria
WS.E.01.1 An emerging approach for parallel quantification
of intracellular protozoan parasites and host cell
characterization using TissueFAXS cytometry
M. Schmid, B. Dufner, J. Dürk, J. Dürk, R. Ecker,
Uwe Ritter; Regensburg, Germany
WS.D.07.5 Dectin‑1 activation unlocks IL12A expression and
reveals the Th1 potency of neonatal dendritic cells
S. Lemoine, B. Jaron, S. Tabka, L. Majlessi, P. Tissieres,
C. Leclerc, Richard Lo‑Man; Paris, France
WS.E.01.2 A bioinformatic framework for immune repertoire
diversity profiling enables detection of immunological
status
Victor Greiff, P. Bhat, S. Cook, U. Menzel, W. Kang,
S.T. Reddy; Basel, Switzerland
WS.D.07.6 Mucosal vaccination strategies against
Mycobacterium tuberculosis infection
Carolina Perdomo, A. Vogelzang, A. Kupz,
S.H. Kaufmann; Berlin, Germany
WS.E.01.3 Visualization of T cell dynamics in the liver by
multispectral optoacoustic tomography (MSOT)
Michael J. Dudek; Munich, Germany
nnWS.D.08
Solid Organ and
Bone Marrow Transplantation
Hall N
15:45 – 17:00
Chairpersons: Michel Braun; Gosselies, Belgium
Gianpietro Semenzato; Padua, Italy
WS.D.08.1 Xenotransplantation combined with bio‑signatures ‑
a milestone towards personalized medicine
Michaela Prchal‑Murphy, S. Fajmann, A. Schumich,
V. Sexl, M.N. Dworzak; Vienna, Austria
WS.D.08.2 Human monocyte‑derived suppressor cells as an
innovative immunotherapy for graft‑versus‑host disease
Nona Janikashvili, M. Samson, A. Gautheron, M. Trad,
M. Thébault, M. Ciudad, S. Audia, B. Bonnotte; Dijon,
France
72
WS.E.01.4 A new reporter system for dissecting the interplay
between pathogen physiology and the immune
system by intravital 2‑photon imaging
P. Formaglio, S. Heyde, R. Olekhnovitch, P. Bousso,
Andreas J. Müller; Magdeburg, Germany
WS.E.01.5 A chimeric protein derived from the major birch pollen
allergen Bet v 1 and its homolog Api g 1 exhibits a
domain‑swapped dimeric arrangement and a fold
distinct from its parent structures
Judith Wortmann, B. Gepp, H. Breiteneder, W. Keller;
Graz, Austria
WS.E.01.6 Mechanism of antibody recognition of neuronal
intrinsically disordered protein tau
O Cehlar, R. Skrabana, M. Novak; Bratislava, Slovakia
Program per Day
Joint-Symposia of the Day
Vaccine Development can Benefit from
Computational Biology (jointly with IUIS) Hall A
14:00 – 15:30
Women in Immunology
nnWO.00
Chairpersons: Jorge Kalil; São Paulo, Brazil
Informal lunch event for members of the German Society for Immunology (DGfI), organized by the ,,Commission on Equality and Career
Support“. Meet senior immunologists and talk about challenges and
solutions in balancing career and family.
Systems biology analysis of influenza vaccines
Bali Pulendran; Atlanta, United States
JS.04.2
Tuberculosis Vaccines and Biomarkers
Stefan H.E. Kaufmann; Berlin, Germany
JS.04.3
Future approaches towards malaria vaccination
I. Bujila, Marita Troye‑Blomberg, M. Cherif, G.S. Sanou,
A. Lennartsson, I. Nebié, A. Östlund Farrants;
Stockholm, Sweden
T Helper Cell Subsets in Health
and Disease (jointly with EAACI)
Hall E
14:00 – 15:30
Chairpersons: Carsten Schmidt‑Weber;
Munich, Germany
Barbara Bohle; Vienna, Austria
JS.05.1
Free Lunch bags will be provided.
Fully booked, registration is no more possible!
nnBA.16
JS.05.3
Th2 cells regulate epithelial immunity
Carsten Schmidt‑Weber; Munich, Germany
nnBA.18
Hall F2
Chairpersons: Rene Van Lier;
Amsterdam, Netherlands
Andreas Radbruch; Berlin, Germany
JS.06.1
Towards 40‑color flow cytometry
Pratip Chattopadhyay; Elkridge, United States
JS.06.2
T cell landscapes
Tim Mosmann; Rochester, United States
nnBA.20
T cell therapies
Dirk Busch; Munich, Germany
closed*
14:00 – 15:30
Chairpersons: Peter Openshaw;
Verena Niederberger; Vienna, Austria
French Society of Immunology (SFI)
Belgian Immunological Society (BIS)
09:45 – 11:15
IUIS Quality Assessment and Standardization
Committee Meeting
closed*L7
10:00 – 12:00
nnBA.21
EEIG ECI-EFIS Meeting
12:15 – 13:45
EFIS General Assembly
closed*
nnBA.22
14:00 – 17:00
Inaugural IUIS Vaccine Committee Meeting
closed*
16:00 -17:30
JS.07.1
Impact of intestinal microbiota in shaping innate
immunity
Kathy McCoy; Bern, Switzerland
JS.07.2
The role of the transcription factor T‑bet in gut mucosal
responses
Graham M. Lord; London, United Kingdom
closed*
JS.07.3
Role of the microbiota in regulation of immunity in the
respiratory tract
Ben Marsland; Epalinges, Switzerland
09:45 – 11:45
General Assembly
nnBA.19.1
The Mucosal Microbiome in Health and
Disease (jointly with SMI)
Hall G
09:45 – 11:15
Annual board meeting
nnBA.19
Cytometry of the 21st Century
(jointly with ISAC)
14:00 – 15:30
nnJS.07
09:45 – 11:15
Retention of effector T cells in inflamed tissues
Valerie Julia, D. Dombrowicz, D. Staumont‑Sallé; IPMC‑
Valbonne, France
JS.06.3
General Assembly
nnBA.17
Stability of human Th17 cells in chronic
inflammatory disorders
Francesco Annunziato; Florence, Italy
JS.05.2
nnJS.06
L7
14:00 – 15:30
JS.04.1
nnJS.05
Career Lunch
for Early Career Immunologists
nnBA.23
EFIS Board Meeting
17:00 -18:00
73
TUESDAY
nnJS.04
Program per Day
Meet the Professor Breakfast
Informal breakfast event for early career scientists. The “Meet the Professor Sessions” will provide participants the opportunity to meet the
most renowned senior scientists in an interactive and casual manner.
Maximum amount of participants: 30
nnME.02
Jürgen Wienands
Meeting Room 1
(1.85-86)
07:15 – 08:15
nnME.03
Ron Germain
Meeting Room 3
(2.15)
Luke O’Neill
nnP.B.24
Mediators of (Neuro) Immune Regulation
nnP.B.25
Allergen Specific Immune Response - Part 2
nnP.B.26
Allergic Disorders - Part 2
nnP.B.27
nnP.B.28
Tumormarkers
nnP.C.11
Macrophages - Part 1
07:15 – 08:15
nnP.C.12
Meeting Room 6
(2.12)
nnP.C.13
07:15 – 08:15
nnP.C.14
nnP.C.15
Cytokines - Part 1
nnP.C.16
Cell Signaling - Part 2
TUESDAY
Animal Models of Autoimmunity
nnP.C.10
Meeting Room 5
(2.17)
nnME.05
nnP.B.23
Innate Immunity - Inflammation - Part 1
07:15 – 08:15
(Chronic) Inflammatory Joint Disease - Part 2
nnP.C.09
nnME.04
nnP.B.22
nnP.A.11
Lymphocyte Development - Part 1
nnP.A.12
Antigen Receptor Signalling
nnP.A.13
nnP.A.14
Th1 and Th2 Cells - Part 2
nnP.A.15
nnP.A.16
nnP.A.17
nnP.A.18
nnP.A.19
Antibody Engineering and B Cell Effector
Molecules
nnP.B.15
Immunity to Virus Infection - Part 1
nnP.B.16
Immunity to Bacterial Infection and Parasites
nnP.B.17
Immunity to Parasite Infection
nnP.B.18
nnP.B.19
nnP.B.20
Inflammatory Bowel Disease
nnP.B.21
Neuroimmunology and Multiple Sclerosis
74
nnP.D.11
Vaccines - Part 2
nnP.D.12
Vaccines & Veterinary Immunology - Part 2
nnP.D.13
Immune Interventions in Autoimmunity - Part 2
nnP.D.14
nnP.D.15
nnP.D.16
Immunotherapy for Infectious Diseases
nnP.D.17
Immunogenicity against Biopharmaceuticals
- Part 2
nnP.D.18
Immunopharmacology
Track E – Other
nnP.E.02
Immune Response in Aging &
Systems Biology - Part 1
nnP.E.03
Metabolism & Immunity
WEDNESDAY
Schedule at a Glance Wednesday. . . . . . . . . . . . . . . . . . . . . 76
Track A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
Track B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
Track C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Track D. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
Track E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
WEDNESDAY
Educational Courses & Scientific Satellite Symposia . . . . . . . 88
Meet the Professor Breakfast. . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Closing and Award Ceremony. . . . . . . . . . . . . . . . . . . . . . . . . 89
Related Post Congressional Events in Vienna
after the 4th ECI Congress. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
75
Program per Day
WEDNESDAY, SEPT. 9, 2015
SCHEDULE AT A GLANCE WEDNESDAY
Room
Hall A
Hall E
Hall F1
Hall F2
Hall G
Hall K
Level
2
0
0
0
-2
-2
07:15 – 08:15
08:15 – 08:30
08:30 – 08:45
08:45 – 09:00
S.A.05
Adaptive Immunity
09:00 – 09:15 Maintenance
09:15 – 09:30
09:30 – 09:45
of Lymphocyte
Memory
S.B.05
Diseases
Autoimmunity
WS.D.09
WS.C.12
Cancer
Dendritic Cell
Immunotherapy and Differentiation and
Anti-Tumor Vaccines Function
WS.D.10
WS.C.13
Intervention and
Therapy of Allergy
Mast Cells
09:45 – 10:00
10:00 – 10:15
EP.01
1st EFIS President's
Symposium
10:30 – 10:45 On NK Cells and NK
Cell-Based Therapy
10:45 – 11:00 of Leukemias
10:15 – 10:30
11:00 – 11:15
11:15 – 11:30
11:30 – 11:45
S.C.05
Innate Immunity
11:45 – 12:00 Innate Lymphocytes
12:00 – 12:15 - Backstage or
12:15 – 12:30
Centerstage
S.D.05
T Cell Mediated
Immunotherapy
WS.A.12
Control of CD8+ T
Cells (part 3)
WS.B.14
WS.B.15
Immune Recognition Immune Regulation
and Control of
at the Intestinal
Infections
Barrier
WS.B.16
Mediators of Airway
Inflammation
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
13:15 – 13:30
JS.08
KL.D.1
World Allergy
Association (WAO)
Mechanisms in
Allergy
13:30 – 13:45 Cancer Therapy
13:45 – 14:00
14:00 – 14:15
JS.09
European Society for
Immunodeficiencies
(ESID)
Newborn
Screening for
Immunodeficiency
14:15 – 14:30
14:30 – 14:45
14:45 – 15:00
WEDNESDAY
15:00 – 15:15
S.A.06
Adaptive Immunity
15:15 – 15:30 Molecular Switches
15:30 – 15:45 in Adaptive
Immunity
15:45 – 16:00
S.B.06
Diseases
Stroma - Immune
Interactions in
Cancer and
Inflammation
WS.D.12
Immune Intervention
in Autoimmune
Diseases
WS.C.15
WS.A.15
WS.D.13
WS.A.16
WS.B.19
WS.B.20
Dendritic Cell
Subsets
Treg Function /
Biology
Immunotherapy of
Infectious Diseases
16:00 – 16:15
16:15 – 16:30
16:30 – 16:45
S.C.06
S.D.06
Inhibitory and
Aging and the
17:00 – 17:15 Activating Receptors Immune System
WS.B.18
Tumor Biology and
Immunosurveillance
Looking at the
"States and Fates of
T Cells"
Immune Modulation
HIV Infection and
Immune Control
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
18:15 – 18:30
Closing and Award
Ceremony
18:30 – 18:45
18:45 – 19:00
19:00 – 19:15
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
20:00 – 20:15
20:15 – 20:30
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
76
Program per Day
SCHEDULE AT A GLANCE WEDNESDAY
Hall M
Hall N
Meeting Room 1
(1.85-86)
1
1
1
Meeting Room 2
(1.61)
Room
1
Level
ME.06
Mirjam Heemskerk
07:15 – 08:15
08:15 – 08:30
08:30 – 08:45
WS.C.14
NK and NKT Cell
Function
08:45 – 09:00
WS.D.11
Imaging & cancer
therapy
09:00 – 09:15
09:15 – 09:30
09:30 – 09:45
09:45 – 10:00
10:00 – 10:15
Poster Session and
Coffee Break
10:15 – 10:30
10:30 – 10:45
10:45 – 11:00
11:00 – 11:15
11:15 – 11:30
WS.A.13
Lymphocyte Subsets
(part 2)
WS.A.14
T Cell Mediated
Control of GC
Reactions
11:30 – 11:45
Meeting
IUIS The Importance of
Standardization for
Immunology
WO.01
11:45 – 12:00
12:00 – 12:15
12:15 – 12:30
12:30 – 12:45
12:45 – 13:00
13:00 – 13:15
13:15 – 13:30
Women in
Immunology
She is a genius
13:30 – 13:45
13:45 – 14:00
14:00 – 14:15
14:15 – 14:30
14:30 – 14:45
14:45 – 15:00
Metabolism &
Immunity
15:00 – 15:15
WS.B.17
WEDNESDAY
WS.E.02
15:15 – 15:30
Immune
Dysregulation
15:30 – 15:45
15:45 – 16:00
16:00 – 16:15
WS.A.17
Extrinsic and Intrinsic
Control of Positive/
Negative T Cell
Selection
WS.A.18
Germinal
Centers: Survival
& Differentiation
Signals
BA.23.1
Österreichische
Gesellschaft für
Allergologie und
Immunologie (ÖGAI)
Board Meeting
(Vorstandssitzung)
16:15 – 16:30
16:30 – 16:45
16:45 – 17:00
17:00 – 17:15
17:15 – 17:30
17:30 – 17:45
17:45 – 18:00
18:00 – 18:15
18:15 – 18:30
18:30 – 18:45
18:45 – 19:00
19:00 – 19:15
BA.24
Österreichische
Gesellschaft für
Allergologie und
Immunologie (ÖGAI)
General Assembly
(Generalversammlung)
19:15 – 19:30
19:30 – 19:45
19:45 – 20:00
20:00 – 20:15
20:15 – 20:30
20:30 – 20:45
20:45 – 21:00
21:00 – 21:15
21:15 – 21:30
77
Program per Day
OVERVIEW PER TRACK
Keynote Lecture of the Day - KL.D.1 – Disease Intervention
13:00 – 14:00
Chairperson:
Hall A
Anne Hosmalin; Paris, France
Cancer Therapy
Michael Milone
University of Pennsylvania, Department of Pathology & Laboralory Medicine; Philadelphia, United States
Dr. Milone received his M.D. and Ph.D. in experimental pathology in 1999 from Rutgers-New Jersey Medical School (formerly the University of Medicine and Dentistry of New Jersey). After an Internship in Internal
Medicine at the Hospital of the University of Pennsylvania, he completed post-graduate medical training
in Clinical Pathology, Transfusion Medicine and Laboratory Toxicology. Following clinical training, Dr. Milone
pursued post-doctoral research training in cancer immunology and adoptive immunotherapy with Dr. Carl
June at the University of Pennsylvania where he performed basic research to develop CTL019, a genetically
modified T cell therapy for B-cell leukemia and lymphoma that has been licensed by Novartis and undergoing early phase clinical testing. He is currently an Assistant Professor of Pathology and Laboratory Medicine
at the University of Pennsylvania School of Medicine. At present, Dr. Milone’s laboratory is focused on T cell
biology and the development of new techniques for culturing and genetically modifying T lymphocytes for
adoptive immunotherapy of cancer.
OVERVIEW PER TRACK
WEDNESDAY
Symposia
S.A.05
Maintenance of Lymphocyte Memory
S.A.06
Molecular Switches in Adaptive Immunity
Symposia
S.C.05
Innate Lymphocytes - Backstage or Centerstage
S.C.06
Inhibitory and Activating Receptors
Workshops
WS.A.12
WS.A.13
WS.A.14
WS.A.15
WS.A.16
WS.A.17
Workshops
WS.C.12
WS.C.13
WS.C.14
WS.C.15
WS.A.18
Lymphocyte subsets - Part 2
T Cell Mediated Control of GC Reactions
Treg Function / Biology
Looking at the "States and Fates of T Cells"
Extrinsic and Intrinsic Control of Positive/Negative
T Cell Selection
Germinal Centers: Survival & Differentiation Signals
Symposia
S.B.05Autoimmunity
S.B.06
Stroma - Immune Interactions in Cancer and
Inflammation
Workshops
WS.B.14
WS.B.15
WS.B.16
WS.B.17
WS.B.18
WS.B.19
WS.B.20
78
Immune Recognition and Control of Infections
Immune Regulation at the Intestinal Barrier
Mediators of Airway Inflammation
Immune Dysregulation
Tumor Biology and Immunosurveillance
Immune Modulation by Infectious Agents
HIV Infection and Immune Control
Dendritic Cell Differentiation and Function
Mast Cells
NK and NKT Cell Function
Dendritic Cell Subsets
Symposia
S.D.05
T Cell Mediated Immunotherapy
S.D.06
Aging and the Immune System
Workshops
WS.D.09
WS.D.10
WS.D.11
WS.D.12
WS.D.13
Cancer Immunotherapy and Anti-Tumor Vaccines
Intervention and Therapy of Allergy
Imaging & Cancer Therapy
Immune Intervention in Autoimmune Disease
Immunotherapy of Infectious Diseases
TRACK E – OTHER
Workshop
WS.E.02
Program per Day
Track A
TRACK A
WS.A.12.4 MicroRNA‑155 overexpression augments acute
anti‑viral and anti‑tumor CD8+ T cell responses
Jennifer L. Hope, E. Stelekati, A. Fike, C. Stairiker,
D.T. Gracias, A.J. Carey, J.A. Fraietta, Y.M. Mueller,
P.D. Katsikis; Rotterdam, Netherlands
Symposia
Maintenance of Lymphocyte Memory Hall A
08:30 – 09:45
Chairpersons: Hans‑Martin Jäck; Erlangen, Germany
Matteo Iannacone; Milan, Italy
S.A.05.1
Shortterm versus Longterm Memory
Andreas Radbruch, C. Cendon, A. Okhrimenko,
H. Chang, H. Mei, T. Dörner, R. Riedel, J. Dong; Berlin,
Germany
S.A.05.2
A systemic B‑cell memory response
in non‑immunized mice
S. Le Gallou, R. Fritzen, J. Weill,
Claude‑Agnès Reynaud; Paris, France
S.A.05.3
Hall A
Chairpersons: Michael L. Dustin; New York, United States
Hannes Stockinger; Vienna, Austria
S.A.06.1
The PI3K signalling switch in adaptive immunity:
don’t forget to turn it off!
Klaus Okkenhaug; Cambridge, United Kingdom
S.A.06.2
Molecular switches in memory B cell formation
Jürgen Wienands; Göttingen, Germany
S.A.06.3
T cell signaling threshold switches and cancer
therapeutic implications
N. Hermann‑Kleiter, V. Klepsch, Gottfried Baier;
Innsbruck, Austria
WS.A.13.1 Establishment of a novel mouse model to study
IL‑7‑driven immune deviation in vivo
Maria Schreiber, A. Hommel, K. Anastassiadis,
E. Bonifacio, K. Kretschmer; Dresden, Germany
WS.A.13.2 CD28 expression is required after T cell priming
for helper T cell responses and protective immunity
to infection
Michelle A. Linterman, A.E. Denton, D. Diverkar,
S. Clare, G. Dougan, M. Espeli, K.G. Smith; Cambridge,
United Kingdom
WS.A.13.3 Direct and indirect induction of T helper cell
differentiation by Notch
Christina Helbig, D. Amsen; Amsterdam, Netherlands
WS.A.13.4 Sialyl Lewis x (CD15s) identifies highly differentiated
and most suppressive Foxp3high regulatory T cells in
humans
M. Miyara, N. Warner, R. Kannagi, S. Sakaguchi,
Guy Gorochov; Paris, France
Workshops
Hall F1
11:15 – 12:30
Chairpersons: Shinya Sakaguchi; Vienna, Austria
Klaas van Gisbergen; Amsterdam, Netherlands
WS.A.12.1 Therapeutic deletion of IL‑17 producing CD8+ T cells
(Tc17) attenuates graft‑versus‑host disease without
impairing anti‑leukemic immunity
Kate H. Gartlan, K.A. Markey, A. Varelias, M. Bunting,
M. Koyama, K. Lineburg, G. Boyle, M. Cheong, S. Lane,
S. Olver, N. Raffelt, R. Kuns, B. Teal, K. MacDonald,
G.R. Hill; Brisbane, Australia
WS.A.12.2 ADAP and SKAP55 regulate PD‑1 expression in
CD8+ cytotoxic T lymphocytes and the efficacy of
anti‑tumor immunotherapy
C. Li, W. Li, J. Xiao, Q. Leng, C.E. Rudd, BIN WEI,
H. Wang; Wuhan, China
WS.A.12.3 Non‑lytic degranulation of cytotoxic T lymphocytes as
a mechanism of immune regulation
Anna Kabanova, M. Bocchia, C.T. Baldari; Siena, Italy
Hall M
11:15 – 12:30
14:45 – 16:00
Lymphocyte Subsets - Part 2
Chairpersons: Christophe Paget; Lille, France
Winfried Pickl; Vienna, Austria
Molecular Switches
in Adaptive Immunity
nnWS.A.12
WS.A.12.6 The immune adaptor ADAP regulates reciprocal
TGF‑beta1‑integrin crosstalk to protect from influenza
virus infection
C. Li, S. Jiao, G. Wang, Y. Gao, C. Liu, X. He, B. Wei,
B. Wei, H. Chen, Hongyan Wang; Shanghai, China
nnWS.A.13
Interdependence of B and T cell memory
David Gray; Edinburgh, United Kindom
nnS.A.06
WS.A.12.5Interferon‑γ regulates CD8+ memory T cell
differentiation and survival in response to weak but not
strong TCR signals
D. Stoycheva, Thomas Schüler; Magdeburg, Germany
WEDNESDAY
nnS.A.05
WS.A.13.5 A critical neutrophil‑γδT cell axis in host response
to respiratory bacterial infection
M. Hassane, J. Fontaine, E. Patin, R. Porte,
I. Prinz, B. Ryffel, J. Sirard, C. Faveeuw, F. Trottein,
Christophe Paget; Lille, France
WS.A.13.6 How many TCR clonotypes does a body maintain?
Grant Lythe, C. Molina Paris, R. Callard, R. Hoare;
Leeds, United Kingdom
nnWS.A.14
T Cell Mediated Control
of GC Reactions
Hall N
11:15 – 12:30
Chairpersons: Denis Thieffry; Paris, France
Michelle A. Linterman; Cambridge, United Kingdom
WS.A.14.1 T follicular helper cell‑independent generation of bone
marrow‑resident resting memory T helper cells
Shintaro Hojyo, J. Sarkander, K. Tokoyoda; Berlin,
Germany
WS.A.14.2 Distinct T helper cell dependence of memory B cell
proliferation versus plasma cell differentiation
Franziska Zabel, A. Fettelschoss, P. Johansen,
T.M. Kündig, M.F. Bachmann; Schlieren/Zurich,
Switzerland
79
Program per Day
Track A
WS.A.14.3 TSLP‑activated dendritic cells induce T follicular helper
cell differentiation through OX40‑ligand
Coline Trichot, L. Pattarini, S. Bogiatzi,
M. Grandclaudon, M. Durand, T. Hori, V. Soumelis;
Paris, France
WS.A.14.4 Uncovering the mechanism of IL‑21 signalling in the
germinal centre response to T‑dependent antigen
Christoph Jandl, S.M. Liu, C. Loetsch, J. Warren,
C. King; Darlinghurst, Australia
WS.A.14.5 ICOS maintains the T follicular helper cell phenotype
by downregulating Krüppel‑like factor 2
Annette Lahmann, J.P. Weber, F. Fuhrmann, R.K. Feist,
M.S. Al Baz, L. Gentz, D. Vu Van, H.W. Mages,
C. Haftmann, R. Riedel, W. Schuh, R.A. Kroczek,
A. Radbruch, M. Mashregi, A. Hutloff; Berlin, Germany
WS.A.14.6 Follicular regulatory T cells control humoral
autoimmunity when NFAT2 overcomes
Blimp1‑mediated CXCR5 suppression
M. Vaeth, A. Koenig, G. Müller, D. Stauss, L. Dietz,
S. Klein‑Hessling, E. Serfling, M. Lipp, I. Berberich,
Friederike Berberich‑Siebelt; Wuerzburg, Germany
nnWS.A.15
Treg Function / Biology
Hall G
14:45 – 16:00
Chairpersons: Iris K. Gratz; Salzburg, Austria
Friederike Berberich‑Siebelt; Wuerzburg, Germany
WS.A.15.1 Deciphering the epigenetic and transcription‑factor
based control of the Foxp3 gene promoter
Michael Delacher, M.M. Barra, A. Kazakov,
D. Kägebein, A. Breiling, K. Eichelbaum, Y. Herzig,
M. Czeh, F. Rosenbauer, F. Lyko, J. Krijgsveld,
J. Abramson, M. Feuerer; Heidelberg, Germany
WEDNESDAY
WS.A.15.2 Enhanced Foxo‑1 and Foxp3 mRNA expression in
poly(ADP‑ribose)polymerase‑1 (PARP‑1) deficient
mice
F. Novelli, Claudio Pioli; Rome, Italy
WS.A.15.3 Role of NF‑kB in the biology of FoxP3+ regulatory
T cells at steady state and during inflammation
Emilie Ronin, A. Rouers, C. Pouchy, S. Grégoire,
B. Zaragoza, A. Burlion, F. Weih, A. Baeyens,
B. Salomon; Paris, France
WS.A.15.4 An unexpected inhibitory role of a Parkinson’s disease
gene DJ‑1 in CD4+ regulatory T Cells
E. Danileviciute, M. Gillespie, R. Balling, Feng Q. He;
Esch‑sur‑Alzette, Luxembourg
WS.A.15.5 Activation of TGF‑beta by integrin alpha v beta 8
is essential for effector regulatory T‑cell‑mediated
suppression of T‑cell‑mediated inflammation
J.J. Worthington, A. Kelly, C. Smedley, D. Bauché,
S. Campbell, J. Marie, Mark Travis; Manchester, United
Kingdom
WS.A.15.6 In vivo TNFR2‑mediated expansion of host regulatory
T cells to protect from acute graft‑versus‑host disease
Andreas Beilhack, M. Chopra, M. Biehl, A. Brandl,
J. Amich, M. Vaeth, J. Findeis, R. Holtappels,
J. Podlech, A. Mottok, S. Kraus, A. Jordán Garrote,
C. Bäuerlein, E. Ribechini, A. Fick, A. Seher, J. Polz,
S. Krappmann, H. Einsele, T.D. Müller, M. Reddehase,
M.B. Lutz, D.N. Männel, F. Berberich‑Siebelt, H. Wajant;
Wuerzburg, Germany
80
nnWS.A.16
Looking at the
“States and Fates of T Cells”
Hall F2
16:15 – 17:30
Chairpersons: Johannes Huppa; Vienna, Austria
Maria L. Toribio; Madrid, Spain
WS.A.16.1 Label‑free identification of T cell subpopulations
Maria Danner, V.C. Hirschfeld‑Warneken, J.P. Spatz;
Heidelberg, Germany
WS.A.16.2 Intravital imaging of physical interactions between
regulatory and effector T‑cells in a murine retrovirus
model
Lucas Otto, M. Gunzer, K. Dietze, U. Dittmer; Essen,
Germany
WS.A.16.3 Synchronizing transcriptional control of T cell
metabolism, differentiation and function
K. Man, A. Vasanthakumar, Axel Kallies; Parkville,
Australia
WS.A.16.4 The soluble cytoplasmic tail of CD45 (ct‑CD45) is
an inhibitory factor in human serum and induces an
anergy‑like state in T cells
Alexander Puck, M. Seyerl, S. Hopf, R. Aigner, P. Cejka,
O. Majdic, S. Blüml, E. Thell, G. Zlabinger, J. Leitner,
P. Steinberger, J. Stöckl; Vienna, Austria
WS.A.16.5 The contained self‑reactive peripheral T cell repertoire:
size, diversity and cellular composition
David M. Richards, E. Ruggiero, A. Hofer, J.P. Sefrin,
M. Schmidt, C. von Kalle, M. Feuerer; Heidelberg,
Germany
WS.A.16.6 THEMIS controls the fate of beneficial and pathogenic
self‑reactive T cells
Leen Baudewijn, F. Lambolez, R. Spiering,
K. Kakugawa, H. Cheroutre; La Jolla, United States
nnWS.A.17
Extrinsic and Intrinsic Control of Positive/
Negative T Cell Selection
Hall M
16:15 – 17:30
Chairpersons: Ludger Klein; Munich, Germany
Wilfried Ellmeier; Vienna, Austria
WS.A.17.1 Identifying and tracking autoimmune‑inducing T cell
clones in Aire‑/‑Cblb‑/‑ mice
Mandeep Singh, C. Teh, A. Enders, C. Goodnow;
Canberra, Australia
WS.A.17.2 Mice with thymic epithelial von Hippel‑Lindau deletion
are lacking a functional thymus
A. Hollenbeck, S. Weber, M. Necke, K. Händschke,
K. Dietze, U. Dittmer, K.S. Lang, J.W. Fischer, B. Opalka,
U. Dührsen, Joachim R. Göthert; Essen, Germany
WS.A.17.3 Aire‑dependent transcripts have shortened 3’UTRs and
show greater stability by evading microRNA‑mediated
repression.
Clotilde Guyon, N. Jmari, Y. Li, J. Denoyel, N. Fujikado,
C. Blanchet, D. Root, M. Giraud; Paris, France
WS.A.17.4 Characterization of a unique model of APECED‑like
Aire deficient rat with strong auto‑immune symptoms
Jason Ossart, S. Menoret, E. Autrusseau, C. Usal,
A. Moreau, F. Hubert, I. Anegon, R. Josien,
C. Guillonneau; Nantes, France
Program per Day
Track B
WS.A.17.6 RRas2 (TC21) sets the threshold for negative selection
in the thymus
Ana Martínez‑Riaño, B. Alarcón; Madrid, Spain
nnWS.A.18
Germinal Centers:
Survival & Differentiation Signals
Hall N
16:15 – 17:30
Chairpersons: Rushad Pavri; Vienna, Austria
Simon Fillatreau; Berlin, Germany
WS.A.18.1 A novel role for CD248 in controlling the differentiation
of follicular dendritic cells (FDCs) following immune
challenge
Nathalie Steinthal, S. Nayar, A.J. Naylor, G.E. Desanti,
J.L. Marshall, Y. Zhang, K.M. Toellner, J.H. Caamaño,
D.R. Withers, C.D. Buckley, F. Barone; Birmingham,
United Kingdom
WS.A.18.2 FAS inactivation releases rogue Germinal Center
B cells that escape antigen control and drive IgE and
autoantibody production
Danyal Butt, T. Chan, K. Bourne, J. Hermes, L. O’Reilly,
A. Strasser, S. Tangye, T. Phan, V. Rao, R. Brink; Sydney,
Australia
WS.A.18.3 RRas2 plays a fundamental non‑redundant role in
germinal center formation by activating the PI3K and
non‑canonical NFkB pathways in B cells
Pilar Mendoza, N. Martínez‑Martín, B. Cubelos,
X.R. Bustelo, T. Kurosaki, B. Alarcón; Madrid, Spain
WS.A.18.4 Antigen‑affinity mediates B cell survival through
differential BAFF receptor signaling via the PI3K/Mcl‑1
cascade
Felix M. Wensveen, A. Kater, R. Brink, E. Eldering;
Amsterdam, Netherlands
WS.A.18.5 Treatment with tofacitinib inhibits human naïve
B lymphocyte development and function
Jens D. Thiel, K. Fischer, R.E. Voll, R. Lorenzetti,
N. Venhoff, M. Rizzi; Freiburg, Germany
WS.A.18.6 IL‑35‑producing B cells regulate immunity during
autoimmune and infectious diseases
Ping Shen, T. Roch, E. Hilgenberg, S. Ries, V. Dang,
I. Sakwa, S.M. Anderton, S. Fillatreau; Berlin, Germany
TRACK B
Symposia
nnS.B.05
Autoimmunity
Hall E
08:30 – 09:45
Chairpersons: Reinhold Schmidt; Hannover, Germany
Marie Wahren‑Herlenius; Stockholm, Sweden
S.B.05.1
Rheumatoid athritis
Reinhold Schmidt; Hannover, Germany
S.B.05.2
T cell responses against neurons
Roland Liblau; Toulouse, France
S.B.05.3
Behcet’s Disease: From autoimmunity to
autoinflammation
Ahmet Gül; Istanbul, Turkey
nnS.B.06
Stroma - Immune Interactions
in Cancer and Inflammation
Hall E
14:45 – 16:00
Chairpersons: Wlodzimierz Maslinski; Warsaw, Poland
Catherine Sautès‑Fridman; Paris, France
S.B.06.1
Stromal immune cell interaction
Jasper Koning; Amsterdam, Netherlands
S.B.06.2
The interplay between L‑arginine metabolism and
adoptive immunity in cancer
Vincenzo Bronte; Verona, Italy
S.B.06.3
Immune sensing of fat tissue
Bojan Polic; Rijeka, Croatia
Workshops
nnWS.B.14
Immune Recognition and
Control of Infections
Hall F2
11:15 – 12:30
Chairpersons: Michael Lohoff; Marburg, Germany
Anca Dorhoi; Berlin, Germany
WS.B.14.1 Autoimmune associated gene Ptpn22 negatively
regulates Dectin‑1 signalling in dendritic cells and
controls the development of pathogenic IL‑17+IFNy+
CD4+ T‑cells
Harriet A. Purvis, F. Clarke, C. Sanchez Blanco,
R. Zamoyska, G.H. Cornish, A.P. Cope; London, United
Kingdom
WS.B.14.2 Role of CD64+CX3CR1+ mononuclear phagocytes
during Helicobacter pylori infection
Barbara Kronsteiner‑Dobramysl, M. Viladomiu,
J. Bassaganya‑Riera, C. Phillipson, R. Hontecillas;
Blacksburg, United States
WS.B.14.3 Lung‑residing myeloid‑derived suppressor cells
control susceptibility to disease in murine pulmonary
tuberculosis
J. Knaul, L. Scheuermann, V. Brinkmann, H. Mollenkopf,
V. Yeremeev, S.H. Kaufmann, Anca Dorhoi; Berlin,
Germany
81
WEDNESDAY
WS.A.17.5 T cell receptor upregulation creates a feedback loop
during negative selection
R. Sapkota, S. Hemmers, B. Polic, O. Gorka,
R. Mejias‑Luque, M. Gerhard, J. Ruland, K. Rajewsky,
A. Waisman, B. Becher, Thorsten Buch; Zurich,
Switzerland
Program per Day
Track B
WS.B.14.4 Chronic lung inflammation enhances humoral
immunity to Streptococcus pneumonia via the pIgR/
sIg axis
Andreas Jeron, J. Boehme, S. Stegemann‑Koniszewski,
J. Wissing, L. Jänsch, D. Bruder, Infection Immunology
Group; Magdeburg, Germany
WS.B.14.5 EphA2 promotes the development of experimental
cerebral malaria
T.P. King, P.N. Mimche, C.F. Bray, L.M. Brady,
M. Galinski, Tracey J. Lamb; Atlanta, United States
WS.B.14.6 Enhancement of pathogen‑specific natural killer
cell ‘memory’ by removal of a viral innate immune
signalling inhibitor
Hongwei Ren, C.T. Benfield, R.P. Sumner, B.J. Ferguson,
C. Huber, F. Colucci, G.L. Smith; Cambridge, United
Kingdom
nnWS.B.15
Immune Regulation
at the Intestinal Barrier
Hall G
11:15 – 12:30
Chairpersons: Maria Rescigno; Milan, Italy
Helena Tlaskalova‑Hogenova, Prague,
Czech Republic
WS.B.15.1 Impact of microbiota on intestinal immune cell
composition and intestinal barrier function
Franziska Schmidt, T. Kruis, A. Batra, G. Loh,
M. Schumann, A.A. Kühl, M. Blaut, B. Siegmund; Berlin,
Germany
WEDNESDAY
WS.B.15.2 Microbes isolated from inflammatory bowel disease
patients disrupt the gut epithelial barrier
Adela Dusilova, J. Malkova, M. Hornova,
H. Tlaskalova‑Hogenova, M. Kverka; Prague,
Czech Republic
WS.B.15.3 The effect of long‑term probiotic intervention
in fast‑aging Ercc1‑/Δ7 mice
Adriaan A. van Beek, B. Sovran, F. Hugenholtz,
M. Boekschoten, P. de Vos, J.M. Wells, J.J. Hoeijmakers,
P.J. Leenen, R.W. Hendriks, H.F. Savelkoul; Wageningen,
Netherlands
WS.B.15.4 Plasmacytoid and conventional cDC1 DCs in the
secretory IgA response towards rotavirus
Katharina Lahl, A. Sen, N. Feng, H. Greenberg,
E. Butcher; Frederiksberg, Denmark
WS.B.15.5TGF‑β signaling in ILC3 prevents spontaneous
microbiota‑induced colorectal cancer
D. Bauché, I. Treilleux, M. Veldhoen, Julien C. Marie;
Lyon, France
WS.B.15.6 The crucial role of the transcription factor GATA‑3
in the development of TH2‑cell mediated ulcerative
colitis
Vanessa Popp, I. Ho, B. Weigmann; Erlangen, Germany
nnWS.B.16
Mediators of Airway Inflammation
Hall K
11:15 – 12:30
Chairpersons: Ronald van Ree; Amsterdam, Netherlands
Peter Openshaw; London, United Kingdom
WS.B.16.1 RelB‑deficient dendritic cells promote the
development of spontaneous allergic airway
inflammation in mice
P.M. Nair, Malcolm R. Starkey, T.J. Haw, R. Ruscher,
M.R. Maradana, R. Thomas, B. O’Sullivan,
P.M. Hansbro; New Lambton Heights, Australia
82
WS.B.16.2 The dual role of Leukotriene A4 hydrolase in allergic
airway disease
Dhiren F. Patel, S. Akthar, T. Peiró, S.A. Walker,
L.G. Gregory, C.M. Lloyd, R.J. Snelgrove; London,
United Kingdom
WS.B.16.3 The danger receptor FPR2 controls the initiation of
allergic immune responses
Ursula Smole, J. Phelan, N. Yao, Z. Lijie, S. Lajoie,
M. Wills‑Karp; Baltimore, United States
WS.B.16.4IFN‑γ‑STAT1‑IRF1‑axis restricts IL‑9 in Th9 cells by
opposing IRF4 functions and is dysregulated in asthma
Lucia Campos Carrascosa, M. Klein, C. Lückel,
L. Thomas, S. Hagner‑Benes, A. König, D. Riedel,
T. Decker, A. Bock, M. Lohoff, H. Garn, B. Schaub,
F. Berberich‑Siebelt, T. Bopp, M. Huber; Marburg,
Germany
WS.B.16.5IFN‑γ and IL‑17A drive distinct airway changes in a
murine model of steroid‑unresponsive severe asthma
Mahesh Raundhal, C. Morse, A. Khare, T.B. Oriss,
J. Kolls, S. Wenzel, A. Ray, P. Ray; Pittsburgh, United
States
WS.B.16.6 Compound A modulates steroid insensitive
chemokines in airway smooth muscle cells via IRF‑1
dependent and independent pathways
Adelina Gavrila, L. Chachi, O. Tliba, Y. Amrani,
C. Brightling; Leicester, United Kingdom
nnWS.B.17
Immune Dysregulation
Hall N
14:45 – 16:00
Chairpersons: Hendrik Poeck; Munich, Germany
Ludovic Martinet; Toulouse, France
WS.B.17.1 Ultraviolet light converts propranolol, a non‑selective
β‑blocker and potential lupus‑inducing drug, into a
pro‑inflammatory AhR ligand
K. Dorgham, A. Mathian, Z. Amoura, Hans Yssel,
G. Gorochov; Paris, France
WS.B.17.2 Modulatory capacities of soluble Fc‑epsilon RI in the
IgE‑mediated immune response
Sherezade Moñino Romero, C. Bannert,
K. Schmidthaler, T. Eiwegger, E. Dehlink, A. Fiocchi,
A.S. Amoah, M. Yazdanbakhsh, B. Bohle, E. Fiebiger,
Z. Szépfalusi; Vienna, Austria
WS.B.17.3 RIG‑I‑induced type I IFNs promote regeneration of the
intestinal stem cell compartment during acute tissue
damage
J.C. Fischer, M. Bscheider, G. Eisenkolb, C. Lin,
A. Wintges, V. Otten, C. Lindemans, S. Heidegger,
M. Rudelius, S. Monette, K.A. Porosnicu Rodriguez,
S. Liebermann, C. Liu, S. Lienenklaus, U. Kalinke,
J. Ruland, C. Peschel, M. Docampo, E. Velardi, R. Jenq,
A.M. Hanash, J.A. Dudakov, T. Haas, M.R. van den
Brink, Hendrik Poeck; Munich, Germany
WS.B.17.4 Immunosurveillance and therapy of multiple myeloma
is CD226‑dependent
C. Guillerey, L. Ferrari de Andrade, S. Vuckovic,
M. Chesi, L. Bergsagel, G.R. Hill, M.J. Smyth,
Ludovic Martinet; Toulouse, France
WS.B.17.5 NFATc1 proteins are critical survival factors in Burkitt
lymphomagenesis
K. Murti, H. Fender, R. Busch, V. Wild, E. Serfling,
Andris Avots; Wuerzburg, Germany
Program per Day
Track B
nnWS.B.18
Tumor Biology and
Immunosurveillance
Hall F1
16:15 – 17:30
Chairpersons: Bojan Polic; Rijeka, Croatia
Günes Esendağlı; Ankara, Turkey
WS.B.18.1 Identification and characterization of putative
neoplastic stem cells in human mast cell leukemia
Gregor Eisenwort, B. Peter, I. Sadovnik, K. Blatt,
G. Stefanzl, S. Cerny‑Reiterer, G. Hoermann, T. Rülicke,
M. Willmann, M. Bilban, C. Mannhalter, J. Schwaab,
W.R. Sperr, M. Arock, A. Reiter, P. Valent; Vienna,
Austria
WS.B.18.2 The telomeric protein TRF2 overexpression in cancer
cells induces immune escape through MDSC
recruitment and activation
Julien Cherfils‑Vicini, L. Cervera, C. Iltis, F. Allain,
A. Biroccio, E. Vivier, E. Gilson; Nice, France
WS.B.19.4 AP‑1 transcription factor serves as a molecular switch
between Chlamydia pneumoniae replication and
persistence
S. Krämer, P. Crauwels, R. Bohn, C. Radzimski,
M. Szaszák, M. Klinger, J. Rupp, Ger van Zandbergen;
Langen, Germany
WS.B.19.5 Helminths protect against autoimmunity through IL‑5
and IL‑33‑induced eosinophils
Conor M. Finlay; Dublin, Ireland
WS.B.19.6 Host genetic polymorphisms affect p24 Gag epitope
presentation and T‑cell engagement in HIV‑1 infection
Tracy M. Josephs, J.E. McLaren, K. Ladell,
C. Geldmacher, J. Rossjohn, D.A. Price, S. Gras;
Melbourne, Australia
nnWS.B.20
HIV Infection and Immune Control
Hall K
16:15 – 17:30
Chairpersons: Ana Sousa; Lisboa, Portugal
Florence Niedergang; Paris, France
WS.B.18.3 Necroptotic effector molecules regulate tumor
immunogenicity
Yuting MA, H. YANG, G. Kroemer; Paris, France
WS.B.20.1 CD40L‑inducible tunneling nanotube networks
facilitate HIV‑1 transmission to CD4+ T cells by
pro‑inflammatory dendritic cells
Colleen R. Zaccard, R.B. Mailliard, G. Rappocciolo,
V. Ayyavoo, S.C. Watkins, C.R. Rinaldo; Pittsburgh,
United States
WS.B.18.4 sCYLD expression causes B‑CLL development in mice
and men
M. Hahn, J. Bürckert, C. Pallasch, A. Waisman,
T. Wunderlich, Nadine Hövelmeyer; Mainz, Germany
WS.B.20.2 HIV‑1 infection increases S1P‑R1 expression in the
human thymus
Rachel S. Resop, J.F. Craft, D.N. Vatakis, B. Blom,
C.H. Uittenbogaart; Los Angeles, United States
WS.B.18.5 The effect of NF‑κB on tumour‑stromal interactions in
colorectal cancer
Grace A. O’Malley, P. Lohan, S. Rani, K. Lynch,
S. Naicker, G. Shaw, T. Ritter, L.J. Egan, A.E. Ryan;
Galway, Ireland
WS.B.20.3 Impaired clearance activity in HIV‑1 infected
macrophages and development of opportunistic
bacteria
A. Dumas, G. Lê‑Bury, C. Deschamps, F. Herit,
P. Bourdoncle, S. Benichou, D. Russell, M. Gordon,
Florence Niedergang; Paris, France
WS.B.18.6 Effects of PKC412 and its metabolites CGP52421 and
CGP62221 on proliferation of neoplastic mast cells and
IgE‑mediated histamine release
Barbara Peter, G.E. Winter, K. Blatt, U. Rix, K.L. Bennett,
G. Stefanzl, E. Hadzijusufovic, C. Dutreix, J. Roesel,
P.W. Manley, G. Superti‑Furga, P. Valent; Vienna,
Austria
nnWS.B.19
Immune Modulation
Hall G
16:15 – 17:30
Chairpersons: Sebastian Lang; Essen, Germany
Irma Schabussova; Vienna, Austria
WS.B.19.1 Microbiota transfer to non‑obese diabetic mice ‑
impact of Akkermansia muciniphila on the delay of
diabetes
Arno Hänninen, R. Toivonen, C. Belzer, J. Ouwerkerk,
S. Pietilä, R. Emani, A. Rintala, W.M. de Vos; Turku,
Finland
WS.B.19.2 Mechanisms of disease tolerance to gram‑negative
sepsis
Riem Gawish, B. Maier, K. Lakovits, A. Hladik,
A. Korosec, M. Ildiko, F. Oakley, B. John, I. Lang,
S. Knapp; Vienna, Austria
WS.B.20.4 Impairment of CCR6+ and CXCR3+ T‑helper cell
migration in HIV‑1 infection is rescued by modulating
actin polymerization
Valentina Cecchinato, E. Bernasconi, R.F. Speck,
M. Proietti, U. Sauermann, G. Danelon, T. Rezzonico
Jost, F. Grassi, L. Raeli, F. Schöni‑Affolter,
C. Stahl‑Hennig, M. Uguccioni, Swiss HIV Cohort Study
(SHCS); Bellinzona, Switzerland
WS.B.20.5 Sex‑dependent functional impact of TLR7 c.32A>T
polymorphism on type I IFN‑production by
plasmacytoid dendritic cells: implication in the
susceptibility to HIV‑1 infection
Pascal Azar, J. Méjia, C. Cénac, S. Laffont,
M. Requena, M. Cazabat, R. Carcénac, J. Izopet,
P. Delobel, J. Guéry, ANRS EP53 X‑LIBRIS Study Group;
Toulouse, France
WS.B.20.6 Central memory CD4 T cells gene expression signature
in HIV infection shows G2/M arrest, but reduced
apoptosis
Gustavo Olvera‑García, T. Aguilar‑García,
I. Imaz‑Rosshandler, C. Rangel‑Escareño, L. Orozco,
J. Zúñiga, J. Vazquez‑Pérez, I. Aguilar‑Delfín,
S. Pérez‑Patrigeon, E. Espinosa; Tlalpan, Mexico
WS.B.19.3 Lung resident memory CD4+ T cells (Trm) play a critical
role in protective immunity to Bordetella pertussis
Mieszko M. Wilk, R.M. McManus, A. Misiak, M.A. Lynch,
K.H. Mills; Dublin, Ireland
83
WEDNESDAY
WS.B.17.6 Plasmacytoid dendritic cells promote HIV‑1‑induced
group‑3 innate lymphoid cell depletion
Zheng Zhang, J. Zhao, L. Cheng, F. Wang, L. Su; Beijing,
China
Program per Day
Track C
TRACK C
WS.C.12.5 Innate‑to‑innate cell communication privileges mast
cells with dendritic cell key features
Jan Dudeck, A. Medyukhina, A. Hoppe, A. Karutz,
M. Gerlach, C. Svensson, S. Speier, M. Figge,
A. Dudeck; Dresden, Germany
Symposia
nnS.C.05
Innate Lymphocytes Backstage or Centerstage
Hall A
11:15 – 12:30
Chairpersons: Bruno Silva‑Santos; Lisbon, Portugal
Vladka Curin Šerbec; Ljubljana, Slovenia
S.C.05.1
NK cells
nnWS.C.13
S.C.05.2
The Biology of Human ILC Populations
Hergen Spits, J. Bernink, S. Bal, X. Romero; Amsterdam,
Netherlands
Chairpersons: Massimo Triggiani; Salerno, Italy
Peter Valent; Vienna, Austria
S.C.05.3
Gamma/Delta T cells
Adrian Hayday; London, United Kingdom
nnS.C.06
Inhibitory and Activating Receptors
Hall A
16:15 – 17:30
S.C.06.1
Role of the CD94/NKG2C activating receptor in
the adaptive-like human NK-cell response to
cytomegalovirus
Miguel Lopez Botet; Barcelona, Spain
S.C.06.2
Prevention of collateral damage by immune inhibitory
receptors
Linde Meyaard; Utrecht, Netherlands
S.C.06.3
Sensing intracellular nucleic acids
Veith Hornung; Bonn, Germany
Workshops
nnWS.C.12
Dendritic Cell Differentiation
and Function
Hall F2
08:30 – 09:45
Chairpersons: Maria Carla Bosco; Genova, Italy
Diana Dudziak; Erlangen, Germany
WS.C.12.1 Lipid peroxidation causes antigen release from
endosomes for cross‑presentation
Ilse Dingjan, D.R. Verboogen, L.M. Paardekooper,
L.J. Visser, G. Fisher von Mollard, S.S. Henriet,
C.G. Figdor, M. ter Beest, G. van den Bogaart;
WS.C.12.2 Regulation of IL‑6 secretion by dendritic cells
Daniëlle Verboogen, M. ter Beest, G. van den Bogaart;
WS.C.12.3 Modulation of dendritic cells function by dermal
fibroblasts.
Anna Malecka, Q. Wang, S. Shah, A. Saalbach,
M.J. Gough, P.M. Patel, A.M. Jackson; Nottingham,
United Kingdom
WS.C.12.4 Estrogen receptor α expression in human
plasmacytoid dendritic cells is required to promote
optimal production of type I interferons and
pro‑inflammatory cytokines in response to TLR‑7
stimulation
Pascal Azar, S. Laffont, C. Cénac, J. Plumas, C. Aspord,
J. Guéry; Toulouse, France
84
Mast Cells
Hall G
08:30 – 09:45
Chairpersons: Stipan Jonjic; Rijeka, Croatia
Gunnur Deniz; Istanbul, Turkey
WEDNESDAY
WS.C.12.6 MAPK‑activated kinase MK2 exerts immune regulatory
functions in dendritic cells involving JAK1 signaling
Klara Soukup, A. Halfmann, F. Poyer, E. Sahin,
G. Schabbauer, T. Felzmann, A.M. Dohnal; Vienna,
Austria
WS.C.13.1 The yin and yang function of IL‑33‑ST2 axis in murine
mast cells: A systems immunological approach
Peter Natesan Pushparaj, A. Chaudhary,
A. Abuzenadah, M.H. Al‑Qahtani; Jeddah, Saudi
Arabia
WS.C.13.2 Real‑time imaging of mast cell interactions with
Foxp3+ regulatory T cells and dendritic cells in skin
inflammation
R. Msallam, G. Gautier, U. Blank, B. Malissen, P. Launay,
Jean Davoust; Paris, France
WS.C.13.3 Mast cells rapidly control resident macrophage
phagocytosis decreasing survival in severe sepsis
Gregory Gautier, A. Dahdah, T. Attout, F. Fiore,
E. Lebourdais, J. Davoust, U. blank, B. Malissen,
P. Launay; Paris, France
WS.C.13.4 Evaluation of effects of various targeted drugs on
IgE receptor‑dependent signal transduction and
activation of mast cells and basophils
Dubravka Smiljkovic, K. Blatt, G. Wedeh, G. Stefanzl,
M. Arock, P. Valent; Vienna, Austria
WS.C.13.5 Role of IL‑17A and mast cells in intestinal reperfusion
injury
Mayya Geha, M. Tsokos, G. Tsokos; Boston, United
States
WS.C.13.6 Interleukin‑33 promotes the proliferation of
mouse mast cells through ST2/MyD88 and p38
MAPK‑dependent and Kit‑independent pathways.
Rohit Saluja, T. Hawro, J. Eberle, M.K. Church,
M. Maurer; Bhopal, India
nnWS.C.14
NK and NKT Cell Function
Hall M
08:30 – 09:45
Chairpersons: Adelheid Cerwenka; Heidelberg, Germany
Veronika Sexl; Vienna, Austria
WS.C.14.1 iNKT cells control cancer progression by restraining
pro‑angiogenic tumor infiltrating macrophages
Filippo Cortesi, G. Delfanti, A. Calcinotto, F. Gorini,
F. Pucci, M. Grioni, M. De Palma, M. Bellone,
G. Casorati, P. Dellabona; Milan, Italy
WS.C.14.2 Innate iNKT cell recognition of HIV‑1 infected dendritic
cells is an early detection mechanism targeted by
viral immune evasion
D. Paquin‑Proulx, A. Gibbs, S. Bächle, A. Checa,
A. Introini, E. Leeansyah, C.E. Wheelock, D.F. Nixon,
K. Broliden, A. Tjernlund, M. Moll, Johan K. Sandberg;
Stockholm, Sweden
Program per Day
Track D
WS.C.14.4 Ex vivo generation of therapeutically relevant numbers
of activated natural killers with potent anti tumor
activity in vitro and in vivo
Markus Granzin, M. Miller, M. Berg, R. Childs,
V. Huppert, A. Cerwenka; Bergisch Gladbach,
Germany
WS.C.14.5 Decidual stromal cells display a strong inhibitory effect
on NK cell function and dendritic cell differentiation.
Daniele Croxatto, P. Vacca, F. Canegallo, R. Conte,
P. Venturini, L. Moretta, M. Mingari; Genoa, Italy
WS.C.14.6 Regulatory T cells suppress effector NK cell responses
during an acute retroviral infection by consumption of
IL‑2
Elisabeth Littwitz‑Salomon, U. Dittmer, K. Gibbert; Essen,
Germany
nnWS.C.15
Dendritic Cell Subsets
Hall F2
14:45 – 16:00
Chairpersons: Muzlifah Haniffa; Newcastle, United Kingdom
Martin Zenke; Aachen, Germany
WS.C.15.1 CyTOF analysis reveals proinflammatory and
antiinflammatory DC subsets in newborn blood with
distinct reactivity to pathogens
S. Lemoine, X. Zhang, A. Abbas, B. Beitz,
M. Velpaux‑Lefevre, M. Burlandy, F. Porcheray,
C. Leclerc, Richard Lo‑Man; Paris, France
WS.C.15.2PI3Kγ has a distinct and essential role in regulating
lung‑specific dendritic cell development downstream
of Flt3
Samuel P. Nobs, C. Schneider, M.G. Dietrich, T. Brocker,
A. Rolink, E. Hirsch, M. Kopf; Zürich, Switzerland
WS.C.15.3 IL‑12p40 and IL‑10 producing preCD8α/Clec9A+
dendritic cells are induced in neonates upon Listeria
monocytogenes infection.
Arnaud Köhler, D. Torres, S. Delbauve, I. Caminschi,
M. Lahoud, K. Shortman, V. Flamand; Gosselies,
Belgium
WS.C.15.4 Specialization of human myeloid Dendritic Cells type 1
for extracellular pathogens
Lukas Heger, G.F. Heidkamp, N. Eissing, A. Hartmann,
K. Rogler, C. Alexiou, J. Zenk, B. Spriewald,
A. Mackensen, G. Schuler, A. Purbojo, R. Cesnjevar,
F. Nimmerjahn, D. Dudziak; Erlangen, Germany
WS.C.15.5 Bone Morphogenic Protein 7 (BMP7) promotes in vitro
generation of high numbers of inflammatory type
Langerhans‑like dendritic cells
Izabela Borek, R. Köffel, I. Fedorenko, N. Yasmin,
C. Krump, H. Strobl; Graz, Austria
WS.C.15.6 Identification of the triggering receptor expressed
on myeloid cells‑1 (TREM‑1) as a novel regulator of
Langerhans cells functions in a hypoxic environment
F. Raggi, D. Pierobon, I. Cambieri, S. Occhipinti,
P. Cappello, F. Novelli, T. Musso, C. Castagnoli,
L. Varesio, M. Giovarelli, Maria Carla C. Bosco;
Genova, Italy
TRACK D
Symposia
nnS.D.05
T Cell Mediated Immunotherapy
Hall E
11:15 – 12:30
Chairpersons: Wilfried Ellmeier; Vienna, Austria
Piotr Trzonkowski; Gdańsk, Poland
S.D.05.1
When transgenes shape immunity
Chiara Bonini; Milan, Italy
S.D.05.2
TCR engineered virus‑specific T cells for treatment of
high risk leukemia
Mirjam H.M. Heemskerk; Leiden, Netherlands
S.D.05.3
Regulatory T cells in allogeineic stem cell
transplantation
Matthias Edinger; Regensburg, Germany
nnS.D.06
Aging and the Immune System
Hall E
16:15 – 17:30
Chairpersons: Beatrix Grubeck‑Loebenstein; Innsbruck, Austria
Rafael Solana; Cordoba, Spain
S.D.06.1
Causes and Consequences of Cellular Immune Aging
Victor Appay; Paris, France
S.D.06.2
The immune system from childhood to old age
Martina Prelog; Würzburg, Germany
S.D.06.3
Functional immunosenescence of NK and T cells:
relative impact of age and CMV infection.
Rafael Solana, A. Pera, C. Campos, S. Cantisan,
R. Tarazona; Cordoba, Spain
Workshops
nnWS.D.09
and Anti-Tumor Vaccines
Hall F1
08:30 – 09:45
Chairpersons: Stephan Wagner; Vienna, Austria
Laurence Zitvogel; Villejuif, France
WS.D.09.1 A novel systemically applied TLR‑agonist with potent
anti‑tumoral effects
Jutta Petschenka, F. Vascotto, K. Reuter, M. Vormehr,
R. Roth, A. König, C. Worm, M. Brkic, N. Krause,
U. Schmitt, M. Diken, S. Kreiter, S. Hamm, S. Strobl,
Ö. Türeci, U. Sahin; Mainz, Germany
WS.D.09.2 Glyco‑engineering of monoclonal antibodies
enhances potential to promote adaptive immunity
Aniekan Etuk, C. Klein, C. Gerdes, A. Passioukov,
F. Farzaneh, L.D. Barber; London, United Kingdom
WS.D.09.3 Virotherapy with a Semliki Forest virus‑based vector
encoding IL‑12 synergizes with PD‑1/PD‑L1 blockade
J.I. Quetglas, S. Labiano, M.Á. Aznar, E. Bolaños,
A. Azpilicueta, I. Rodríguez, E. Casales,
A.R. Sánchez‑Paulete, V. Segura, C. Smerdou,
WS.D.09.4 Vdelta1 T cells expressing natural cytotoxicity
receptors for adoptive cell therapy of leukemia
D.V. Correia*, A. Almeida*, D.R. Anjos,
Bruno Silva‑Santos; Lisbon, Portugal
85
WEDNESDAY
WS.C.14.3 Interleukin‑1 receptor 8 (IL‑1R8) plays a crucial role in
Natural Killer (NK) cell differentiation and function
Martina Molgora, E. Bonavita, A. Ponzetta,
M. Barbagallo, G. Benigni, G. Bernardini, F. Riva,
A. Santoni, A. Mantovani, C. Garlanda; Rozzano, Italy
Program per Day
Track D
WS.D.09.5 A TLR7 agonist enhances the anti‑tumour efficacy of
obinutuzumab through an NK cell/CD4 dependent
mechanism in murine lymphoma models
Eleanor J. Cheadle, G. Lipowska‑Bhalla, C. Klein,
S.J. Dovedi, J. Honeychurch, T.M. Illidge; Manchester,
United Kingdom
WS.D.09.6 Preclinical analysis of novel targeted therapies against
Notch‑dependent human T‑ALL
M. García‑Peydró, S. González‑García, M. Mosquera,
Maria L. Toribio; Madrid, Spain
nnWS.D.10
Intervention and Therapy of Allergy
Hall K
08:30 – 09:45
Chairpersons: Peter Korosec; Golnik, Slovenia
Barbara Bohle; Vienna, Austria
WS.D.10.1 Melatonin supplement for children with atopic
dermatitis and sleep disturbance ‑ A randomized,
double‑blind, placebo‑controlled crossover study
Yung‑Sen Chang, M. Lin, J. Lee, P. Lee, Y. Dai, K. Chu,
C. Chen, K. Wan, B. Chiang; Taipei, Taiwan
WS.D.10.2 Improved lung function and reduced asthmatic
phenotype by adenoviral vaccines encoding for
Dec‑targeted antigen
Andre Maaske, T. Niezold, F. Devos, J. Vanoirbeek,
M. Peters, M. Tenbusch; Bochum, Germany
WS.D.10.3 Changes in markers associated with regulatory and
pro‑allergic dendritic cell in peripheral blood correlate
with clinical efficacy
Laurent Mascarell, C. Gueguen, H. Moussu, J. Bouley,
M. le Mignon, E. Nony, V. Bodo, P. Moingeon; Antony,
France
WEDNESDAY
WS.D.10.4 Monitoring the epitope recognition profiles of IgE, IgG1
and IgG4 during birch pollen immunotherapy
Barbara Gepp, N. Lengger, C. Möbs, W. Pfützner,
C. Radauer, B. Bohle, H. Breiteneder; Vienna, Austria
WS.D.10.5 Safety, dose finding and clinical effects of BM32,
a recombinant B cell epitope‑based grass pollen
vaccine, evaluated in the Vienna Challenge Chamber
(VCC) in patients with grass pollen‑induced allergic
Rhinitis
Petra Zieglmayer, P. Lemell, R. Zieglmayer, F. Horak,
A. Neubauer, R. Henning, R. Valenta; Vienna, Austria
WS.D.10.6 Efficient IgE‑depletion by IgEnio, a novel IgE‑adsorber,
shows beneficial effects on allergy symptoms
Christian Lupinek, K. Derfler, S. Lee, T. Prikoszovich,
O. Movadat, E. Wollmann, V. Petkov, V. Schoder,
R. Cervenka, T. Plaichner, G. Stegfellner, H. Huber,
R. Henning, J. Kozik‑Jaromin, A. Gauly, H. Leinenbach,
I. Uhlenbusch‑Koerwer, R. Valenta; Vienna, Austria
nnWS.D.11
Imaging & Cancer Therapy
Hall N
08:30 – 09:45
Chairpersons: Patrizio Giacomini; Rome, Italy
Jeanette Leusen; Utrecht, Netherlands
WS.D.11.1 S100A8/A9 as an imaging target for in vivo
visualisation of tumor‑mediated immune remodelling
in pre‑metastatic tissue
Fabian Flores‑Borja, M. Eisenblaetter, J.J. Lee,
C. Wefers, H. Smith, R. Hueting, M. Cooper, P. Blower,
T. Vogl, J. Roth, A. Tutt, T. Schaeffter, T. Ng; London,
United Kingdom
86
WS.D.11.2 Single molecule microscopy of T‑cell signaling
components in live cells
Florian Baumgart, A. Arnold, G. Schütz; Vienna, Austria
WS.D.11.3 Interplay between chemokine driven actin flow and
substrate adhesion in migratory T cells
Miroslav Hons, V. Bierbaum, M. Foelser, J. Abe,
T. Bollenbach, G. Schuetz, M. Sixt, J.V. Stein;
Klosterneuburg, Austria
WS.D.11.4 Sub‑apoptotic dosages of pro‑oxidant vitamin
cocktails sensitize human melanoma cells to NK cell
lysis
E. Tremante, L. Santarelli, E. Lo Monaco,
C. Sampaoli, T. Ingegnere, R. Guerrieri, M. Tomasetti,
Patrizio Giacomini; Rome, Italy
WS.D.11.5 Phase I and Phase II clinical trials of MVA‑EBNA1/
LMP2, a therapeutic cancer vaccine designed to treat
Epstein‑Barr Virus (EBV) positive malignancies
Graham S. Taylor, H. Jia, K. Harrington, L. Wai Lee,
C. Roberts, A. Hartley, C. Edwards, L. McGuigan,
E.P. Hui, A.T. Chan, A. Rickinson, N. Steven;
WS.D.11.6 Improved in vivo anti‑tumor effects of IgA‑Her2
antibodies through half‑life extension and serum
exposure enhancement by FcRn targeting
Saskia Meyer, M. Nederend, J.H. Jansen,
S.R. Jacobino, J. Meeldijk, N. Bovenschen, T. Valerius,
R. Ubink, P. Boross, G. Rouwendal, J.H. Leusen; Utrecht,
Netherlands
nnWS.D.12
Immune Intervention
in Autoimmune Disease
Hall F1
14:45 – 16:00
Chairpersons: Thomas Wekerle; Vienna, Austria
Gabriella Sármay; Budapest, Hungary
WS.D.12.1 Inorganic‑organic hybrid nanoparticles in the
treatment of CNS autoimmune responses with
glucocorticoids
Elena Montes Cobos, S. Ring, J. Heck, C. Feldmann,
F. Lühder, H.M. Reichardt; Göttingen, Germany
WS.D.12.2 A vascular targeting IL‑4 immunocytokine synergizes
with dexamethasone to support tolerogenic
macrophages and expand functional regulatory
T cells in a murine model of arthritis
Joanna Z. Kawalkowska, T. Hemmerle, F. Doll, F. Pretto,
M. Matasci, D. Neri, R.O. Williams; Oxford, United
Kingdom
WS.D.12.3 Selective depletion of citrullinated protein specific
B cells in rheumatoid arthritis by an auto‑epitope
peptide and a killing peptide coupled together to the
surface of biodegradable nanobeads
Judit Pozsgay, A. Magyar, G. Gyulai, F. Babos, K. Uray,
B. Rojkovich, F. Hudecz, G. Nagy, É. Kiss, G. Sármay;
Budapest, Hungary
WS.D.12.4 IL‑35 maintains regulatory T cells phenotype to
suppress autoimmune disease
Kailash Singh, J. Lindroos, E. Kadesjö, M. Hjört,
M. Lundberg, D. Espes, P. Carlsson, S. Sandler,
L. Thorvaldsson; Uppsala, Sweden
WS.D.12.5 Selective suppression of autoreactive B and T cells by
chimeric molecules in a humanized mouse model of
Autoimmune Diabetes
Iliyan Manoylov, N. Delcheva, I. Atanassova,
A. Tchorbanov; Sofia, Bulgaria
Program per Day
Track E
nnWS.D.13
Immunotherapy
of Infectious Diseases
Hall K
14:45 – 16:00
Chairpersons: Sylvia Knapp; Vienna, Austria
Jacek Rolinski; Lublin, Poland
WS.D.13.1 Activation of circulating platelets lead to the release
of potent antiviral IgG
A. Assinger, A. Tuiskunen Bäck, A. Luik, M. Salzmann,
S. Badrnya, J. Kral, W. Schrottmeier, M. Karlsson,
M N. Forsell; Stockholm, Sweden
WS.D.13.2 Evaluation of a novel passive immunotherapy
approach targeting HMGB1 in the treatment of sepsis
Natalie E. Stevens, C.K. Fraser, M.J. Chapman,
T.R. Kuchel, K.R. Diener, J.D. Hayball; Adelaide,
Australia
WS.D.13.3 Identification of novel CD8+ T‑cell epitopes from the
human adenovirus to improve immunomonitoring
and recruitment of antiviral T cells for adoptive
immunotherapy
Sabine Tischer, C. Bunse, J. Lahrberg,
J. Kwoczek, A. Heim, R. Geyeregger, R. Blasczyk,
B. Maecker‑Kolhoff, B. Eiz‑Vesper; Hannover, Germany
TRACK E
Workshop
nnWS.E.02
Hall M
14:45 – 16:00
Chairpersons: Klaus G. Schmetterer; Vienna, Austria
Valery Chereshnev; Perm, Russian Federation
WS.E.02.1 Superoxide dismutase 1 protects from type I
interferon‑driven oxidative damage in viral hepatitis
Anannya Bhattacharya, A.N. Hegazy,
N. Deigendesch, L. Kosack, J. Cupovic,
R.K. Kandasamy, A. Hildebrandt, D. Merkler, A.A. Kühl,
B. Vilagos, C. Schliehe, I. Panse, K. Khamina, H. Baazim,
I. Arnold, L. Flatz, H.C. Xu, P.A. Lang, A. Aderem,
A. Takaoka, G. Superti‑Furga, J. Colinge, B. Ludewig,
M. Löhning , A. Bergthaler; Vienna, Austria
WS.E.02.2 Metabolic requirements for γδ cell development
Stefania Martin, N. Sumaria, D.J. Pennington; London,
United Kingdom
WS.E.02.3 Immunological recognition of dietary proteins are
required for intestinal development and barrier
function
S. Hartmann, A. Visekruna, H. Mollenkopf,
K. Rajalingam, Ulrich Steinhoff; Marburg, Germany
WS.D.13.4 Adoptive T cell therapy for treatment of chronic
hepatitis B
Nina Böttinger, K. Wisskirchen, P. Knolle, U. Protzer;
Munich, Germany
WS.E.02.4 Macrophages rearrange the mitochondrial electron
transport chain upon sensing live bacteria
J. Garaude, R. Acín‑Pérez, S. Martínez‑Cano,
M. Ugolini, E. Nistal‑Villán, S. Hervás‑Stubbs, L.E. Sander,
J.A. Enríquez, David Sancho; Madrid, Spain
WS.D.13.5 G‑CSF directly affects CD8+ cytotoxic T‑cell
characteristics resulting in impaired T cell functionality
in hematopoietic stem cell donors
Carola E. Bunse, S. Tischer, J. Lahrberg, J. Kwoczek,
M. Oelke, C. Figueiredo, S. Thomas, R. Blasczyk,
B. Eiz‑Vesper; Hannover, Germany
WS.E.02.5 Placental heme oxigenase 1 expression promotes
immune adaptation to pregnancy and fetal growth in
mice
Maria E. Solano, M.K. Kowal, G.E. O’Rourke, R. Barikbin,
K. Karimi, P.C. Arck; Hamburg, Germany
WS.D.13.6 First‑in‑man treatment with polypeptide generated
adenovirus‑specific T cell lines
René Geyeregger, C. Freimueller, J. Stemberger,
M. Artwohl, V. Witt, T. Lion, G. Fischer, A. Lawitschka,
J. Ritter, M. Hummel, W. Holter, G. Fritsch,
S. Matthes‑Leodolter; Vienna, Austria
WS.E.02.6 Immunometabolic phenotype of prototypical Th1‑ and
Th2‑type mouse strains
Nada Pejnovic, N. Jovicic, I. Jeftic, I. Jovanovic,
G. Radosavljevic, N. Arsenijevic, M.L. Lukic;
Kragujevac, Serbia
nnJS.08
Mechanisms in Allergy
(jointly with WAO)
Hall F1
12:45 – 14:15
Chairpersons: Ruby Pawankar; Tokyo, Japan
JS.08.1
The epithelium as a key regulator of barrier defense
and immune regulation in allergic airway disease
Ruby Pawankar; Tokyo, Japan
JS.08.2
Innate immunity and Omics in allergy
Lanny Rosenwasser; Kansas City, United States
JS.08.3
The role of oxidative stress in allergic sensitization
Ronald van Ree; Amsterdam, Netherlands
87
WEDNESDAY
WS.D.12.6 Antigen‑specific T cell deletion by
erythrocyte‑targeted antigens: memory of tolerance
and induction of regulatory T cells
Alizée J. Grimm, J.A. Hubbell; Lausanne, Switzerland
Program per Day
Other Sessions and Meetings
nnJS.09
Newborn Screening for
Immunodeficiency (jointly with ESID) Hall F2
12:45 – 14:15
Chairpersons: Bobby Gaspar; London,
United Kingdom
Elisabeth Förster‑Waldl; Vienna, Austria
JS.09.1
nnIUIS - The Importance of Standardization for Immunology
NBS for SCID ‑ Why is it so important
Bobby Gaspar; London, United Kingdom
JS.09.2
NBS for primary immunodeficiencies ‑ not only SCID
Stephan Borte; Stockholm, Sweden
JS.09.3
The European experience with NBS for SCID so far
Marie Audrain; Nantes, France
On NK Cells and NK Cell-Based
Therapy of Leukemias
Hall A
09:45 – 11:15
Chairpersons: Lorenzo Moretta; Rome, Italy
Franco Locatelli; Rome, Italy
EP.01.1
Features of CMV‑induced memory‑like human NK cells
Alessandro Moretta; Genoa, Italy
EP.01.2
On Innate Lymphoid cell signature, plasticity and
redundancy
Eric Vivier, S. Ugolini; Marseille, France
EP.01.3
The role of NK cells in T‑cell depleted haploidentical
stem cell transplantation in pediatric patients
Franco Locatelli; Rome, Italy
WEDNESDAY
Manipulation of the innate and adaptive immune
response to improve the outcome of allogeneic stem
cell transplantation
Hermann Einsele; Wuerzburg, Germany
Women in Immunology
nnWO.01
She is a Genius
Hall M
12:45 – 14:15
Chairpersons: Anna Fogdell‑Hahn; Stockholm, Sweden
Sylvia Cohen Kaminsky; Paris, France
WO.01.1
Historical perspective of active exclusion from
academy to where we are today
Agnes Wold; Gothenburg, Sweden
WO.01.2
A gut feeling from a woman immunologist
Nadine Cerf‑Bensussan; Paris, France
WO.01.3
10:45 – 11:15
Current developments in complement analysis and
international quality assessment
Michael Kirschfink; Heidelberg, Germany
11:45 – 12:15
International Standardization in Autoantibody Testing
Luis Andrade; São Paulo, Brasil
EFIS President’s Symposium
EP.01.4
Chairpersons: Rudolf Valenta; Vienna, Austria
Michael Kirschfink; Heidelberg, Germany
11:15 – 11:45
Challenges in monoclonal antibody standardization
Pablo Engel; Barcelona, Spain
nnEP.01
10:45 – 14:30
Why have we missed the female genius?
Fabrice Papillon; Paris, France
12:15 – 12:45
Approaches for detection and quantification of multiple
allergens in allergen extracts
Stefan Vieths; Langen, Germany
12:45 – 14:30
Get together for discussion and networking
nnBA.23.1
Austrian Society for
Allergology und Immunology (ÖGAI)
Board Meeting
(Vorstandssitzung)
closed*
nnBA.24
16:15 – 17:30
Austrian Society for
Allergology und Immunology (ÖGAI)
General Assembly (Generalversammlung)
19:15 – 20:45
07:15 – 08:15
Informal breakfast event for early career scientists. The “Meet the
Professor Sessions” will provide participants the opportunity to meet
the most renowned scientists in an interactive and casual manner.
Maximum amount of participants: 30
nnME.06
Mirjam Heemskerk 88
Meeting Room 2
(1.61)
07:15 – 08:15
Program per Day
Posters of the Day according to Tracks A, B, C, D, E
nnP.C.17
Innate Immunity - Inflammation - Part 2
nnP.C.18
nnP.C.19
nnP.A.20
Dynamics of T Cell Activation and
Contraction - Part 1
nnP.C.20
nnP.A.21
Lymphocyte Development - Part 2
nnP.C.21
nnP.A.22
nnP.C.22
Complement and Fc Receptors
nnP.A.23
Costimulatory Pathways in Immunity and
Tolerance
nnP.C.23
Cytokines - Part 2
nnP.C.24
microRNAs and Epigenetics
nnP.A.24
Th17 Cells - Part 2
nnP.A.25
nnP.A.26
nnP.D.19
Vaccines for Infectious Diseases
nnP.A.27
nnP.D.20
Vaccine Adjuvants
nnP.A.28
Dynamics of T cell activation and
contraction - Part 2
nnP.D.21
Intervention & Therapy of Allergy - Part 2
nnP.D.22
nnP.D.23
Stem Cells & Cell Based Therapies - Part 2
nnP.D.24
Immunogenicity against Biopharmaceuticals
- Part 3
nnP.D.25
Organ Transplantation
nnP.D.26
Immunosuppressive and Tolerogenic
Treatment
nnP.D.27
MHC and other Gene Polymorphisms
in Health & Disease
nnP.B.29
nnP.B.30
nnP.B.31
Secondary Immunodeficiencies
nnP.B.32
nnP.B.33
Environmental and Genetic Factors
in Autoimmunity
nnP.B.34
Multiple Sclerosis
nnP.B.35
Immune Regulation at Barrier Sites - Part 1
nnP.B.36
Immune Regulation at Barrier Sites - Part 2
nnP.B.37
Cytokines in Regulation of Disease
nnP.B.38
Allergen Specific Immune Response - Part 3
nnP.B.39
nnP.B.40
Myelo-and Lymphoproliferative Disorders
nnP.B.41
Atherosclerosis and Cardiovascular Diseases
nnP.B.42
WEDNESDAY
Track E – Other
nnP.E.04
Immune Response in Aging & Systems
Biology - Part 2
nnP.E.05
Reproductive Immunology
CLOSING AND AWARD CEREMONY
17:45 – 18:45
Hall A
EFIS-Biolegend Bright Sparks Awards
Hannes Stockinger, EFIS treasurer
Gene Lay, CEO Biolegend
Poster Awards
Barbara Bohle, President Scientific Program Committee 4th ECI
ECI 2018
Gunnur Deniz, President 5th ECI
Closing Words
Winfried F. Pickl, President 4th ECI
89
Program per Day
RELATED POST CONGRESSIONAL EVENTS
IN VIENNA AFTER THE 4TH ECI
WEDNESDAY
September 10, 2015
2nd TRAINING FOR TRAINERS - International Network of
Universities for Molecular Allergology and Immunology
Medical University of Vienna, Jugendstilhörsaal,
Spitalgasse 23, 1090 Vienna
September 10, 2015, 9:00 – 18:00
90
INDUSTRY
SPONSORED
SYMPOSIA,
SPONSORS AND
EXHIBITORS
Acknowledgements. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
Sponsors‘ Company Descriptions. . . . . . . . . . . . . . . . . . . . . . . 95
Industry Sponsored Symposia . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Exhibition Information. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Exhibition Floorplan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
This section contains information that is promotional in nature,
distinct from the scientific / educational elements of the congress.
91
PROGRESS AND
POSSIBILITY IN
IMMUNOLOGY.
VISIT ABBVIE
AT BOOTH #111
Industry Sponsored Symposia, Sponsors and Exhibitors
ACKNOWLEDGEMENTS
ECI wishes to thank the following main sponsors for their support of ECI 2015 as follows:
SPONSORS
PLATINUM SPONSOR
GOLD SPONSOR
SILVER SPONSORS
BRONZE SPONSOR
EFIS OFFICIAL JOURNALS
93
The MojoSort™ Magnetic Cell Separation System is designed for the
separation of target populations using positive or negative selection.
MojoSort™ nanoparticles deliver excellent purity and yield at an
unmatched, affordable price. Magnetically sorted cells can be used
for multiple downstream applications.
MojoSort™ advantages:
•
Small and large test size formats to meet research needs
•
Robust performance
•
Preserved cell functionality after sorting
•
Excellent price
Add some Mojo to your experiment and explore the possibilities!
Before Isolation
After MojoSort™ Isolation
After Competitor Isolation
A suspension of single cells from pooled C57BL/6 mouse spleen and lymph nodes was prepared to isolate CD4+ T cells using
the MojoSort™ Mouse CD4 T Cell Isolation Kit. Cells were stained with PE anti-mouse CD4 (clone RM4-4), APC anti-mouse CD3ε
(145-2C11), and 7-AAD. Grateful Dead cells were excluded from the analysis.
To learn more, visit: biolegend.com/mojosort
Tel: 858.768.5800
biolegend.com
08-0052-04
SPONSORS’ COMPANY DESCRIPTIONS
nnAbbVie
AbbVie, a global, research-based biopharmaceutical company, is committed to addressing some of today’s toughest health
challenges. As a leader in Immunology, our scientists use their diverse perspectives and insights to develop new medicines
and therapies for addressing chronic, progressive diseases. Our treatments and pipeline in Immunology are designed to target
complex, unmet medical needs for patients suffering from difficult-to-treat autoimmune or immune-mediated inflammatory
diseases. It’s all part of AbbVie’s promise to pursue the possibilities that help more patients lead healthier lives.
nnBD Biosciences
BD Biosciences, a segment of Becton, Dickinson and Company, is one of the world’s leading businesses focused on bringing
innovative tools to life science researchers and clinicians. Principal product lines include flow cytometers and cell sorters,
monoclonal antibodies and kits, reagent systems, and tools to aid in life science research, drug discovery and diagnostic
assays. BD Biosciences customers are involved in basic research, discovery and development of drugs and vaccines, clinical
trials, diagnostic testing, and disease management. This diverse customer base includes academic and government institutions, pharmaceutical and biotech companies, and clinical laboratories.
nnBeckman Coulter
Flow Cytometry – Research / Life Science
Offering the broadest range of cellular analysis systems in the world, Beckman Coulter provides a variety of reagents, instruments and software to meet the diverse needs of today’s research laboratories. Our extensive line of reagents include human
and non-human antigens, signal transduction and immunotoxicology.
nnBioLegend
BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents for biomedical research, at an
outstanding value to customers. The broad product portfolio includes flow cytometry, cell biology, and functional reagents
for research in immunology, neuroscience, cancer research, stem cells, and more. BioLegend is certified for ISO 9001:2008
and ISO 13485:2003.
nnMiltenyi Biotec
Miltenyi Biotec provides products that advance biomedical research and cellular therapy. Our innovative tools support
research from basic research to translational research to clinical application. Our more than 25 years of expertise includes
immunology, stemcell biology, neuroscience, and cancer. Miltenyi Biotech as more than 1,500 employees in 25 countries.
nnFresenius Medical Care/Therapeutic Apheresis
Therapeutic Apheresis is a “special care” division of Fresenius Medical Care, the world’s largest provider of dialysis care
products and services.
nnWiley
Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research,
professional practice and education.
nnElsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services.
95
Flow Cytometer
POWERFUL PERFORMANCE
WITH MAXIMUM FLEXIBILITY
EASY TO LEARN, EASY TO OPERATE, EASY TO MAINTAIN
The CytoFLEX flow cytometer is designed to deliver superior
performance, flexibility, and ease of operation for research
applications. Innovation in the design of both the hardware
features and new CytExpert software provides intuitive tools
for researchers. Simplified system setup, data acquisition,
analysis, and export of experimental results are integrated into
a complete workflow solution.
The CytoFLEX system features a compact footprint, integrated
detection optics and lasers, and a simplified, highly reliable
fluidics system. In addition, the flow cell design is integrated
into the optical path, to greatly improve system performance,
stability and signal resolution.
The instrument is designed to be compact and fits easily on
a bench top or a standard biohood. Twenty one (21) standard
configurations are available to provide the ultimate in
application flexibility with up to three lasers and 15 parameters.
The CytoFLEX flow cytometer is easily installable and
upgradeable. All lower configuration systems have full upgrade
capability to higher configurations enabling future application
expansion.
Together, the CytoFLEX system and CytExpert software brings
high performance flow cytometry to a variety of researchers
with simple to complex needs.
Please contact your Beckman Coulter representative for more information.
For Research Use Only. Not to be used in diagnostic procedures.
Beckman Coulter, the stylized logo, CytoFLEX, CytExpert and fast track to success. are trademarks of Beckman Coulter,
Inc. Beckman Coulter and the stylized logo are registered in the USPTO.
INDUSTRY SPONSORED SYMPOSIA
MONDAY
nnIS.01
Industry Sponsored Lunch Symposium: Fresenius Medical Care
New Treatment Opportunities with Immunoadsorption Technology
Chairperson:
Hall F1
14:00 -15:30
Treatment of Encephalitis with Immunoadsorption
Nico Melzer; Muenster, Germany
Apheresis in Autoimmune Disease
Georg Böhmig; Vienna, Austria
New Option for Allergy Treatment. Why IgE?
Questions and Answers
nnIS.02
Industry Sponsored Lunch Symposium: Beckman Coulter
New reagent and instrument concepts for your Immunology research
Chairperson:
Andreas Böhmler; Krefeld, Germany
Hall N
14:00 -15:30
Innovative Technologies for phenotypic and functional Cell Characterization in Stem cell and Immune therapy
Lutz Uharek; Berlin, Germany
MAIT cells: their role in antibacterial immunity and beyond
Emmanuel Treiner; Toulouse, France
Small - smaller - smallest: Extracellular vesicles in inflammation
Andreas Spittler; Vienna, Austria
nnIS.03
Industry Sponsored Evening Symposium: Phadia Austria GmbH (Thermo Fisher Scientific)
Towards a molecular diagnosis of allergies
Hall F1
19:15 -20:15
Chairpersons: Petra Zieglmayer; Vienna, Austria / Rudolf Valenta; Vienna, Austria
Molecular diagnosis of lgE-associated allergies
Marianne van Hage; Stockholm, Sweden
Early childhood lgE reactivity predicts later disease development
Magnus Wickman; Stockholm, Sweden
nnIS.04
Industry Sponsored Progress in Technology Session: Pfizer
Personalized Vaccinology
Hall G
19:15 -20:15
Chairpersons: Ursula Wiedermann; Vienna, Austria / Martina Prelog; Würzburg, Germany
Vaccine responsiveness in patients with autoimmune disorders
Martina Prelog; Würzburg, Germany
Vaccine failures ‑ why and what to do?
nnIS.05
Industry Sponsored Evening Symposium Bristol-Myers Squibb (BMS)
Immune checkpoint modulation – The standard in lung cancer and rheumatoid arthritis?
Chairperson:
Christoph Zielinski; Vienna, Austria
Hall N
19:15 -20:15
Rational to target immune checkpoints in diseases
Eric Tartour; Paris, France
Evolving immunotherapy combinations for cancer treatment
Abatacept: T-cell modulation in rheumatoid arthritis.
Clemens-Maria Scheinecker; Vienna, Austria
97
Personalizing vaccination for high risk children
Rita Carsetti; Rome, Italy
Value through Innovation
For more than 100 years we have demonstrated our strong
research spirit in the interest of future generations.
Research is our key to success. Thanks to our innovative medicines, Boehringer
Ingelheim is one of the world’s top 20 pharmaceutical companies.
Our global center for cancer research as well as facilities for biopharmaceutical
research, development and production are located at the Boehringer Ingelheim
Regional Center Vienna. In addition, the commercial activities for over 30
countries in Central and Eastern Europe are managed from the Vienna site.
Having 1400 employees and investing around 200 million euros in nonclinical and clinical research, Boehringer Ingelheim is considered one of the
most important employers in the Austrian life science sector.
www.boehringer-ingelheim.at
Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, 1121 Vienna, phone 01/801 05-0*, fax 804 08 23
INDUSTRY SPONSORED SYMPOSIA
TUESDAY
nnIS.06
Industry Sponsored Progress in Technology Session: Fluidigm
Connect cell diversity, stimulus and response with single-cell biology
Hall N
10:00 -11:00
The future of single-cell biology
Mark Lynch / Robert Ellis; Amsterdam, The Netherlands
Resolving bifurcation of Th1 and Tfh cell fates during Plasmodium infection using single-cell RNA sequencing
Tapio Lonnberg; Hinxton, United Kingdom
Further Topic & Speaker - To be confirmed
nnIS.07
Industry Sponsored Lunch Symposium: Becton Dickinson
Revealing Immune Cell Biology with Multicolor Flow Cytometry
Chairperson:
Nicolas Quoix; Erembodegem, Belgium
Hall F1
14:00 -15:30
Optimizing Strategies for Reliable Multicolor Flow Data
Guerric Epron; Erembodegem, Belgium
Nutrient control of stem cell and T cell differentiation
Naomi Taylor; Montpellier, France
99
HOW WOULD YOU USE
£20 MILLION TO BEAT
CANCER SOONER?
This October Cancer Research UK will
launch our Grand Challenge the world’s
biggest boldest cancer grant. A series
of £20 million awards for multinational,
multidisciplinary teams willing to tackle
the toughest questions in cancer today.
Find out more visit:
cruk.org/grandchallenge
#CRUKGrandChallenge
Cancer Research is a registered charity in England and Wales (1089464), Scotland (SC041666) and the Isle of Man (1103).
C 2014 Cancer Research UK. The Cancer Research UK name and logo are registered trademarks of Cancer Research UK.
EXHIBITION INFORMATION
The exhibition is an important component of the ECI congress, providing participants with an ideal platform to network with
industry partners in the field and an opportunity to gain further insights into the newest advancement from the industry side.
58 companies and publishers are exhibiting at the ECI 2015 congress.
The technical exhibition takes place in the hall X2 on the level -2. Please see further details on pages 104 & 105.
Exhibition & Society Village - opening hours:
Monday, September 7, 2015
Tuesday, September 8, 2015
Wednesday, September 9, 2015
9:00–18:00
9:00–18:00
9:00–16:30
Exhibitor Registration Counter
Exhibitor badges and complimentary congress badges are
available for pick-up at the exhibitor registration desk in
the entrance hall. Opening times – please see Exhibition
Service Desk.
Exhibitor badges are to be used solely for staff members
of the exhibiting companies and only allow access to the
exhibition hall.
The complimentary congress registrations allow access to
the scientific sessions and receipt of the congress bag including final program. These are also to be used solely by
staff members of the exhibiting companies, as they will not
show a barcode on the badge, hence will not abtain any
CME credits.
Exhibition Service Desk – opening hours
Saturday, September 5, 2015
Sunday, September 6, 2015
Monday, September 7, 2015
Tuesday, September 8, 2015
Wednesday, September 9, 2015
Thursday, September 10, 2015
8:00–20:00
8:00–20:00
8:00–18:30
8:00–18:30
8:00–22:00
8:00–14:00
Exhibitor access
Exhibitors may enter the exhibition area one hour prior to the
official opening and must leave the exhibition halls at the
latest 30 min after closing, therefore at 18.30.
Meetings or customer events on the booth area before 9:00
and after 18:00 are not allowed.
Tickets to visit only the exhibition are not available.
101
Neurology journey through time
60 Years Novartis Neuroscience in Austria
Rilatin® / later Ritalin®
Tegretol®
Leponex® & Anafranil®
Lioresal®
Sirdalud®
Trileptal®
Comtan® & Exelon®
Datum der Erstellung: Februar 2015
Gilenya®
AT1503302302
Stalevo®
Novartis Pharma GmbH, Stella-Klein-Löw-Weg 17, 1020 Wien, Tel.: 01-866 57-0, Fax: 01-866 57 6353
EXHIBITION INFORMATION
Exhibitors (alphabetical)
The following companies are exhibiting at the ECI 2015 (as per August 2015)
Booth no.
Company Name
Booth no.
AbbVie Immunology R&D, North Chicago,
Illinois, United States
111
MILTENYI BIOTEC GmbH, Bergisch Gladbach, Germany112
MERCK SHARP & DOHME, Wien, Austria
133
Abcam plc, Cambridge, United Kingdom
114
PBL Assay Science, Piscataway, United States
143
AID GmbH, Straßberg, Germany
135
PEPperPRINT GmbH, Heidelberg, Germany
116
AYOXXA Biosystems GmbH, Köln, Germany
117
PeproTech EC Ltd., London, United Kingdom
142
BECTON DICKINSON FRANCE S.A.,
Erembodegem, Belgium
110
PerkinElmer Inc., Hopkinton, United States
115
BECKMAN COULTER Eurocenter S.A., Nyon 1, Schweiz 119
BioLegend, San Diego, United States 102
Bio-Rad Laboratories GesmbH, Vienna, Austria
125
BIO-TECHNE, Abingdon, United Kingdom
103
BioVendor Research & Diagnostic Products,
Brno, Czech Republic
134
BIOZOL Diagnostica Vertrieb GmbH, Eching, Germany 136
Biozym Biotech Trading GesmbH, Wien, Austria
102
BRISTOL-MYERS SQUIBB GesmbH, Wien, Austria
113
Cell Signaling Technology, Leiden, Netherlands
126
CHEMOMETEC A/S, Allerod, Denmark
145a
CTL Europe GmbH, Bonn, Germany
105
Cytognos S.L., Flow Cytometry Solutions,
Salamanca, Spain
144
Danone, Paris, France
100
eBioscience, an Affymetrix company, Wien, Austria
147
Enzo Life Sciences, Farmingdale, NY, United States
109
EXBIO Antibodies, Vestec, Czech Republic
129
Fluidigm Europe B.V., Amsterdam, Netherlands
123
Fresenius Medical Care Deutschland GmbH,
Bad Homburg, Germany
122
Hycult Biotech, Uden, Netherlands
139
Illumina, San Diego, United States
140
Immudex, Copenhagen, Denmark
145b
IntelliCyt Corp., Albuquerque, United States
120
InvivoGen, Toulouse, France
106
Jackson ImmunoResearch Europe Ltd,
Newmarket, United Kingdom
107
JPT Peptide Technologies GmbH, Berlin, Germany
124
LGC Standards, Teddington, Middlesex,
United Kingdom
Lophius Biosciences GmbH, Regensburg, Germany
Pivotal Scientific Limited, Oxfordshire, United Kingdom 128
PromoCell GmbH, Heidelberg, Germany
127
Proteintech Europe, Manchester, United Kingdom
146
QUANTA Biosciences, Germantown MD, United States 137
Randox Biosciences, Crumlin, Co. Antrim,
United Kingdom
145
Seahorse Bioscience Europe, Copenhagen, Denmark 132
Sony Biotechnology Inc., San Jose, United States
101
STEMCELL Technologies, Grenoble, France
104
SYSMEX Europe GmbH, Norderstedt, Germany
141
Szabo-Scandic HandelsgmbH & Co KG, Wien, Austria 136
Thermo Fisher Scientific, Darmstadt, Germany
138
VWR International GmbH, Wien, Austria
137
Publishers
ELSEVIER B.V., Amsterdam, Netherlands
P101
Wiley Blackwell, John Wiley & Sons, Oxford,
United Kingdom
P102
Wisepress Ltd, London, United Kingdom
P103
S.KARGER AG, Medical and Scientific Publishers,
Basel, Switzerland
P104
Frontiers, Lausanne, Switzerland
P105
Society Village
American Association of Immunologists (AAI)
S10
S02
European Federation of Immunological Societies (EFIS) S09
French Society for Immunology (SFI)
S07
S04
International Congress of Immunology (ICI 2016) S01
130
International Union of Immunological Societies (IUIS)
S01
131
Irish Society for Immunology (ISI)
S05
Mabtech AB, Nacka Strand, Sweden
108
Italian Society for Immunology (SIICA)
S06
Merck Millipore, Vienna, Austria
121
S08
Meso Scale Discovery, Rockville, United States
118
Turkish Society for Immunology (TSI)
S03
103
Company Name
EXHIBITION FLOORPLAN
LEVEL -2
Level
-2
Anouncement Industry
Sponsored Sessions
S01
S02
Desk
Poster Help
Information
S03
S04
IUIS/ BRITISH TURKISH
ICI 2016 SOC. SOC.
Society Village
Society Village
DGfI
Lecture
halls
AAI
EFIS
100
S10
S09
S06
S07
Society Village
P102
ELSE- WILEY
VIER
P103
P104
WISEPRESS
KARGER
CTL
STEM-CELL
BIO-TECHNE
BIOLEGEND
SONY
105
104
103
102
101
113
Poster
Poster
106
INVIVO- JACKGEN SON
107
108
MAB- ENZO
TECH
109
ABBVIE
BECTON
DICKINSON
116
117
AYO- MESOXXA SCALE
118
130
Level
0
132
134
PIVO- EXBIO
TAL
FRESENIUS
BECKMAN
COULTER
LGC LOPHIUS
SEAHORSE MSD
BIOVENDOR
AID
129
131
MERCK
120
121
145b
SZABO
SCAN- QUANTA
DIC
145
146
CELL
SIGNALING
126
141
133
136
BIORAD
125
123
137
HYTHER- CULT
MOFISHER ILLUMINA
138
145a
FLUIDIGM
139
IMMUPROCHEMO- DEX RAN- TEINDOX TECH
METEC
JPT
124
122
INTELLICYT
135
114
112
119
128
ABCAM
Exhibition (X2)
110
PER- PEPKIN PERELMER PRINT
127
BMS PROMOCELL
111
MILTENYI
BIOTEC
115
P105
S08
ISI SIICA FRENCH
SOC. SSI FRONTIERS
Society Village & Publishers
P101
DANONE
S05
140
142
SYS- PEPROMEX TECH
PBL
CYTOGNOS
143
144
147
eBIOSCIENCE
Exhibition (X2)
104
€
€
EXHIBITION FLOORPLAN
S
ge
PosterPoster
AwardAward
Candidates
Candidates
Booth # Booth Company
#
Company
name
name
List of Exhibitors
List of Exhibitors
€
€
Danone
Danone
Sony Biotechnology
Sony Biotechnology
Inc.
Inc.
BioLegend BioLegend
Biozym Biotech
Biozym
Trading
Biotech
GesmbH
Trading GesmbH
BIO-TECHNEBIO-TECHNE
STEMCELL Technologies
STEMCELL Technologies
CTL Europe GmbH
CTL Europe GmbH
InvivoGen InvivoGen
Jackson ImmunoResearch
Jackson ImmunoResearch
Europe Ltd Europe Ltd
Mabtech AB Mabtech AB
Enzo Life Sciences
Enzo Life Sciences
BECTON DICKINSON
BECTON DICKINSON
FRANCE S.A.FRANCE S.A.
AbbVie Immunology
AbbVie Immunology
R&D
R&D
MILTENYI BIOTEC
MILTENYI
GmbH
BIOTEC GmbH
BRISTOL-MYERS
BRISTOL-MYERS
SQUIBB GesmbH
SQUIBB GesmbH
Abcam plc Abcam plc
PerkinElmerPerkinElmer
Inc.
Inc.
PEPperPRINTPEPperPRINT
GmbH
GmbH
AYOXXA Biosystems
AYOXXA GmbH
Biosystems GmbH
Meso Scale Discovery
Meso Scale Discovery
BECKMAN COULTER
BECKMAN
Eurocenter
COULTERS.A.
Eurocenter S.A.
IntelliCyt Corp.
IntelliCyt Corp.
Merck Millipore
Merck Millipore
Fresenius Medical
Fresenius
CareMedical
Deutschland
Care Deutschland
GmbH
GmbH
Fluidigm Europe
Fluidigm
B.V. Europe B.V.
JPT Peptide Technologies
JPT Peptide Technologies
GmbH
GmbH
Bio-Rad Laboratories
Bio-Rad Laboratories
GesmbH GesmbH
Cell Signaling
Cell
Technology
Signaling Technology
PromoCell GmbH
PromoCell GmbH
Pivotal Scientific
Pivotal
Limited
Scientific Limited
EXBIO Antibodies
EXBIO Antibodies
LGC Standards
LGC Standards
Lophius Biosciences
Lophius GmbH
Biosciences GmbH
Seahorse Bioscience
SeahorseEurope
Bioscience Europe
MERCK SHARP
MERCK
& DOHME
SHARP & DOHME
BioVendor Research
BioVendor
& Diagnostic
Research &Products
Diagnostic Products
100
101
102
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
100
101
102
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
AID GmbH AID GmbH
BIOZOL Diagnostica
BIOZOL Diagnostica
Vertrieb GmbH
Vertrieb GmbH
Szabo-Scandic
Szabo-Scandic
HandelsgmbH
HandelsgmbH
& Co KG & Co KG
QUANTA Biosciences
QUANTA Biosciences
VWR International
VWR International
GmbH
GmbH
Thermo Fisher
Thermo
Scientific
Fisher Scientific
Hycult Biotech
Hycult Biotech
Illumina Illumina
SYSMEX Europe
SYSMEX
GmbH
Europe GmbH
PeproTech ECPeproTech
Ltd.
EC Ltd.
PBL Assay Science
PBL Assay Science
Cytognos S.L.Cytognos S.L.
Randox Biosciences
Randox Biosciences
Proteintech Europe
Proteintech Europe
eBioscience eBioscience
CHEMOMETEC
CHEMOMETEC
A/S
A/S
Immudex Immudex
Booth # Booth #
135
136
136
137
137
138
139
140
141
142
143
144
145
146
147
145a
145b
135
136
136
137
137
138
139
140
141
142
143
144
145
146
147
145a
145b
ELSEVIER B.V.
ELSEVIER B.V.
P101
Wiley Blackwell,
WileyJohn
Blackwell,
Wiley &John
SonsWiley & Sons
P102
Wisepress Ltd
Wisepress Ltd
P103
S.KARGER AG,
S.KARGER
Medical AG,
andMedical
Scientific
and
Publishers
Scientific Publishers
P104
Frontiers Frontiers
P105
P101
P102
P103
P104
P105
PublishersPublishers
CompanyCompany
name
name
Poster
Poster
Society Village
Society Village
InternationalInternational
Congress of Congress
Immunology
of Immunology
(ICI 2016) (ICI 2016)
S01
InternationalInternational
Union of Immunological
Union of Immunological
Societies (IUIS)
Societies
S01
(IUIS)
British Society
British
for Immunology
Society for Immunology
(BSI)
(BSI)
S02
Turkish Society
Turkish
for Immunology
(TSI)
(TSI)
S03
German Society
German
for Immunology
(DGfI)
(DGfI)
S04
Irish SocietyIrish
for Immunology
(ISI)
(ISI)
S05
Italian Society
Italian
for Immunology
(SIICA)
(SIICA)
S06
French Society
French
for Immunology
(SFI)
(SFI)
S07
ScandinavianScandinavian
(SSI)
(SSI) S08
European Federation
EuropeanofFederation
Immunological
of Immunological
Societies (EFIS)
Societies
S09(EFIS)
American Association
American of
Association
Immunologists
of Immunologists
(AAI)
(AAI) S10
S01
S01
S02
S03
S04
S05
S06
S07
S08
S09
S10
105
T
A
S
U
MEET
2
1
1
#
H
B O OT
Your trusted partner on
the path to immunotherapy
Learn how you can simplify every step of your immunology workflow:
Tissue
dissociation
Cell
isolation
Cell activation
and expansion
Miltenyi Biotec provides products and services worldwide.
Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.
Flow
cytometry
Clinical
applications
miltenyibiotec.com
Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use.
MACS is a registered trademark of Miltenyi Biotec GmbH. Copyright © 2015 Miltenyi Biotec GmbH. All rights reserved.
EFIS
Info . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Appointments with EFIS during the ECI 2015. . . . . . . . . . . . . 109
Upcoming Meetings (Sponsored by EFIS) . . . . . . . . . . . . . . . 109
107
EFIS
INFO
The European Federation of Immunological Societies (EFIS) is a non-profit umbrella
organization that represents 31 immunological societies from all across Europe, and
even beyond the borders to Israel. Every active member of any of our member
societies is automatically considered an EFIS member and can as such benefit from
the EFIS programs. Thus EFIS represents more than 14,000 individual immunologists.
The main goals of EFIS are the support of immunological research and education
as well as strengthening scientific interaction amongst its members. EFIS especially
focuses on supporting early career scientists, e.g. through fellowships or travel grants.
The EFIS was founded at a meeting held in Amsterdam in September 1975. In the
beginning, the legal body of this society was the International Union of Immunological Societies (IUIS). During a meeting held in Helsinki in 1991, it was decided to
incorporate the articles in a notarial deed. EFIS was registered as an individual legal
body on the 5th of April 1995, in the form of a society as was stated in the deed of
notary Oosterdijk. See the EFIS website www.efis.org to read the statues of EFIS and
the minutes of previous EFIS general assemblies.
EFIS Board
The EFIS Board is composed of the President, the Vice President, the Past President, the Treasurer and the Secretary General.
The Board meets about three times a year. Board Members are elected by the EFIS General Assembly, composed of delegates of national societies (each society is entitled to have one delegate per 500 members), and they are appointed for
a period of three years.
Lorenzo Moretta (Rome, Italy)
President
Ospedale Pediatrico Bambino Gesù
V.le Ferdinando Baldelli, 41
00146 Rome
Anna Erdei (Budapest, Hungary)
Secretary General
Department of Immunology
University Eötvös Lorand
Pazmany s. 1/C
H-1117 Budapest, Hungary
René A.W. van Lier (Amsterdam, Netherlands)
President elect
Sanquin Blood Supply Foundation
Plesmanlaan 125
1066 CX Amsterdam
Catherine Sautès-Fridman (Paris, France)
Past President
Centre de recherche des Cordeliers, UMRS 872
15, rue de l'école de médecine
F-75006 Paris, France
Hannes Stockinger (Vienna, Austria)
Treasurer
Institute for Hygiene and Applied Immunology
Center for Pathophysiology, Infectiology and Immunology
Lazarettgasse 19
A-1090, Vienna, Austria
Contact
For general inquiries, please contact:
108
Mr. Thomas Wiley
EFIS Coordinator
[m]: 0039 347 197 7015
EFIS
APPOINTMENTS WITH EFIS DURING THE ECI 2015
Mark your congress program app to make sure you don’t miss these important EFIS events!
Monday, September 7th
- EFIS Awards Lecture Symposium, featuring the winners of the EFIS-IL Most Cited Article and Review Prizes and
the EFIS-EJI Ita Askonas Prize, as well as the Laureates of the ACTERIA Prizes awarded by EFIS, from 14:00 – 15:30
c/o Hall F2 of the Austria Center.
- "Bright Sparks" Workshops, throughout the day on Monday (c/o Hall F1), during which the 24 authors of abstracts
selected by the ECI 2015 Scientific Program Committee will present their work. In addition to her/his recognition as
an ECI 2015 "Bright Spark", all speakers in Bright Sparks Workshops will also receive a EUR 500,- cash prize (made possible
in part by BioLegend).
- Meet the Editor of Immunology Letters, Vito Pistoia, c/o the EFIS Booth from 14.00 to 15.00.
- Meet the Editors of European Journal of Immunology - with Hans-Martin Jäck, Steffen Jung and Andreas Radbruch c/o the EFIS Booth from 17.00 to 17.45.
Tuesday, September 8th
- Meet the Editors of European Journal of Immunology - with Britta Engelhardt and Francesco Annunziatoc/o the EFIS Booth from 9.45 to 11.15.
- Meet the Editors of European Journal of Immunology - with Francesco Annunziato, Hans-Martin Jäck and
Andreas Radbruch- c/o the EFIS Booth from 17.00 to 17.45.
Wednesday, September 9th
- The inaugural EFIS President’s Symposium, convened by standing EFIS Board President, Prof. Lorenzo Moretta,
from 9.45 to 11.15 c/o Hall A, entitled “On NK Cells and NK Cell-Based Therapy of Leukemias”.
- Meet the Editor of Immunology Letters, Dr. Vito Pistoia, c/o the EFIS Booth from 12.30 to 13.30.
ECI 2015 delegates are also cordially invited to visit the EFIS Booth c/o the Immunology Village for a coffee and to take part
in the traditional “EFIS Passport to Prizes” raffle for a chance to win numerous prizes, including travel grants to future immunology events and subscriptions and textbooks from EFIS’ Official Journals.
UPCOMING MEETINGS (SPONSORED BY EFIS)
2015
2016
September 16 – 18, 2015
Cancer: Inflammation and Immunity
Finale Ligure, Italy
www./nibit.org/meeting/index.php
August 21 – 26, 2016
16th International Congress of Immunology - ICI 2016
Melbourne, Australia
www.ici2016.org
October 06 – 08, 2015
15th International Conference on Progress in Vaccination
Against Cancer - PIVAC15
Tübingen, Germany
www.eacr.org/pivac15/
2018
September 12 – 15, 2018
5th European Congress of Immunology - ECI 2018
Istanbul, Turkey
www.eci2018.org
October 07 – 09, 2015
Natural Killer Cell Symposium
Göttingen, Germany
www.nk-symposium.org
October 16 – 19, 2015
7th EFIS/EJI South East European Immunology School
Becici, Montenegro
www.bnitm.de/seeis2015
109
International Congress of Immunology 2016
Invitation from the ICI 2016 President
ICI 2016 promises to be an unforgettable event that
will bring together delegates from all over the world.
We anticipate over 3000 participants, including
international leaders at the forefront of the discipline
that will present the most recent advances in basic
immunology and clinical treatments.
This is an opportunity to be part of a major international immunology
meeting in Australia as the last ICI was held in Sydney back in 1977.
The Congress will provide a key networking and educational interface
for colleagues from industry, university, health providers and
independent research organisations to come together.
Jose Villadangos
President, International Congress of Immunology 2016
Peter Doherty Institute and Bio21 Institute, The University of Melbourne
Scientific Program Highlights
The following disciplines / themes will form part of the program.
Innate immunity
Dendritic cells
Inflammation
T cell differentiation
Acquired immunity
B cell immunity
Vaccines
Life and death decisions in
the immune system
Tumour Immunology
Transplantation
Allergy
Autoimmunity and the
maintenance of tolerance
Immunoregulatory gene
networks
Immune deficiencies
Metabolic control of
immunity
Regulation of the immune
system by commensal flora
Immunotherapeutic drugs
Therapeutic antibodies
Mathematic modeling of
immune responses.
FAST FACTS
IMMUNOTHERAPY:
HARNESSING THE POWER
OF THE IMMUNE SYSTEM
Registration opens
September 2015
Call for Abstracts open
July 2015
ICI
2016
www.ici2016.org
Come and say G’day in Melbourne
in 2016!
Experience the best that Melbourne has to offer – its beaches,
entertainment, heritage, culinary traditions, food and wine, festivals,
sporting events, friendly people and much more.
Melbourne is recognised as an R&D centre of excellence in medical
science, business and finance. With Australia’s most culturally diverse
population, and repeatedly voted the world’s most liveable city,
Melbourne has something to offer for everyone.
It is also the perfect opportunity to discover Australia’s famous
destinations: the Great Barrier Reef, Twelve Apostles, Ayers Rock, the
Sydney Opera House, the iconic MCG Stadium and so much more!
Hosted by
Supported by
Congress Managed by Arinex Pty Ltd
91 – 97 Islington Street, Collingwood Victoria 3066 Australia
P: +61 3 8888 9510 F: +61 3 9417 0899
E: [email protected]
NETWORKING
EVENTS
Networking Events. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
111
Networking Events
NETWORKING EVENTS
Historic Exhibition
Emerging Immunology – Vienna’s Contribution
Opening: Sunday, September 6 | 19:00 |
Austria Center Vienna | Level 0
Exhibition Opening Hours: Sunday, September 6 – Wednesday, September 9 | Austria Center Vienna | Level 0
Vienna has been a cradle of immunology research at the end
of the 19th beginning of the 20th century.
In fact, some outstanding immunologists around Karl Landsteiner,
discoverer among many other immunologically relevant findings
of human blood groups, and Clemens von Pirquet, who coined
the term ‘allergy’, made ground-breaking contributions to early
immunology research.
It was the time when the concepts of active and passive vaccination started to become understood from a mechanistic
point of view and first preventive but also therapeutic treatment
modalities for the devastating infectious diseases threatening
large parts of our population at that time became feasible.
Some of the outstanding Austrian immunologists - from Karl Landsteiner to Clemens von Pirquet including their colleagues and
contemporaries - will be commemorated in this exhibition, which
has been curated by Johann Eibl, Othmar Förster and Winfried
F. Pickl. Moreover, a short outlook describing major immunology
research centers in the Vienna area in the 21st century will be
provided.
Networking Mixer
Sunday, September 6 | 19:00 | Austria Center Vienna |
Level 2
We are pleased to invite you to our Networking Mixer that will
take place just after the opening ceremony, starting at 19:00.
There you can catch up with “old” colleagues and friends and
meet new ones. Having always been a melting pot for numerous
cultures, Vienna has strongly been influenced among others,
by Jewish, Balkan and Turkish traditions. That is why Klezmer,
Kebab, and Coffee have grown to become almost as Viennese as Apfelstrudel and Johann Strauss. You will be able to
get a taste of very diverse and wonderful Viennese traditions
while being surrounded by an international atmosphere. We
are looking very much forward to an interactive, delightful &
multicultural evening!
Buffet: traditional Viennese cuisine with a touch of international
street food.
One of our three music acts will be playing in each corner of
the triangle-shaped location.
Classic:
Klezmer:
Jazz:
Michael Zlabinger (string quartett)
Frejlech
Thomas Kugi & Band
The event is entirely at the participants’ own expenses.
Participation is included in the registration fee but registration
for the event is necessary in advance. No sponsoring is used to
fund any part of the evening.
ECI Bright Sparks Pub Crawl
Monday, September 7 | 20:15 | Wiener Naschmarkt
The ECI 2015 Bright Sparks Pub Crawl connects international Early
Career Scientists with their Austrian colleagues to foster networking between the future experts of the discipline. Since networking, apart from many other skills, is an important ingredient of a
successful scientific career, ECI offers an informal platform for
the facile exchange of thoughts, experiences and perspectives
within the community of Early Career Scientists.
For that purpose, ECI organizes an event exclusively for this
group of participants. We would like to invite our international
colleagues to visit typical places in Vienna and to enjoy Viennese hospitality.
How to register:
Please register at the onsite registration desk. Participants will
receive a coupon stating the assigned group, meeting time
and meeting point.
Participants are divided into 10 groups with approx. 30 people
and two local hosts.
Each group will be assigned to two different Pubs. The first location is exclusively for the assigned group whereas the second
location is a melting pot for all groups.
Meeting time:
Meeting Point:
20:15
Foyer Hall E / Level 0
Departure: a group departs as soon as the group is complete
No sponsoring is used to fund any part of the evening.
ECI Networking Heurigen Evening
Tuesday, September 8 | 19:15
Enjoy a nice exclusive evening with your colleagues at a traditional Viennese “Heurigen” wine tavern where you are served
with wine produced from the surrounding vineyards. We will take
you to the picturesque village of Gumpoldskirchen, where you
will have the opportunity to experience a very typical Austrian
summer evening tradition: enjoying a glass of local wine together
with rustic food and embedded into authentic ‘Heurigen’-culture while being surrounded by vineyards.
Price per Person: EUR 60,-/limited availability
Price includes: shuttle bus to and from Gumpoldskirchen, a meal
(a variety of cold & warm dishes), 3 x 0,25 liter of red-or white
wine or soft drinks or water.
Participants are assigned to a specific Heurigen for Dinner. They
will receive one ticket for Dinner & Shuttle Bus together with three
tickets for drinks.
After Dinner Guests are free to walk around in the picturesque
streets or change to another Heurigen to meet their colleagues.
19:15 – 19:30:
20:00:
20:30:
From 22:30:
Departure with shuttle busses
from the congress venue
Reception and folklore dance show
at Gumpoldskirchen
Dinner and Music
at the assigned Heurigen
Shuttle busses back
to Vienna City Centre (Opera House)
No sponsoring is used to fund any part of the evening.
112
THE CITY OF
VIENNA
The City of Vienna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Vienna City Map. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
Vienna Public Transport Map . . . . . . . . . . . . . . . . . . . . . . . . . 118
113
The City of Vienna
THE CITY OF VIENNA
Where to go in Vienna –
Dancing, Beer Gardens, Restaurants - websites
If you like fine dining, casual beer gardens, to party, dance
or just sit in a bar, there are many places to go to, with a
wide range of different music styles. We understand that not
everyone has the desire nor the energy to dance the night
away after a long day at the congress so do not forget that
there is always the possibility to spend a very calm evening in
a hotel bar, typical Viennese restaurant or one of the many
fantastic coffee houses dotted around the city.
The following links will make it easy to find your favorite place
according to your mood:
www.wien.info/en/shopping-wining-dining/restaurants
www.wien.info/en/lifestyle-scene/nightlife
114
Public Transportation
The fastest and cheapest way to move around Vienna is by
public transportation. The easiest to use is the metro – with 5
different lines (identifiable by different colors) running from
5 am to midnight on Mondays-Thursdays as well as Sundays
and 24 hours on Fridays, Saturdays and holidays.
A regular one-way fare costs EUR 2,20.
Twenty-four-, 48- and 72-hour tickets cost
EUR 7,60; EUR 13,30; and EUR 16,50; respectively.
Tickets are checked before boarding and it may be a good
idea to get a deal using multiple-trip tickets.
Tickets for public transport can also be purchased online.
There are several types of tickets ranging from single fare to
weekly ticket. These tickets are valid for all public transportation services in Vienna (busses, trams, subways).
Business Travel
HIGHLIGHT
What I especially look forward to about flights with myAustrian?
First class service, delicious food – and Austrian hospitality.
the charming way to fly
The City of Vienna
VIENNA CITY MAP
Vienna City Hall
Hotel Intercontinental
116
The City of Vienna
VIENNA CITY MAP
ALL DISTRICTS OF VIENNA
ACV
LEGEND
© FREYTAG-BERNDT u. ARTARIA KG, 1230 VIENNA, AUSTRIA, EUROPE
FIRST DISTRICTS - CITY
117
The City of Vienna
VIENNA PUBLIC TRANSPORT MAP
ACV
© Wiener Linien, Okt. 2014
118
Notes
119
Notes
120
Beauty. Brains.
And now more brawn.
Meet the “more choice” iQue Screener PLUS.
Just when you thought the iQue® Screener had
everything, the iQue Screener PLUS gives you
even more insight:
• Richest content – up to 15 parameters of
information from up to 3 lasers.
• Fastest time to results – 384 wells in < 20 mins;
96 wells in < 5 mins!
• Miniaturized assays – as low as 9 μL assay volume
saves reagents and conserves precious cells.
• ForeCyt – The easiest software you’ll ever love!
Learn more or request a demo at
www.intellicyt.com/iQSP
See us at Booth #120
The IntelliCyt Advantage
BD OneFlow™ Solution
Leukemia and lymphoma immunophenotyping
3 45 5 7640
82 693 901
Individuals need standards.
A standard is the unifying force that
allows us to collaborate.
A
oved b
p pr
y
Built on the standard defined by the
EuroFlow™ Consortium(1), BD OneFlow™
solution brings the standardization in
leukemia and lymphoma immunophenotyping one step forward, maximizing
laboratory efficiency and increasing
reliability and accuracy of results.
The new standard brings pre-configured,
single-dose and ready-to-use 8-color
antibody reagents in a single test tube
format, allowing for direct specimen
staining hence maximizing laboratory
efficiency.
The pre-defined disease-specific panels
provide high diagnostic utility and
deliver accuracy and consistency of
patient outcomes across care venues.
Optimized on the BD FACSCanto™ II
system with ready-to-use software
templates, the BD OneFlow™ solution
delivers innovation and standardization
for each individual’s outcome.
(1) J.J.M. van Dongen, et al., on behalf of the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized
n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes’; Leukemia 2012, 26 (9): 1908-75.
EuroFlow Logo and Trademark are property of the EuroFlow Consortium.
BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2015 BD.
A076-00
BD Biosciences
Erembodegem-Dorp 86
B-9320 Erembodegem
Tel.: + 32 2 400 98 95
www.bdbiosciences.com/eu

final program

Transcription

Similar documents

Content AgendaEvent: 5th Viennese Neighbour`s Day

Every Child, Inc. Implements Staunton Farm

Austria Update - ABC Air and Sea Cargo Distribution

CV English

here - STA Travel

IRC channels

Your Reliable Partner for Central and Eastern Europe

`Loimer wines convey a zest for life and uncomplicated pleasure. Sip

Vienna Choir Boys